Dosimetric impact of organ motion with 4D-CT based treatment planning in lung stereotactic ablative radiotherapy by Tajaldeen, A
Dosimetric Impact of Organ Motion 
with 4D-CT Based Treatment Planning 
in Lung Stereotactic Ablative 
Radiotherapy 
A thesis submitted in fulfilment of the requirements for the degree of Doctor of 
Philosophy 
Abdulrahman Amin A Tajaldeen 
M.Sc
School of Health and Biomedical Sciences 
 College of Science, Engineering and Health 
RMIT University 
September 2017 
ii 
 
Declaration  
 
I hereby certify that all of the work described within this thesis is the original work of the 
author; the work has not been submitted previously in whole or in part, to quantify for any 
other academic award; the content of the thesis is the result of work which has been carried 
out since the official commencement date of the approved research program; and any 
published (or unpublished) ideas and/or results from the work of the others are fully 
acknowledged in accordance with the standard referencing guidelines. 
 
   
Abdulrahman Amin A Tajaldeen 
4/9/2017  
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Acknowledgments  
 
Foremost, I would like to express my sincere gratitude to my main supervisor A/Prof Dr 
Moshi Geso for the continuous support of my PhD study and research, for his patience, 
motivation, enthusiasm, and immense knowledge. His guidance helped me in all the time of 
research and writing of this thesis. I could not have imagined having a better advisor and 
mentor for my PhD study. My sincere thanks also go to my second supervisor A/Prof Dr 
Prabhakar Ramachandran for his valuable advises and his fully support during my PhD study. 
This research project would not has been possible without the support of many people. I 
would like to express my gratitude to Mr Paul Archer who was abundantly helpful and 
offered invaluable assistance, support and guidance. I would like also express my gratitude to 
Mr Frank Gagilardi for his valuable assistance in my project. At the last, I like to thank my 
sponsor Imam Abdulrahman bin Faisal University for their financially support during my 
studying period.   
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Table of Contents  
Declaration................................................................................................................................ ii 
Acknowledgments .................................................................................................................. iii 
Table of Contents .................................................................................................................... iv 
List of Figures ........................................................................................................................... x 
List of Tables ......................................................................................................................... xix 
List of abbreviations ............................................................................................................ xxii 
Dedication ............................................................................................................................ xxvi 
Publications ........................................................................................................................ xxvii 
Conference participation ................................................................................................... xxvii 
Abstract ..................................................................................................................................... 1 
Chapter 1 Project Overview ................................................................................................... 5 
1.1 Project overview ........................................................................................................ 5 
1.2 Aims of the thesis..................................................................................................... 16 
1.3 Hypotheses ............................................................................................................... 17 
1.4 Research Questions .................................................................................................. 17 
1.5 Outcomes/benefits.................................................................................................... 18 
1.6 Final outcome........................................................................................................... 19 
1.7 Outline of the thesis ................................................................................................. 20 
Chapter 2 Literature Review ................................................................................................ 26 
2.1 Physics of radiation therapy ..................................................................................... 27 
2.1.1 X-ray and gamma ray production ........................................................................ 28 
2.1.2 Interactions of photons with matter ..................................................................... 29 
2.1.2.1 Photoelectric effect ..................................................................................... 29 
2.1.2.2 Compton scattering ..................................................................................... 30 
2.1.2.3 Pair production ........................................................................................... 31 
2.2 Lung cancer and Stereotactic Ablative Radiotherapy (SABR) ................................ 33 
2.2.1 Stage 1: Patient evaluation ................................................................................... 36 
2.2.2 Stage 2: Simulation/Imaging................................................................................ 36 
2.2.2.1 Computed tomography (CT) ...................................................................... 37 
2.2.2.2 Four dimensional computed tomography (4D-CT) .................................... 39 
v 
 
2.2.2.3 Formation of four dimensional computed tomography (4D-CT) images... 39 
2.2.2.4 Image acquisition of 4D-CT ....................................................................... 40 
2.2.2.5 Maximum intensity projection and average intensity projection ............... 42 
2.2.2.6 Dosimetric impact of respiratory motion and tumour margins .................. 44 
2.2.2.7 Planning target volume (PTV) generation .................................................. 45 
2.2.3 Stage 3: Treatment planning ................................................................................ 46 
2.2.3.1 Plan classification ....................................................................................... 47 2.2.3.1.1 Three-dimensional conformal radiotherapy (3D CRT)..................... 47 
2.2.3.1.2 Intensity modulated radiation therapy (IMRT) ...................................... 50 
2.2.3.1.3 Volumetrically modulated arc therapy (VMAT) ................................... 50 
2.2.3.2 Plan evaluation parameter .......................................................................... 53 
2.2.3.2.1 Conformity index (CI) ............................................................................ 54 
2.2.3.2.2 Homogeneity index (HI) ........................................................................ 56 
2.2.3.2.3 Dose fall-off ........................................................................................... 57 
2.2.3.3 Dose calculation algorithms ....................................................................... 58 
2.2.3.3.1 The effect of the heterogeneous treatment sites on dose calculation 
algorithms. ............................................................................................................... 59 
2.2.3.3.2 The types of dose calculation algorithms in radiation therapy............... 60 
2.2.3.3.2.1 Correction-based algorithms ........................................................... 61 
2.2.3.3.2.2.1 Establishing dose calculation data ........................................................ 61 
2.2.3.3.2.2.2 Reconstruction of the dose distribution ................................................ 62 
2.2.3.3.2.2.2.1 Correction for an irregular field ..................................................... 62 
2.2.3.3.2.2.2.2 Correction for contour irregularities .............................................. 63 
2.2.3.3.2.2.2.3 Heterogeneous correction .............................................................. 65 
2.2.3.3.2.2 Model-based algorithms .................................................................. 66 
2.2.3.3.2.2.1 Convolution-superposition with point dose kernels.............................. 67 
• FFT convolution algorithms (XiO-TPS) ............................................................. 68 
• Superposition algorithms (XiO-TPS) .................................................................. 69 
• Fast superposition algorithms (XiO-TPS) ........................................................... 72 
• Fast superposition algorithms vs. superposition algorithms................................ 72 
2.2.3.3.2.3 Convolution superposition with pencil beam dose kernels ............. 73 
• AAA (Eclipse-TPS) .............................................................................. 73 
2.2.3.3.2.4 Monte Carlo (MC) algorithms......................................................... 74 
2.2.3.3.2.5 Acuros XB algorithms (Eclipse-TPS) ............................................. 75 
vi 
 
2.2.4 Stage 4: Treatment delivery ................................................................................. 80 
2.2.4.1 Linear accelerator (Linac) .......................................................................... 80 
2.2.4.1.1 X-ray target and flattening filter............................................................. 82 
2.2.4.1.2 Beam collimation and monitoring .......................................................... 82 
2.2.4.1.3 Gantry ..................................................................................................... 83 
2.2.5 Quality assurance QA .......................................................................................... 83 
Chapter 3 General Materials and Methods ......................................................................... 86 
3.1 The custom-designed thorax dynamic phantom ...................................................... 87 
3.1.1 Mechanical parts of the phantom ......................................................................... 87 
3.1.2 The phantom’s accessories .................................................................................. 91 
3.2 The written code for the phantom ............................................................................ 94 
3.3 PRESAGE dosimeter ............................................................................................... 96 
3.4 Optical CT ................................................................................................................ 97 
3.4.1 Pre- and post-scan for the PRESAGE .................................................................. 99 
3.5 Image J software .................................................................................................... 100 
3.6 PolyGeVero software ............................................................................................. 102 
3.7 Radiochromic Films ............................................................................................... 104 
3.7.1 Film calibration .................................................................................................. 105 
3.8 Rod phantom .......................................................................................................... 108 
3.9 ArcCheck phantom ................................................................................................ 109 
3.10 Gamma index ......................................................................................................... 110 
3.11 Farmer chambers or ion chambers (IC) ................................................................. 114 
3.11.1 Farmer chamber’s components ...................................................................... 115 
3.11.1.1 Chamber wall ............................................................................................ 115 
3.11.1.2 Outer electrode ......................................................................................... 115 
3.11.1.3 Central electrode ....................................................................................... 115 
3.11.1.4 Guard electrode ......................................................................................... 115 
3.12 Electrometer ........................................................................................................... 116 
3.13 IPSM phantom ....................................................................................................... 118 
3.14 CIRS thorax phantom ............................................................................................ 121 
3.15 Statistical Analyses ................................................................................................ 122 
Chapter 4 Investigation of MIP based and Phase Specific Planning in Lung SABR .... 123 
4.1 Summary ................................................................................................................ 123 
vii 
 
4.2 Introduction ............................................................................................................ 123 
4.3 Material and method .............................................................................................. 126 
4.3.1 SABR protocol for lung cancer utilising the 3D CRT technique ...................... 127 
4.3.2 MIP based planning and phase specific planning methods ............................... 132 
4.4 Results .................................................................................................................... 138 
4.4.1 Comparison between GTV1 of the MIP based planning method and GTV2 of the 
phase specific planning method ...................................................................................... 138 
4.4.2 Comparison between PTV1 of the MIP based planning method and PTV2 of the 
phase specific planning method ...................................................................................... 141 
4.5 Discussion .............................................................................................................. 143 
4.6 Conclusion ............................................................................................................. 146 
Chapter 5 Dosimetric Impact of Organ Motion in Static and Dynamic Conditions for 
Three SABR Techniques: 3D CRT, IMRT, and VMAT by Using PRESAGE 3D 
Dosimeters ............................................................................................................................ 147 
5.1 Summary ................................................................................................................ 147 
5.2 Introduction ............................................................................................................ 147 
5.3 Materials and methods ........................................................................................... 149 
5.3.1 Validation of movement distance of in-house custom-designed thorax dynamic 
phantom .......................................................................................................................... 149 
5.3.2 PRESAGE 3D dosimeters.................................................................................. 150 
5.3.2.1 Calibration curve of PRESAGE 3D dosimeters ....................................... 152 
5.3.2.2 Validation of dose distribution of PRESAGE 3D dosimeter ................... 156 
5.3.3 Static and motion conditions for three techniques of lung SABR: 3D CRT, 
IMRT, and VMAT .......................................................................................................... 159 
5.4 Results .................................................................................................................... 163 
5.4.1 Validation of the movement distance of the in-house custom-designed thorax 
dynamic phantom ........................................................................................................... 164 
5.4.2 Validation of dose distribution of PRESAGE 3D dosimeters ........................... 167 
5.4.3 Static and motion conditions for three techniques of lung SABR: 3D CRT, 
IMRT, and VMAT .......................................................................................................... 168 
5.5 Discussion .............................................................................................................. 175 
5.6 Conclusion ............................................................................................................. 177 
Chapter 6 A Study of Dose Calculation Algorithms Using IPSM Phantom with Different 
Density Materials for in-field and out-of-field Conditions ............................................... 178 
6.1 Summary ................................................................................................................ 178 
viii 
 
6.2 Introduction ............................................................................................................ 178 
6.3 Materials and Methods ........................................................................................... 180 
6.3 Results .................................................................................................................... 183 
6.3.1 In-field condition ............................................................................................... 183 
6.3.2 Out-of-field condition ........................................................................................ 190 
6.4 Discussion .............................................................................................................. 193 
6.4.1 In-field condition ............................................................................................... 193 
6.4.2 Out-of-field condition ........................................................................................ 196 
6.5 Conclusion ............................................................................................................. 197 
Chapter 7 Evaluation of Dose Calculation Algorithms for Lung Cancer Patients 
Undergoing Stereotactic Ablative Radiotherapy (SABR) using 3D CRT technique ..... 198 
7.1 Summary ................................................................................................................ 198 
7.2 Introduction ............................................................................................................ 199 
7.3 Material and Methods ............................................................................................ 200 
7.3.1 CIRS thorax phantom (phantom study) ............................................................. 201 
7.3.2 Twenty one lung cancer cases using 3D CRT technique (clinical study).......... 204 
7.4 Results .................................................................................................................... 207 
7.4.1 CIRS thorax phantom (phantom study) ............................................................. 208 
7.4.2 Twenty one lung cancer cases using 3D CRT technique (clinical study).......... 210 
7.5 Discussion .............................................................................................................. 221 
7.6 Conclusion ............................................................................................................. 225 
Chapter 8 Investigation of AAA and Acuros XB Algorithms for Three Different 
Stereotactic Ablative Radiotherapy techniques (SABR): Volumetric Modulated Arc 
Therapy (VMAT), Intensity Modulated Radiation Therapy (IMRT) and 3D Conformal 
Radiotherapy (3D CRT) ...................................................................................................... 226 
8.1 Summary ................................................................................................................ 226 
8.2 Introduction ............................................................................................................ 227 
8.3 Methods and Materials ........................................................................................... 230 
8.4 Results .................................................................................................................... 234 
8.5 Discussion .............................................................................................................. 243 
8.6 Conclusion ............................................................................................................. 246 
Chapter 9 Feasibility of Using ArcCheck as a Tool for Patient Specific QA in 
Stereotactic Ablative Radiotherapy ................................................................................... 247 
9.1 Summary ................................................................................................................ 247 
ix 
 
9.2 Introduction ............................................................................................................ 248 
9.3 Material and Methods ............................................................................................ 249 
9.4 Results .................................................................................................................... 255 
9.5 Discussion .............................................................................................................. 260 
9.6 Conclusion ............................................................................................................. 263 
Chapter 10 Conclusions, Limitations and Future Directions .......................................... 264 
10.1 Conclusions ............................................................................................................ 264 
10.2 Limitations ............................................................................................................. 267 
10.3 Future Direction ..................................................................................................... 267 
References ............................................................................................................................. 268 
Appendices ............................................................................................................................ 283 
I. Peter MacCallum Cancer Centre Authorisation to conduct a research project (1) .... 283 
II. Peter MacCallum Cancer Centre Authorisation to conduct a research project (2) .... 284 
III. A registration certificate from college human ethics advisory network (CHEAN) 
for a research project (1) .................................................................................................... 285 
IV. A registration certificate from college human ethics advisory network (CHEAN) 
for a research project (2) .................................................................................................... 286 
V. Accuracy of Dose Calculation Algorithms for Patients Undergoing Stereotactic 
Ablative Radiotherapy........................................................................................................ 287 
VI. A feasibility study of using ArcCheck for patient specific QA in Stereotactic 
Ablative Radiotherapy (SABR) ......................................................................................... 288 
VII. ArcCheck for Patient Specific QA in Stereotactic Ablative Radiotherapy ........... 289 
VIII. A study of dose calculation algorithms using IPSM phantom with different density 
materials for in-field and out-of-field conditions ............................................................... 290 
IX. Investigation of AAA and Acuros XB algorithms for three different Stereotactic 
Ablative Radiotherapy techniques (SABR): Volumetric Modulated Arc Therapy (VMAT), 
Intensity modulated radiation therapy (IMRT) and 3D Conformal Radiotherapy (3D CRT)
 ……………………………………………………………………………………291 
X. The written codes and commands for the in-house custom-designed thorax dynamic 
phantom .............................................................................................................................. 292 
 
 
 
x 
 
List of Figures 
Figure  1-1: The sinusoidal wave (bottom image) shows the 10 respiratory phases for a full 
respiratory cycle including end-inspiration and end-expiration.  
Figure  2-1: Release of characteristic X-rays, bremsstrahlung X-rays and gamma rays. 
Figure  2-2: Process of the photoelectric effect. 
Figure  2-3: Process of Compton scattering effect. 
Figure  2-4: Process of pair production. 
Figure  2-5: Process flow of the SABR in radiation therapy. 
Figure  2-6: Principle of helical CT scanners. 
Figure  2-7: Different window levels provided by CT scanner for the thorax.  
Figure  2-8: Overhead and side views of the pneumatic belt (bellows) (red arrow) and the 
RPM system (blue arrow). 
Figure  2-9: The sorting of 4D-CT data which illustrates the retrospective process. 
Figure  2-10: The diagram illustrates one of the reconstruction methods in displaying 
reformatted and 3D images. 
Figure  2-11: Comparison of MIP, AIP and individual respiratory phase (end of exhalation).  
Figure  2-12: Schematic diagram demonstrates different volumes of tumours to be included in 
the treatment planning system recommended by the (ICRU reports 50 and 62). 
xi 
 
Figure  2-13: Axial plan of lung case treated with the SABR technique using the 3D CRT 
technique.  
Figure  2-14: BEV of the PTV shows the tumour volume in 3D view in Eclipse TPS utilising 
phase number 10 of 4D-CT.  
Figure  2-15: Demonstration of progressive sample optimization technique.  
Figure  2-16: Axial plan of one full arc by VMAT for lung SABR. 
Figure  2-17: An example of differential DVH and its corresponding cumulative DVHs.  
Figure  2-18: An illustration of patient surface irregularities. 
Figure  2-19: An illustration of tissue heterogeneity correction for dose calculation algorithms. 
Figure  2-20: Schematic diagram demonstrates the shape of dose kernel in different situations. 
The kernel is known as the dose matrix produced per unit of TERMA at the interaction site.  
Figure  2-21: Schematic diagram of typical medical linear accelerator. 
Figure  3-1: The mechanical parts of the custom-designed thorax dynamic phantom. 
Figure  3-2: (A) The bellows is placed on the aluminium bar to monitor the patient specific 
respiratory motion; (B) the phantom motion provides respiratory information in amplitude or 
wave form, and the bellows’ monitor signals and displays the information in terms of breaths 
per minute (bpm).  
Figure  3-3: A PRESAGE holder for a large sample size.  
Figure  3-4: Cork material used in the phantom.  
Figure  3-5: Two measurers are placed on the phantom to measure the displacement distance 
for: (A) superior/inferior motion and (B) anterior/posterior motion.  
xii 
 
Figure  3-6: The interface of the in-house software called real position movement (RPM); it 
was developed to control the motion of the custom-designed thorax dynamic phantom.  
Figure  3-7: Two PRESAGE samples illustrate the colour changes during irradiation.  
Figure  3-8: Schematic diagram shows light rays through the CCD-based optical CT scanner.  
Figure  3-9: (A) an example of the pre-scan sample of PRESAGE. (B) The post-scan sample 
after irradiation for the same PRESAGE sample. 
Figure  3-10: The interface of Image J software depicts the PRESAGE’s sample analysis.  
Figure  3-11: Comparison between the PRESAGE dosimeter and the DICOM image of EBT3 
film for the same delivered dose of 30 Gy.  
Figure 3-12: A 3D view of the PRESAGE sample (irradiated by 10 Gy) using the 
PolyGeVero® software.  
Figure  3-13: Eight calibrated films demonstrate the dose-response data for irradiated films 
ranging from 0–3,300 cGy (100 cGy = 1 Gy); the size of each film is 2 x 2 cm2.  
Figure  3-14: Calibration curve information (dose-response data) for EBT3 films using 
FilmQA pro software. 
Figure  3-15: The rod phantom consists of several slabs. The EBT3 film was resized to 12.5 x 
20.5 cm2 to fit into the film slot.  
Figure  3-16: (A) The ArcCheck phantom placed on the table of the Linac system. (B) The 
cavity plug is located at the rear of the phantom.  
Figure  3-17: Interface of the FilmQA Pro software.  
xiii 
 
Figure  3-18: Interface of the SNC patient software depicts the gamma index evaluation of 3% 
DD and 3 mm DTA between the measured doses and calculated doses of an irradiated field 
size (10 x 10 cm2).  
Figure  3-19: Schematic diagram of the Farmer graphite or aluminium chamber. 
Figure  3-20: Schematic diagram of the three types of simplified circuits when the ion 
chamber is connected to the negative-feedback operational amplifier.  
Figure  3-21: The ion chamber (0.6 cc) (the left image) and electrometer device (the right 
image).  
Figure  3-22: (A–D) Images of different density inserts for the IPSM phantom: (A) Lung 
density insert; B) water density insert; (C) dense bone insert; and (D) rib density insert.  
Figure  3-23: CIRS thorax phantom placed on Linac treatment delivery table with gantry 
angle 0o.  
Figure  4-1: CT images of a lung tumour in the right lung.  
Figure  4-2: The breathing trace box. The black arrow is pointed to a tag incorrectly located, 
after the editing the tag is moved to the peak of the wave.  
Figure  4-3: Schematic illustration of tumour volumes: GTV (red circle), CTV (blue circle 
outlined GTV), ITV (green dashed line) and PTV (orange outline) of the two methods: MIP 
based planning and phase specific planning.  
 
Figure  4-4: The MIP based planning method (conventional method) indicating GTV1 and 
PTV1 contours.  
xiv 
 
Figure  4-5: Phase specific planning method indicating the manual contours for GTV2 and 
PTV2 (violet coloured contours) used for patient number 4 (28 Gy/1frction).  
Figure  4-6: The delivery of the prescription doses for the MIP based planning (upper image) 
and phase specific planning (lower image) methods for patient number 4 (28Gy/1frction).  
Figure  4-7: Line graphs illustrating the differences between the GTV1 and GTV2 volumes 
for the two methods.  
Figure  4-8: Line graphs illustrating the difference between the GTV1 and GTV2 mean doses 
(Gy) for the two methods.  
Figure  4-9: Line graphs illustrating the difference between the GTV1 and GTV2 maximum 
doses (Gy) for the two methods.  
Figure  4-10: Line graphs illustrating the differences between the PTV1 and PTV2 volumes 
for the two methods.  
Figure  4-11: Line graphs illustrating the difference between the PTV1 and PTV2 mean doses 
(Gy) for the two methods.  
Figure  4-12: Line graphs illustrating the differences between the PTV1 and PTV2 maximum 
doses (Gy) for the two methods.  
Figure  5-1: A) a PRESAGE dosimeter (4 cm length × 4 cm diameter) covered by cork 
material: the white circle indicates the small rounded object inside the PRESAGE dosimeters 
with 0.5 cm diameter.  
Figure  5-2: Process of irradiating small PRESAGE dosimeters (4 cm length × 4 cm diameter) 
inside the rod phantom to obtain the calibration curve.  
xv 
 
Figure  5-3: Axial CT image of the rod phantom showing the planned dose distribution of an 
irradiated field size of 2 × 2 cm2 (box technique) by 30 Gy in TPS.  
Figure  5-4: Relationship between optical attenuation per pixel and dose.  
Figure  5-5: Process of irradiating large PRESAGE dosimeters for the static and dynamic 
conditions using in-house custom-designed thorax dynamic phantom.  
Figure  5-6: CT images of three SABR techniques in TPS: 3D CRT, IMRT, and VMAT.  
Figure  5-7: Two CT images of small PRESAGE dosimeters surrounded by cork illustrating 
the movement distance in the A/P direction by 1 cm [see Figure 5-1 (A)].  
Figure  5-8: MIP images showed the movement distance of the small object (0.5 cm length × 
0.5 cm diameter) inside the thorax phantom (see Figure 5-1).  
Figure  5-9: A small PRESAGE dosimeters with dose distribution of 2 × 2 cm2 field size (box 
technique) irradiated by 30 Gy.  
Figure  5-10: Isodose line distribution of the PRESAGE 3D dosimeter and the planned dose in 
TPS using retrospective clinical cases of patients who underwent SABR of the lung (Patient 
1) treated by 3D CRT with a prescription dose of 28 Gy.  
Figure  5-11: Coloured wash dose distribution of six large PRESAGE dosimeters irradiated in 
two conditions (static and dynamic) for three SABR techniques: 3D CRT, IMRT and VMAT 
in the ZX plane.  
Figure  5-12: Coloured wash dose distribution of six large PRESAGE dosimeters irradiated in 
two conditions (static and dynamic) for three SABR techniques: 3D CRT, IMRT, and VMAT 
in the YZ plane.  
xvi 
 
Figure  5-13: Three-dimensional image of the irradiated PRESAGE dosimeters in dynamic 
condition using IMRT technique for patient 2.  
Figure  5-14: Dosimetric variation between the static and dynamic conditions for individual 
plane/layer of SABR technique using 3D CRT for the 28 Gy isodose line in: A) YZ axes and 
B) ZX axes.  
Figure  5-15: Gamma index analysis using 3%, 3 mm criterion for 3D CRT technique 
demonstrating that most of the PRESAGE dosimeter was <1 in the YZ plane (top image) and 
ZX plane in the (bottom image).  
Figure  6-1: Percentages differences of the calculated points for five algorithms compared 
with the measured dose from the ion chamber for A) water and B) rib density inserts.  
Figure  6-2: Percentages differences of the calculated points for five algorithms compared to 
the measured dose from the ion chamber for dense bone density at A) 90o and B) 270o.  
Figure  6-3: Percentages differences of the calculated points for:  A) five algorithms compared 
to the measured dose from the ion chamber for lung density and  B) three algorithms using a 
special insert in the lung density for POI6 compared to the measured dose.  
Figure  6-4: Percentages differences of the calculated points for five algorithms in out-of-field 
condition of four different densities: A) water density, B) lung density, C) rib density and D) 
dense bone density.  
Figure  7-1: Two different plans for two lung cancer patients treated by SABR using 3D CRT 
technique. The left column: CIRS phantom and the right column: lung cancer cases.  
Figure  7-2: Discrepancies of four different algorithms Acuros XB, Superposition, PBC and 
AAA algorithms for patient 1 and 2 by using CIRS thorax phantom.  
xvii 
 
Figure  7-3: Dose coloured wash (top row) and isodose lines (bottom row) of 3D CRT 
technique for the dose distribution of three algorithms: AAA, Acuros XB and PBC for same 
dose coverage method.  
Figure  7-4: Dose coloured wash (top row) and isodose lines (bottom row) of 3D CRT 
technique images for the dose distribution of three algorithms: AAA, Acuros XB and PBC 
for same dose monitor unit method.  
Figure  7-5: OAR curves of AAA and the PTV curves for the three algorithms: AAA, PBC 
and Acuros XB for both methods.  
Figure  7-6: The internal skin and the PTV curves for four algorithms calculation by using two 
different methods: same dose coverage and same monitor unit.  
Figure  7-7: Isodose line images of the same dose coverage method for four different 
algorithms’ calculation: superposition, Fast superposition, FFT convolution and Clarkson.  
Figure  7-8: Isodose line images of the same monitor unit method for four different 
algorithms’ calculation: superposition, Fast superposition, FFT convolution and Clarkson.  
Figure  8-1: The dose distribution for the three treatment techniques C-VMAT, NC-IMRT and 
NC- 3D CRT on the transversal plane.  
Figure  8-2: OARs curves of NC-3D CRT and PTV curves of the three different techniques 
calculated by AAA algorithms.  
Figure  8-3: OARs curves of NC-3D CRT and PTV curves of the three different techniques 
calculated by Acuros XB algorithms.  
Figure  9-1: Treatment plans of six different SABR cases.  
xviii 
 
Figure  9-2: A) In-house designed Rod phantom with a CC13 ion chamber inserted to measure 
absolute dose at reference point. B) ArcCheck phantom aligned to the isocentre for 
measurement.  
Figure  9-3: A) The calibrated films were cut in (2 x 2 cm2) and irradiated to different doses 
from 0 – 30 Gy.  
Figure  9-4:  Comparison of passing rates of lung cases for different gamma criteria.  
Figure  9-5:  Comparison of passing rates of spine cases for different gamma criteria.  
Figure  9-6: Comparison of passing rates of Sacrum, Sternum, Ribs, Scapula, Humerus and 
Femur Cases for different gamma criteria.  
Figure  9-7: The relationship between equivalent square field size and passing rates of IMRT 
plans for 3%, 3 mm gamma criterion.  
 
 
 
 
 
xix 
 
List of Tables  
Table  2-1: Comparison of different volume-based CIs in different clinical settings.  
Table  2-2: Five formulae for calculating HI index.  
Table  2-3: Comparison between FFT convolution and Superposition algorithms.  
Table  3-1: List of commercial Gafchromic films for radiotherapy.  
Table  4-1: Planning dose constraints used for SABR of the lungs with a dose prescription of 
26 Gy/1 fraction.  
Table  4-2: Planning dose constraints used for SABR of the lungs with dose prescriptions of 
48 Gy/4 fractions and 54 Gy/3 fractions.  
Table  4-3: The prescription doses (Gy) for the 15 patients who underwent SABR of the lungs. 
Table  4-4: The mean values of the GTV1, GTV2 volumes (cm3), mean dose (Gy) and 
maximum dose (Gy) for the two methods.  
Table  4-5: The mean values of the PTV1, PTV2 volumes (cm3), mean dose (Gy) and 
maximum dose (Gy) for the two methods.  
Table  5-1: Correlation between doses and pixel values of 10 small-sized PRESAGE 
dosimeters.  
Table  5-2: Beam configurations and monitor units in the original treatment plan of patient 1 
treated by SABR with 3D CRT technique. OBL = oblique.  
Table  5-3: Beam configurations and monitor units in the original treatment plan of patient 2 
treated by SABR with 3D CRT technique.  
xx 
 
Table  5-4: Mean volume measurements of the TPS, static and dynamic conditions for the 
three SABR techniques: 3D CRT, IMRT, and VMAT.  
Table  6-1: Measurement points for the measured dose by IC and the five algorithms (AAA, 
PBC, Acuros XB, Superposition and CCC) using water, lung, and dense bone density inserts 
in IPSM phantom for different beam configurations.  
Table  6-2: Measurement points for the measured dose by IC and the three algorithms (AAA, 
PBC and Acuros XB) using a lung insert–IPSM phantom with a special insert at POI6 for 
different beam configurations.  
Table  6-3: Measurement points for the measured dose by IC and the five algorithms (AAA, 
PBC, Acuros XB, Superposition and CCC) using a rib insert–IPSM phantom for different 
beam configurations.  
Table  6-4: Mean differences in percentage of different densities: water, lung, rib and dense 
bone for gantry angles of 90° and 270°.    
Table  6-5: Mean differences in percentage for the special insert in the lung density for POI6 
and calculated by three different algorithms: AAA, PBC and Acuros XB.  
Table  7-1: Beam configurations and monitor units in the original treatment plans of two lung 
cancer patients who treated by SABR with 3D CRT technique.  
Table  7-2: PTV volume and tumour location for 21 patients treated by the 3D CRT technique. 
Table  7-3: Mean differences in percentage of the following algorithms: Superposition, 
Acuros XB, PBC and AAA for patient 1 and patient 2 by using CIRS thorax phantom.  
Table  7-4: Mean values for the conformity index, homogeneity index and dose fall-off for the 
seven different algorithms.  
xxi 
 
Table  7-5: Mean values for V5 and V20 for right, left and whole lung for the seven different 
algorithms.  
Table  7-6: Mean values for Dmax of the heart, oesophagus and spinal cord for the seven 
different algorithms.  
Table  8-1: PTV volume and tumour location for 12 patients computed using AAA and 
Acuros XB algorithms for C-VMAT, NC-IMRT and NC-3D CRT techniques.  
Table  8-2: Dmean, D2, D5, D95, D98 and plan evaluation parameters for the three different 
techniques C-VMAT, NC-IMRT and NC-3D CRT calculated by AAA and Acuros XB 
algorithms.  
Table  8-3: The mean volumes percentage of the right, left and whole lungs that received 5 
and 20 Gy for the three techniques computed by the AAA and Acuros XB algorithms.  
Table  8-4: Mean doses to Heart, Oesophagus and Spinal Canal with C-VMAT, NC-IMRT 
and NC-3D CRT.  
Table  8-5: Mean doses to internal skin for three different techniques: C-VMAT, NC-IMRT 
and NC-3D CRT.  
Table  9-1: Comparison of ArcCheck and EBT3 results.  
 
 
 
 
xxii 
 
List of abbreviations  
 
AAPM                       american association of physicists in medicine 
AAPM TG                 american association of physics in medicine task group 
ACR                           american college of radiology 
ASTRO                      american society for radiation oncology 
ANOVA                     analyses of variance 
AAA                           anisotropic analytic algorithms 
ACDS                         australian clinical dosimetry services 
AIP                             average intensity projection 
BEV                            beam’s eye view 
BED                            biological effective dose 
Br                                bromine 
CPD                            charged particle disequilibrium 
Cl                                chlorine 
CTV                            clinical target volume 
CCC                            collapsed cone convolution 
CT                               computed tomography 
CBCT                          cone beam computed tomography 
CI                                conformity index 
CVMAT                      coplanar volumetric modulated arc therapy 
CF                               correction factor 
DBTDL                       dibutyltin dilaurate 
DC                               direct current 
DTA                            distance to agreement 
DD                               dose difference 
xxiii 
 
ETAR                          equivalent tissue air ratio 
FFT                             fast fourier transformation 
FOV                            field of view 
4DCT                          four dimension computed tomography 
FPS                             frames per second 
GTV                            gross tumour volume 
HI                                homogeneity index 
IGRT                           image guided radiation therapy 
ICFs                            inhomogeneity correction factors 
IPSM                           institute of physical sciences in medicine 
IMRT                          intensity modulated radiation therapy 
ITV                             internal target volume 
ICRU                          international commission on radiation unit 
ICRUM                      international commission on radiation units and measurements 
IEC                             international electrotechnical commission 
ISP                             international specialty products 
I                                  iodine 
IC                               ion chamber 
Linac                         linear accelerator 
LBTE                        linear boltzmann transport equation 
MRI                          magnetic resonance imaging 
MIP                          maximum intensity projection 
MLD                        mean lung dose 
MV                           mega volt 
MU                           monitor unit 
MC                           monte carlo 
MLC                         multi leaf collimators 
xxiv 
 
NCAT                       national cancer action team 
NCRPM                    national council of radiation protection and measurements 
NCIMRT                  non coplanar intensity modulated radiation therapy 
NC-3D CRT             non coplanar three dimensional conformal radiotherapy 
NSCLC                     non small cell lung carcinoma 
NTCPs                      normal tissue complication probabilities 
OARs                        organs at risks 
PBC                           pencil beam convolution 
PACS                         picture archiving and communicating system 
PRV                           planning organ at risk value 
PTV                           planning target volume 
PTCFE                       polytrichlorofluoroethylene 
PD                              prescription dose 
QA                             quality assurance 
RTOG                         radiation Therapy Oncology Group 
RPC                            radiological physics centre 
RPM                           real-time position management 
RI                                refraction index 
SALT                          saint-anne lariboisiere tenon 
SMR                           scatter maximum ratio 
SNR                            signal to noise ratio 
SSD                            source-to-surface distance 
SABR                         stereotactic ablative radiotherapy 
SBRT                          stereotactic body radiotherapy 
SRS                             stereotactic radiosurgery 
3D CRT                      three dimensional conformal radiotherapy 
TMR                           tissue maximum ratios 
xxv 
 
TERMA                      total energy released per unit mass 
TROG                         trans-tasman radiation oncology group 
TPS                             treatment planning system 
VMAT                         volumetrically modulated arc therapy 
 
xxvi 
 
Dedication  
This thesis is dedicated to my beloved parent, brothers and sisters and to my lovely wife 
Rowa Aljondi and my precious son Eyad for their fully support and understanding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxvii 
 
Publications  
• Abdulrahman Tajaldeen, Prabhakar Ramachandran, Moshi Geso, Investigation of the Use 
of the Anisotropic Analytical Algorithm and Acuros XB Algorithm for Three Different 
Stereotactic Ablative Radiotherapy Techniques: Volumetric Modulated Arc Therapy, 
Intensity Modulated Radiation Therapy and 3D Conformal Radiotherapy, Journal of 
Reports of Practical Oncology & Radiotherapy. (under review)  
• Abdulrahman Tajaldeen, Prabhakar Ramachandran, Moshi Geso, Feasibility of using 
ArcCheck as a tool for Patient Specific QA in Stereotactic Ablative Radiotherapy, 
Journal of Medical Physics. (under review)  
Conference participation  
 
• Abdulrahman Tajaldeen, Prabhakar Ramachandran, Moshi Geso,  Accuracy of Dose 
Calculation Algorithms for Patients Undergoing Stereotactic Ablative Radiotherapy, 
Presented as a Poster Presentation at AAPM 2015 conference, USA (Appendix V) .  
• Abdulrahman Tajaldeen, Prabhakar Ramachandran, David Taylor, Derrick Wanigaratine, 
Karl Roozen, Tomas Kron and Moshi Geso, A feasibility study of using ArcCheck for  
patient specific QA in Stereotactic Ablative Radiotherapy (SABR), Presented as a 
Poster Presentation at EPSM 2015 conference, Newzeland (Appendices VI and VII).  
 
• Abdulrahman Tajaldeen, Prabhakar Ramachandran, David Taylor, Derrick Wanigaratine, 
Karl Roozen, Tomas Kron and Moshi Geso, A study of dose calculation algorithms using 
IPSM phantom with different density materials for in-field and out-of-field conditions, 
Presented as a Poster Presentation at EPSM 2016 conference, Syedney (Appendix VIII).  
 
• Abdulrahman Tajaldeen, Prabhakar Ramachandran, Moshi Geso, Investigation of AAA 
and Acuros XB algorithms for three different Stereotactic 
Ablative Radiotherapy techniques (SABR): Volumetric Modulated 
Arc Therapy (VMAT), Intensity modulated radiation therapy (IMRT) and 3D 
Conformal Radiotherapy (3D CRT), Presented as Poster Presentation at ICMP 2016 
conference, Thailand (Appendix IX).  
 
1 
 
Abstract 
Stereotactic ablative radiotherapy (SABR) plays a major role in the treatment of lung cancer. 
Advances in external beam radiotherapy, such as three-dimensional conformal radiotherapy 
(3D CRT), intensity modulated radiation Therapy (IMRT) and volumetric modulated arc 
therapy (VMAT) tightly conform dose to the target volume, in turn reducing dose to the 
surrounding critical structures. Organ motion and setup error are two important parameters 
that have significant effects on the final treatment outcome in lung SABR. The effect of 
organ motion has a greater effect on the dose to the tumour volume that is prone to movement 
due to respiration.  Lung cancer is one such site where the position of the tumour volume is 
significantly affected with respiration.  
 
Several methods have been proposed to combat tumour movement in lung cancer 
radiotherapy.  The most common and widely followed method is to define a Maximum 
Intensity Projection (MIP) based tumour volume obtained from a series of CT images 
scanned at regular respiratory phases. The MIP based target volume encompasses the 
movement of tumour volume during four dimensional computed tomography (4D-CT) 
imaging and a treatment plan is generated based on this volume.  One of drawbacks with this 
methodology is the inclusion of normal tissues as part of the target volume.  The volume of 
normal tissue included as part of the MIP volume increases with increase in tumour volume 
movement. The MIP based volume includes low density areas but it is treated as an Internal 
Target Volume (ITV) and the calculation is based on Average Intensity Projection (AIP) 
images. 
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Besides the organ motion challenge in treating the lung SABR, dose calculation is 
compromised due to the presence of low-density lung tissues surrounding the thoracic 
tumours [1, 2]. Lower lung densities give rise to higher doses inside the lung, and hence there 
is a possibility of under-dosage in the periphery of the tumour when using small fields and 
high-energy beams [1, 2]. The use of small-beam field sizes in the SABR technique with the 
presence of low density in the lung tissue can lead to exacerbating the charged particle 
disequilibrium (CPD) condition, where the electrons increase significantly [1, 2]. 
 
The three main aims of this thesis are as follows: 
The first aim: 
Quantify the dosimetric impact of organ motion during the treatment of lung SABR utilising 
an in-house custom-designed thorax dynamic phantom with the PRESAGE 3D dosimeters.  
This thesis also explores the dosimetric differences between the MIP based planning 
(conventional method) and the phase specific planning methods.   
 
The second aim:  
Investigate the accuracy of different dose calculation algorithms in SABR of lung using 
phantoms and retrospective clinical lung cases. This thesis includes a study on the dosimetric 
variation among three SABR techniques: 3D CRT, IMRT and VMAT using most common 
dose calculation algorithms anisotropic analytic algorithms (AAA) and Acuros XB.  
 
 
3 
 
The third aim: 
Introduce a method for patient-specific quality assurance (QA) for SABR treatment plans as a 
means to replace the traditional film dosimetry.  
These studies will be of great values to the radiation therapy centres by improving the 
simulation/imaging, treatment planning, delivery planning and patient specific QA in SABR 
of lung.    
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Chapter 1 represents the project 
overview, hypotheses, thesis outline 
and outcomes 
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Chapter 1 Project Overview 
 
1.1 Project overview 
 
Radiation therapy is a medical specialty that utilises ionising radiation to treat cancer 
diseases. The ionising radiation can ionise the medium it passes through and deliver a lethal 
dose to tumours (targeted cells) [3]. Radiotherapy treatment planning methods enable and 
maintain the dose delivered to normal tissue below its tolerance level as much as possible. 
Radiation is transmitted as energy that travels in the form of electromagnetic waves (EM), 
charged particles (e.g. electrons) or neutral particles (e.g. neutrons) from varied sources [3] 
(the physics of radiation therapy is described in Chapter 2, Section 2.1). The main goal of 
radiation therapy is to deliver the highest amount of radiation required to destroy cancer cells 
while sparing the normal surrounding tissues [3].  
 
In modern radiation therapy, stereotactic body radiation therapy (SBRT), or stereotactic 
ablative radiotherapy (SABR), is considered as one of the most common techniques used in 
external radiation therapy to treat extracranial sites [3]. This technique entails accurate and 
focused delivery of a small number of fractions in the ablative dose range to extracranial 
tumours. The SABR technique was developed from stereotactic radiosurgery (SRS)[1]. The 
SRS utilises a single fraction of radiation therapy for treating intracranial tumours [2].   
 
For the past several decades, conventional fractionation has been the standard approach for 
radiation therapy. The concept of SRS was first introduced in 1951 by Lars Leksell [1]. He 
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developed a procedure to destroy dysfunctional loci in the brain using a particle accelerator 
and orthovoltage x-rays [2]. The SRS involves the delivery of a single high dose of radiation 
to the focal tumours [1]. This technique is used for treating intracranial lesions utilising a 
combination of narrow multiple beams that are delivered through non-coplanar isocentric 
arcs [2]. It provides a conformal radiation dose to the target with very steep dose fall-off 
around the target volume [1]. This is achieved by using appropriate circular or irregular 
beams or modulated beams to fit the lesion/s, optimising arc weight and angles and also 
dynamically shaping the radiation field during arc rotation with multileaf collimators (MLCs) 
(the MLCs are described in Chapter 2, Section 2.2.3.1.2)[2]. Similar to the SRS procedure, 
SRT refers to the delivery of multiple dose fractions [2]. Later on, Lars Leksell contributed to 
the design of a cobalt unit named the Gamma Knife. The first prototype of a Gamma Knife 
was established in 1968 [1]. The Gamma Knife (which is used for SRS) delivers radiation to 
brain tumours with a large number of isocentric gamma-ray beams (gamma ray and X-ray 
production are explained in Chapter 2, Section 2.1.1) [2]. The Gamma Knife has had 
promising results in treating different intracranial lesions [1]. 
  
In 1991, a small number of research groups attempted to deliver stereotactic treatment to 
extracranial sites simulating the intracranial SRS procedure [4]. Hamilton et al.,1995 [4] 
attempted to deliver SRS to treat spinal tumours with rigid immobilisation by screwing a 
frame to the spinous process [4]. However, the accuracy of the patient setup was affected by 
an inherent motion, which is unlikely to occur in intracranial cases [5]. A stereotactic body 
frame with built-in fiducial markers that can be visualised in a computed tomography (CT) 
scanner and is associated with an abdominal compression device for respiratory motion was 
constructed by Lax and Blomgren from the Karolinska Institute of Sweden [5]. By using 
computer plans with isodose distribution similar to intracranial SRS, they have treated several 
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patients with localised extracranial tumours [6]. For generating the treatment plan, multiple 
non-coplanar beams with great conformal apertures were used for delivering the radiation 
dose [6]. Shirato et al., 1999 [7] investigated techniques to account for the respiratory motion 
during radiation therapy [7]. Uematsu et al., 1998 [8] successfully developed a combination 
of a CT scanner and a linear accelerator (LINAC) treatment system to deliver 
hypofractionated stereotactic radiotherapy to lung tumours (CT scanner and LINAC system 
are explained in Chapter 2, Sections 2.2.2.1 and 2.2.4.1). They used multiple non-coplanar 
arcs and utilised an isodose distribution process similar to intracranial SRS. They treated 45 
patients with 66 lung tumours (43 metastasis and 23 primary lung tumours), and the results 
showed only two failure cases, with minimal toxicities [8]. Most radiation therapy centres 
have investigated the use of SBRT for lung tumours, and promising outcomes have been 
observed. With more clinical experience and more sophisticated technology, prospective 
trials of SBRT have been conducted in different radiation therapy institution worldwide [9-
11]. The SBRT/SABR system has become a very useful tool for treating early stage non-
small cell lung cancer (NSCLC)[12].  
 
NSCLC is predominant in elderly patients who have had a long history of smoking. For 
treating NSCLC, the first option for the physician is surgical resection or lobectomy. The use 
of the SABR technique has provided good results especially to patients who cannot tolerate 
surgical treatment [1]. SABR is an invasive procedure without general anaesthesia, and it is 
fast and convenient for treating lung cancer. It delivers high radiation doses in the range of 8–
20 Gy to targeted tumours in a small number of fractions (five or fewer) [1]. The National 
Cancer Action Team (NCAT) report suggests that “for early NSCLC, the data is sufficiently 
robust for SABR to be recommended as a routine alternative to other forms of non-surgical 
treatment delivered with curative intent” [12]. With SABR, lung tumours are treated with 
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different treatment modalities, such as three-dimensional conformal radiotherapy (3D CRT), 
intensity modulation radiation therapy (IMRT) and volumetric modulated arc therapy 
(VMAT) [13, 14]. These techniques are described in (Chapter 2, Sections 2.2.3.1.1, 2.2.3.1.2 
and 2.2.3.1.3).     
 
SABR in lung treatment has four main stages: 1) patient evaluation; 2) simulation/imaging; 
3) the treatment plan; and 4) treatment delivery. The treatment efficacy of the SABR 
technique is compromised by any weak link in the planning chain process, including 
simulation, the treatment plan and treatment delivery [15]. This thesis is mainly focused on 
improving the last three stages (stage 2 to stage 4) of the SABR technique for treating lung 
cancer. Each stage poses several challenges that have to be mitigated to ensure a smooth 
workflow. In stage 2 (simulation/imaging), the tumour motion compromises the treatment 
plan, affecting the tumour volume delineation. As a result, under-dosing the tumour or over-
dosing normal tissues may occur due to the tumour motion. In stage 3 (the treatment plans), 
dose calculation algorithms play a vital role in calculating the delivered dose to the targeted 
tumour. Lung tissue is characterised by low density, which increase the charged particle 
disequilibrium (CPD) effect. This effect has a significant impact on calculating the radiation 
doses to the targeted volume and surrounding normal tissue. In stage 4 (treatment delivery), 
the patient-specific quality assurance (QA) for the SABR technique is time consuming at 
most radiation therapy centres, as it uses traditional radiochromic films such as EBT3 films 
(Radiochromic films are described in Chapter 3, Section 3.7). Finding and approach to 
minimise the QA time and maintain the efficiency in delivering the doses at the same time is 
needed. More details about these challenges at each stage will be explained below.    
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In stage 2 (simulation/imaging), the patient is immobilised and scanned by imaging modality 
at the same position prior to treatment delivery. The primary imaging modality in the SABR 
technique is through a CT scanner, which displays the anatomical region in three dimensions, 
x, y and z  [16]. Moreover, the CT scanner provides three different windows for viewing: an 
air window, soft-tissue window and dual window. The latter is composed of an air and soft-
tissue window (Figure 2-7) [3]. It is a useful tool to visualise parenchymal diseases, 
pulmonary nodules and chest-wall involvement for superior sulcus tumours in lung cases 
[14]. Because SABR requires an accurate delineation of patient anatomy and the targeted 
volume – especially in lung cases, due to the respiratory motion which cannot be obtained by 
a CT scanner – four-dimensional computed tomography (4D-CT) is widely used in SABR of 
the lung [17]. The 4D-CT system allows physicians to take the tumour motion into account 
when delineating tumour volumes by using external surrogates that are placed on the 
patient’s chest or abdomen, such as bellows or the real-time position management system 
such as RPM (4D-CT is explained in Chapter 2, Section 2.2.2.2) [18].  
 
The 4D-CT system generates a series of CT datasets which relate to different phases of the 
respiratory cycle. The phase of a specific point on the respiratory cycle is defined as the 
percentage of the cycle which has elapsed relative to the origin [2]. The respiratory cycle 
ranges from full inspiration at the start of the cycle (i.e. 0% phase) to full expiration (i.e. 50% 
phase) and back again to full inspiration (i.e. 100% phase) [2]. Generally, 4D-CT images 
represent 10 different respiratory phases from 0% to 90% (Figure 1-1). The main feature in 
4D-CT is the reconstructed dataset images corresponding to the maximal and average CT 
numbers for each voxel in 4D-CT images. The CT number or Hounsfield unit (HU) is 
assigned to different attenuation coefficients in human tissue [2]. In clinical practice, the 
maximum reconstructed CT dataset is known as the maximum intensity projection (MIP) 
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dataset, and the average reconstructed CT dataset is called average intensity projection (AIP). 
In lung, the MIP dataset represents the maximum voxels derived from all phases, and 
represents the full extent of the tumour motion in all respiratory phases [2]. In the treatment 
planning process, the MIP dataset aids in delineating tumour volumes, while the AIP is used 
for dose calculation as it represents the mean density of the voxels from all respiratory phases 
[2].
 
Figure  1-1: The sinusoidal wave (bottom image) shows the 10 respiratory phases for a full 
respiratory cycle including end-inspiration and end-expiration. The dashed lines correlate 
with the respiratory phases from 10% to 60% of their 4D-CT images. The tumour volume 
images (upper images) illustrate the tumour motion during the respiratory process, and the 
range of motion is contoured by the orange coloured contour (see the solid blue arrow at the 
10% phase). At the 10% phase (following the end-inspiration at the 0% phase), the tumour is 
at the top of the orange coloured contour, and gradually it moves down during the respiratory 
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motion until it reaches the bottom of the orange coloured contour at the end of expiration 
(50% phase).        
 
The International Commission on Radiation Units (ICRU) reports 50 (1993), 62 (in 1999) 
and 71 (in 2004) defines target volumes such as Gross tumour volume (GTV), Clinical target 
volume (CTV), Internal target volume (ITV) and Planning target volume (PTV) to ensure that 
a prescription dose is delivered to the targeted tumour [19, 20]. These volumes are delineated 
on the MIP dataset.  
 
As mentioned earlier, the essential characteristic of SABR is the ability to deliver high doses 
in a few fractions. For good treatment results in lung SABR, the PTV should be covered by 
95% of the prescribed dose [21]. The target coverage is determined by a numbers of beam 
parameters such as field size, collimator and gantry angle, energy, prescription depth and 
OARs tolerance that are used in the treatment plan. For example, the PTV must be covered 
by 95% of the prescription dose for a treatment plan of 60 Gy/3 fractions [17]. It has been 
reported that the quality of 4D-CT images is affected by irregular breathing patterns. As a 
result, the MIP dataset may underestimate the actual tumour motion extent, causing 
dosimetric uncertainties to the tumours and surrounding normal tissues [22]. Because the 
MIP dataset is used for delineating the target volumes, it directly affects the delivered doses 
to the PTV due to the intra-fraction or respiratory motion [23]. “It is often thought that the 
use of 4D-CT increases dose to normal lung tissue because of the greater gross tumour 
volume that is contoured” [23]. In this thesis, the dosimetric variation that is caused by the 
tumour motion during the respiratory process is investigated by using 4D-CT images (from 
the MIP and AIP datasets) as follows: 1) clinical study, using retrospective clinical cases of 
lung cancer (15 lung cancer patients) with different tumour sizes to investigate the dosimetric 
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variation between the MIP images and individual respiratory phases (the 10 respiratory 
phases from the 0% phase to the 90% phase); and 2) phantom study, utilising an in-house 
phantom called a custom-designed thorax dynamic phantom to simulate the tumour motion in 
lung cases. It uses material that mimics lung tissue, such as cork. Also, written software 
coded by C++ software [24], to control the phantom motion. This phantom can provide a 
motion in two directions, superior/inferior and anterior/posterior; these motions are recorded 
as dominant tumour movements in lung cancer [25]. Moreover, the phantom is capable of 
integrating PRESAGE 3D dosimeter to quantify the dosimetric variations due to respiratory 
motions.  
 
In stage 3 (treatment planning), the oncologists contour the target volumes and organs at risk 
(OARs) to provide an adequate tumour coverage during the treatment. The contouring 
process is followed by calculating the prescribed dose using algorithms implemented in the 
TPS [1, 2]. The aim of dose calculation algorithms in the TPS is to predict accurate dose 
depositions in tissues. A dose deposition occurs when photons interact with materials and 
release electrons, which deposit the dose inside the tissue (the interaction of photons with 
matter is explained in Chapter 2, Section 2.1.2) [1, 2]. When treating lung cancer with SABR, 
the radiation dose calculation is compromised due to the presence of low-density lung tissue 
surrounding the thoracic tumours. Lower lung density gives rise to higher doses inside the 
lung, and hence there is a possibility of under-dosage in the periphery of the tumour when 
using small fields and high-energy beams. The use of small-beam field sizes in the SABR 
technique with the presence of low density in the lung tissue can lead to exacerbating the 
CPD condition, where the electrons increase significantly [1, 2]. This issue was initially 
discussed by Kornelson and Young ., 1982 [26], who reported the loss of lateral electronic 
equilibrium when a high-energy photon beam crossed the lungs [26]. In this thesis, the 
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accuracy of multiple dose calculation and treatment techniques which are used for treating 
SABR of the lung are investigated. The following types of studies are included:  
1) Phantom study: the utilisation of the Institute of Physical Sciences in Medicine (IPSM) 
phantom to study the accuracy of different dose calculation algorithms by using a small field 
size (relevant to SABR planning) with four different densities: water, lung, ribs and dense 
bone.  
2) Phantom study: the utilisation of the CIRS thorax phantom to evaluate the dose calculation 
by using two retrospective clinical lung studies. 
 3) Clinical study: an investigation of the dosimetric variations and dose calculation accuracy 
of 21 SABR lung cases by using three-dimensional conformal radiotherapy 3D CRT 
techniques.  
4) Clinical study: an investigation of the dosimetric characteristics of three different treatment 
modalities of SABR (3D CRT, IMRT and VMAT). Twelve retrospective clinical cases of 
lung were replanned by these treatment modalities and computed by using two common dose 
calculation algorithms: the anisotropic analytical algorithm (AAA) and the Acuros XB 
algorithm.  
 
Because SABR delivers a high dose in a few fractions, it is essential to provide conformal 
doses to the tumour and a rapid dose fall-off outside the target. Therefore, most radiation 
therapy organisations, such as the American Association of Physics in Medicine AAPM Task 
group 101, recommend parameters to evaluate the dose distribution for SABR planning. 
These parameters are defined as follows [14]: 
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1) Conformity index (CI): The CI is defined as the ratio of PTV to the treated volume and 
demonstrates how well the PTV is covered by the treatment while reducing the dose to 
normal tissue [20]. In this thesis, the dose conformity to the target volume was assessed using 
the CI below [27]:  
 
CI =  𝐓𝐡𝐞 𝐯𝐨𝐥𝐮𝐦𝐞 𝐩𝐞𝐫𝐜𝐞𝐧𝐭𝐚𝐠𝐞 𝐨𝐟 𝐛𝐨𝐝𝐲 𝐫𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐝𝐨𝐬𝐞  
𝐓𝐡𝐞 𝐯𝐨𝐥𝐮𝐦𝐞 𝐩𝐞𝐫𝐜𝐞𝐧𝐭𝐚𝐠𝐞 𝐨𝐟 𝐏𝐓𝐕 𝐫𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐝𝐨𝐬𝐞          ( 1-1) 
 
2) Homogeneity index (HI): The HI is a tool used to analyse the uniformity of dose distribution 
in the target volume. In this thesis, the HI was calculated as follows [28]:  
 
HI =   𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝐝𝐨𝐬𝐞 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐛𝐲 𝟓% 𝐨𝐟  𝐏𝐓𝐕 ( 𝐃𝟓) 
𝐋𝐨𝐰𝐞𝐬𝐭 𝐝𝐨𝐬𝐞 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐛𝐲 𝟗𝟓% 𝐨𝐟 𝐏𝐓𝐕 (𝐃𝟗𝟓)         ( 1-2) 
 
The lower the value of the HI index (close to 1), the better the dose homogeneity [28].  
  
3) Dose fall-off: In the SABR technique, the high doses delivered to the volume of normal tissue 
located outside the target volume should be reduced to limit the risk of treatment toxicity. 
Therefore, the dose fall-off outside the target volume should be sharp [14]. The dose fall-off 
outside the target volume is defined as follows [14]:  
 
Dose fall-off =  The Volume of the 50% prescription isodose 
PTV Volume         ( 1-3) 
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Stage 4 involves delivering treatment, in which the therapist places the patient in the same 
treatment plan position for radiation dose delivery [15]. At this stage, patient-specific QA is a 
vital component in the overall QA of radiation treatment because it provides assurance that 
the delivered dose accurately matches the planned dose distribution. QA, in particular, 
verifies whether the treatment device, such as a linear accelerator (Linac), is physically 
capable of delivering the planned dose distribution and that the patient setup in the treatment 
room matches as closely as possible to the patient setup at the simulation time in stage 2 [29]. 
In SBRT, patient-specific QA becomes more critical because SBRT delivers highly 
conformal and hypofractionated doses. In general, the current SBRT protocols involve three 
to five treatments with a dose of 6–22 Gy per fraction to sites such as the lung, liver and spine 
[30-36]. One of the most common methods to evaluate patient-specific QA is film dosimetry, 
such as that using EBT2/EBT3 radiochromic films. Over the years, this method has been 
developed into a powerful tool for radiation therapy treatment verification and QA [37]. It is 
characterised by high spatial resolution associated with low spectral sensitivity and near 
tissue equivalent [38, 39]. These features make radiochromic film an ideal tool for the 
measurement of dose distribution in regions of high-dose gradients as in SABR. However, 
the post-irradiation scan time is considered the main drawback in radiochromic films. Most of 
the current radiochromic film dosimetry protocols suggest that radiochromic films should be 
scanned at least 8 hours post-irradiation, which is the time assumed to be required for films to 
saturate [38, 39]. In recent years, different ionisation chambers and diode detector arrays, 
such as the ArcCheck phantom (the ArcCheck phantom is explained in Chapter 3, Section 
3.9), have become commercially available. The ArcCheck phantom provides good results for 
pre-treatment absolute dose verification, especially for the VMAT technique, with near real-
time results [40].   
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In this thesis, the feasibility of using ArcCheck phantom (3D information) is investigated as a 
tool for conducting patient-specific QA, particularly for SABR treatment plans of varied sites 
instead of traditional radiochromic films (2D information) by using a global gamma index 
evaluation (the gamma index is explained in Chapter 3, Section 3.10). Twenty-five 
retrospective clinical cases with different diagnosis sites (the lung, spine, sacrum, sternum, 
ribs, scapula and head of the femur or acetabulum) undergoing SABR were selected for this 
study utilising three treatment plans: 3D CRT, IMRT and VMAT.  
 
1.2 Aims of the thesis 
1 Determine the dosimetric changes due to the respiratory process with the MIP-based target 
volume and PTV in SABR of the lung by using retrospective clinical lung cases and in-house 
custom-designed thorax dynamic phantom with PRESAGE 3D dosimeters. 
2 Investigate the accuracy of different dose calculation algorithms applied in the SABR 
technique for lung cancer radiotherapy by using IPSM phantom, CIRS thorax phantom and 
retrospective clinical lung cases.  
3 Investigate the dosimetric variations among three different SABR techniques: coplanar 
VMAT, IMRT and 3D CRT involving non-coplanar beams by using two different 
algorithms: AAA and Acuros XB. This study includes retrospective clinical lung cases. 
4 Introduce a method of patient-specific QA for SABR cases by using the ArcCheck phantom 
to replace the traditional radiochromic films.  
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1.3 Hypotheses  
1. In SABR lung treatment, the current practice of using MIP affects the tumour dosimetry due 
to variations in the structure density and tumour position, which are influenced by patient 
respiration during treatment. 
2. Several dose calculation algorithms have been proposed in radiotherapy centres for SABR 
technique, and the accuracy of these algorithms varies with the treatment site. Lung cancer 
radiotherapy is one area in which most of the current algorithms fail to predict the dose 
precisely. 
3. Different modern SABR treatment techniques, such as VMAT, IMRT and 3DCRT, are 
commercially available and provide varied doses to the tumour target and OARs for lung 
cancer patients.  
4. SABR is one of the most preferred treatment techniques for early stage lung cancer. This 
technique has been extended to other treatment sites, including the spine, scapula and 
sternum, increasing the physical QA time on the treatment machine. 
 
 
1.4 Research Questions 
 
Q1: What are the differences between the MIP-generated target volume and individual phase-
based target volume in terms of volume sizes and delivered doses (mean and maximum 
doses) to the lung tumour volume in the SABR technique? 
Q2: Can a 3D dosimeter, such as PRESAGE, be used to evaluate the dose uncertainty 
associated with tumour movement in the lung SABR technique? 
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Q3: How good are the current dose calculation algorithms used in lung SABR in terms of 
accuracy for a wide range of clinically relevant densities? 
Q 4: What are the dosimetric variations among the three treatment modalities of lung SABR: 
3D CRT, IMRT and VMAT.  
Q5: Can the pre-treatment or patient-specific QA time of SABR techniques be reduced 
without compromising the dose accuracy.  
 
1.5 Outcomes/benefits 
1. Evaluate a method for treatment planning named phase specific planning method that can 
provide a tight GTV to PTV volumes which could spare the normal surrounding tissues in the 
SABR technique. Also, it avoids missing the target by tracking the target in each respiratory 
phase. 
 
2. Design and develop a custom-designed thorax dynamic phantom which can be used in 
dosimetric measurement for lung cases in radiation therapy. The phantom can 1) simulate the 
patient respiratory motion in two directions (A/P and S/I). 2). It is characterised by a special 
holder that can integrate a 3D dosimeter (e.g. PRESAGE). 3) It is controlled by software 
utilising a well-known coding programme (e.g. C++) with an option to edit/add more codes 
in the future. 4) It is characterised by an aluminium bar to place the bellows for detecting 
respiratory signals.    
   
3. Quantify the dosimetric variations due to simulated respiratory motions by using a 
PRESAGE 3D dosimeter in the SABR technique.  
19 
 
4. Evaluate the performance of different dose calculation algorithms in varied-density media, 
such as water, lungs, ribs and dense bone, in the SABR technique. 
 
5. Identify the most accurate dose calculation algorithms which provide better computation, 
especially in heterogeneous media, such as lung density material, and in clinical lung cases in 
the SABR technique.  
 
6. Quantify the dosimetric variations among three treatment modalities in the SABR technique 
(3D CRT, IMRT and VMAT).  
 
7. Introduce a method for patient-specific QA for SABR technique that can provide a shorter 
QA time period compared with the traditional radiochromic films in the radiation therapy 
department. 
 
1.6 Final outcome 
Our expectation/aims from this project are to enhance the efficiency of delivering an accurate 
dose to the tumour volume in SABR lung cases by 1) quantifying the dosimetric variation of 
lung tumours due to respiratory motion, 2) determining the most accurate dose calculation 
and the appropriate SABR techniques (e.g. 3D CRT, IMRT and VMAT) that are used for 
lung cancers treatment, and 3) increasing the efficiency of patient-specific QA in SABR lung 
treatment.  
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1.7 Outline of the thesis 
This thesis is divided into 10 chapters; Chapters 4–9 represent the experimental work in this 
thesis, which are ordered according to the treatment stages of lung SABR. A description of 
each chapter is as follows: 
 
Chapter 2 mainly contains a review of the physics of radiation therapy, including X-ray and 
gamma ray production and the most common photon interactions with matter which may 
occur in radiation therapy. The treatment of lung cancer by the SABR technique is explained, 
and the four main stages in the SABR treatment process, particularly in lung cases, are also 
described. Each stage of the SABR technique demonstrates a specific detail related to lung 
SABR. For instance, the 4D-CT modality that has been used in tracking the tumour motion is 
described in stage 2. In stage 3, the modern treatment modalities (e.g. 3D CRT, IMRT and 
VMAT) that have been used in treating lung cases using the SABR technique are outlined. 
Also, in the same stage, the most common plan evaluation parameters (CI, HI and dose fall-
off) that help in assessing treatment plans and dose calculation algorithms for the SABR 
technique are delineated. Moreover, this chapter illustrates the most common dose calculation 
algorithms that are commercially available in the TPS and indicates the calculation concept 
behind each type. In stage 4, the Linac components are illustrated, and the vital parts in 
shaping the beams (e.g. jaws and MLCs) are defined. The QA of radiation therapy is 
explained at the end of the chapter.                    
 
Chapter 3 provides general information about the main materials and methods used in this 
thesis. It contains a description of the five phantoms that were used in this thesis: 1) the in-
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house phantom (i.e. a custom-designed thorax dynamic phantom with written codes) to 
simulate the tumour motion and investigate the dosimetric variations in SABR of lung cases 
(used for Chapter 5); 2) IPSM phantom and 3) CIRS thorax phantom, used to study the dose 
calculation algorithms in SABR lung cases (used for Chapters 6 and 7); 4) rod phantom; and 
5) ArcCheck phantom, used to investigate the feasibility of using the ArcCheck phantom to 
replace traditional radiochromic films (used for Chapter 9). Moreover, the chapter includes an 
explanation of dosimetric tools, such as radiochromic films and the PRESAGE dosimeters, 
and useful analysis software, such as QA film Pro and PolyGevero®, used to read 
radiochromic film and PRESAGE dosimeter data. Also, the methods that were used in this 
thesis, such as gamma index, film calibration and optical CT scanning, are detailed. The 
materials and methods sections in Chapters 4–9 contain specific details related to the 
individual experiments.  
 
Chapter 4 includes an assessment of tumour volumes (GTV and PTV) and the dosimetric 
variation (mean and maximum doses) between the current practice of the MIP based planning 
(conventional method) and the phase specific planning method using a 4D-CT dataset in 
SABR lung tumours. Fifteen patients who underwent lung SABR using the 3D CRT 
technique were used in this study. This SABR protocol for lung cancer utilising the 3D CRT 
technique is also outlined. The SABR protocol of 3D CRT was used in most of the thesis’ 
chapters (Chapter 4, 5, 7, 8 and 9).   
 
In Chapter 5, the dosimetric impact of organ motions is investigated in three SABR 
techniques (i.e. 3D CRT, IMRT and VMAT). The tumour motion was simulated by using the 
in-house custom-designed thorax dynamic phantom. Special codes were written and 
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developed to control the phantom motion (Appendix X). The developed software is called 
real position management (RPM). Moreover, PRESAGE 3D dosimeters were used to 
demonstrate the dose distribution in the three SABR lung techniques and to quantify the 
dosimetric variations in two conditions: static and dynamic.   
 
In Chapter 6, the accuracy of varied dose calculation algorithms namely pencil beam 
convolution (PBC); Acuros XB; anisotropic analytical algorithm (AAA), implemented in an 
Eclipse-TPS; collapsed cone convolution (CCC), implemented in Mobius3D; and 
superposition, implemented in the XiO-TPS are evaluated using a phantom designed by the 
IPSM Radiotherapy Topic Group [41]. The IPSM phantom consists of six removable water-
equivalent rods (3 cm in diameter) that can be substituted by ion chamber (IC). Also, four 
different densities-inserts media are provided: lung (low density), water equivalent, rib and 
dense bone (high density). Initially, the absolute dose is measured for a specific point by the 
IC using different beam configurations, such as the small fields used in the SABR technique 
and the different densities-inserts in the IPSM phantom technique. Then these measurements 
are recalculated using the five algorithms with the same condition as the IPSM phantom 
measurements (beam configurations and densities-inserts). The calculated points from the 
dose calculation algorithms in the TPS are then validated against the measurements by the IC.     
 
Chapter 7 continues the investigation of different dose calculation algorithms. In this chapter, 
21 retrospective clinical cases of lung SABR are utilised to quantify the dosimetric variations 
in the field of lung cancer radiotherapy utilising seven dose calculation algorithms in two 
different TPS systems: 1) the XiO-TPS, which includes superposition, fast superposition, fast 
Fourier transform (FFT) convolution and Clarkson algorithms, and 2) the Eclipse-TPS, which 
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includes AAA, PBC and Acuros XB algorithms. Two methods are applied to evaluate the 
dose calculation performances as follows: the same dose coverage to the target volume and 
the same monitor unit method. Moreover, a comparison among the different algorithms is 
achieved by utilising different dosimetric parameters, such as CI, HI, dose fall-off, V5, V20 
for the right, left and whole lung, and the maximum dose received by the OARs (heart, 
oesophagus and spinal cord). Followed by the clinical lung SABR cases, the accuracy of four 
dose calculation (Superposition, AAA, PBC and Acuros XB) are also investigated using a 
CIRS thorax phantom with IC. The calculated points from the dose calculation algorithms in 
the TPS are validated against the measurements by the IC. 
 
Chapter 8 includes an investigation of the dosimetric characteristics of three SABR 
techniques using two widely used dose calculation algorithms [42]: AAA and Acuros XB. 
The three SABR techniques include coplanar volumetrically modulated arc therapy (C-
VMAT), non-coplanar intensity modulated radiation therapy (NC-IMRT) and non-coplanar 
three-dimensional (3D) conformal radiotherapy (NC-3D CRT). The dosimetric study 
includes 12 retrospective clinical lung cases, and the following dosimetric indices are used to 
compare the treatment plans: CI, HI and dose fall-off. Moreover, the maximum dose and the 
dose received by the OARs are recorded for the heart, oesophagus and spinal cord. In 
addition, the percentage volume of the right, left and whole lung receiving 5 Gy (V5) and 20 
Gy (V20) are recorded for all studied cases. The right lung V5 and V20 are calculated for 
right lung tumours, and the left lung V5 and V20 are calculated for left lung tumours.  
 
In Chapter 9, the feasibility of using ArcCheck was evaluated as an alternative method to 
replace the traditional radiochromic film for patient-specific QA in SABR cases. Twenty-five 
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patients with varied diagnoses of lung, spine, sacrum, sternum, ribs, scapula and femur 
cancers undergoing SABR were selected for this study. Patient-specific QAs are performed 
for all the patients using two methods: EBT3 film dosimetry and ArcCheck phantom. The 
results of both methods are analysed using a global gamma index analysis. The planned and 
measured doses from the ArcCheck device and EBT3 films are compared using four different 
gamma criteria: 2%/2 mm, 3%/2 mm, 3%/1 mm and 3%/3 mm.  
 
Chapter 10 contains a summary of the conclusions and the findings of the thesis for all 
chapters.  
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Chapter 2 reviews the physics of 
radiation therapy and the stages of 
SABR of lung cancer treatment   
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Chapter 2 Literature Review  
Intracranial stereotactic radiosurgery (SRS) was introduced in the twentieth century as a 
novel method for treating brain tumours that can deliver tight spatial or temporal dose 
distribution utilising a high precision technique [43]. The stereotactic ablative radiotherapy 
(SABR) technique originates from the combination of the clinical experience obtained from 
the SRS and the technical development of conventional radiotherapy. The underlying 
principle behind SABR is the delivery of a very high dose per fraction in a short time for 
extracranial tumours [43]. This technique was initially developed at the Swedish Karolinska 
University Hospital in 1991 by Bromgren and Lax and was targeted for liver and lungs 
tumours [6, 44, 45]. This technique was also developed in Japan and used clinically for lung 
tumours in 1994 [8, 46, 47]. From 1994 to 1999, SABR was introduced in different centres 
worldwide in the USA, Europe and Japan [43]. The early clinical results using the SABR 
technique for lung cancer was reported by Wulf and Herfarth (2001) in Germany [48] 
followed by Timmerman (2003) in the USA [49]. These reports exhibit very promising 
results in terms of local control and toxicity for the hypo-fractionations which were 
associated with a dose prescription of 10-15 Gy/fraction given in 3-5 fractions over a short 
period [43]. The term stereotactic body radiation therapy (SBRT) was introduced by 
Timmerman in 2002. In Europe in the late 1990s, the SBRT technique was called extracranial 
stereotactic radiation therapy (ESRT) [43]. By 2010, a new term for the SBRT technique was 
introduced by Loo et al., 2011 [50], stereotactic ablative radiotherapy (SABR). Currently, 
SABR and SBRT are the most common terms used to describe this new technique [43].         
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This chapter will review the physics of radiation therapy and will also explain the different 
stages involved in the SABR technique: 1) patient history; 2) simulation/Imaging; 3) 
treatment planning and 4) treatment delivery. This chapter will discuss each stage of the 
SABR technique in detail, including the main core techniques/modalities that are described in 
this thesis: 1) four dimensional computed tomography (4D-CT); 2) modern treatment plans 
used in SABR, such as three dimensional conformal radiation therapy (3D CRT), intensity 
modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT); 3) 
types of dose calculation algorithms with examples of commercially available algorithms, 
such as Acuros XB, and superposition algorithms used in the treatment planning systems 
(TPS) in most radiation therapy centres and 4) the linear accelerator (Linac) system for 
delivering radiation doses.  
 
2.1 Physics of radiation therapy  
The radiation utilised in radiotherapy includes gamma rays and high-energy X-rays; both are 
types of electromagnetic waves [43]. Electromagnetic waves have properties of waves and 
particles. The radiation energy in radiotherapy is expressed by units of MeV and the energy 
of electromagnetic waves (E) is expressed by the following equation [43]:  
 
E[MeV] = h. ʋ = 𝒉 .𝒄
𝝀
  ≈ 𝟒.𝟏𝟒 𝒙 𝟏𝟎−𝟐𝟏 . ʋ [ 𝒔−𝟏] ≈ 𝟏.𝟐𝟒 𝒙 𝟏𝟎−𝟏𝟐 𝝀(𝒎)   ( 2-1) 
where (h) is Planck’s constant, 𝜆 is wavelength, ʋ is frequency and c is speed of light [43].  
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2.1.1 X-ray and gamma ray production  
There are two varied mechanisms of X-ray production: 1) characteristic X-rays and 2) 
bremsstrahlung X-rays (braking radiation) [2]. X-rays are released in the form of 
electromagnetic waves from outside of the nucleus, which occurs when matter, such as 
tungsten, is irradiated with incident charged particles (Figure 2-1). Gamma rays are also 
released in the form of electromagnetic waves, but from the nucleus (Figure 2-1) [43]. A 
bremsstrahlung X-ray is generated when the direction of incident charged particle (electron) 
is deflected by the Coulomb force of the nucleus (Figure 2-1). The characteristic X-rays are 
electromagnetic radiation with a specific energy [43]. They are produced by the transition of 
the outer-shell electron to the inner-shell electron vacancy which is generated by the emission 
of the inner-shell electron (Figure 2-1)[43]. Because the emission of X-rays are produced 
from the electron transition from specific shells or orbits, such as the K-shell and L-shell 
associated with certain energy, it is known as characteristic X-ray [2](Figure 2-2).          
 
 
Figure  2-1: Release of characteristic X-rays, bremsstrahlung X-rays and gamma rays [43].  
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2.1.2 Interactions of photons with matter 
The interaction of photons with matter relies on the photons’ energy [43]. In radiation 
therapy, it is essential that transfer of the energy to the tumours is from charged particles like 
electrons. Thus, the most important interactions of photons with matter in radiation therapy 
are described in the following sections [43].      
 
2.1.2.1 Photoelectric effect 
In this phenomenon, the incident photon is absorbed entirely by an atom. As a result, one of 
its orbital electrons is ejected which is known as photoelectron (Figure 2-2) [2]. The kinetic 
energy of the ejected electron is calculated by hʋ −  𝐸𝐵 where 𝐸𝐵: is the binding energy of 
the electron. The photoelectric effect occurs with electrons in the K, L and M orbits (Figure 
2-2). The atom transit to the excited state because of the ejected electron and creates a 
vacancy in the orbit [2]. In this case, the characteristic X-rays may occur when the vacancy is 
occupied by an outer orbital electron. Moreover, the emission of Auger electrons may occur 
when the outer electron filling the vacancy is provided to another electron in a higher orbit 
(Figure 2-2). The binding energy of the K-shell for soft tissue is about 0.5 keV, and, hence, 
the characteristic photons generated in the biologic absorber are very low. The photoelectric 
effect mainly depends on the atomic number of the absorbing material [2].      
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Figure  2-2: Process of the photoelectric effect [2].  
 
 
2.1.2.2 Compton scattering  
The incident photon interacts with an electron of the atom; this electron (free electron) has a 
binding energy less than the energy of the bombarding photon. The photon transfers some of 
its energy to the electron; then, the electron is emitted at angle θ, and the photon with the 
decreased energy is scattered at an angle ɸ (Figure 2- 3) [2]. The electron gains some energy 
from the bombarded photons and travels with this energy as its kinetic energy while the 
scattered photon loses energy. The analysis of the Compton process, in terms of a collision 
between two particles (electron and photon), can be explained by applying the laws of 
conservation of energy and momentum as follows [43]: 
    
             𝑬 = 𝑬𝒊𝒏
𝟏+ 𝜸 .(𝟏−𝐜𝐨𝐬𝜽)  ,           𝑬𝒆 = 𝟐 .𝜸 .𝒄𝒐𝒔𝟐 ɸ(𝟏+𝜸)𝟐− 𝜸𝟐.𝒄𝒐𝒔𝟐ɸ                ( 2-2) 
Cot(𝜃
2
) = (1+ γ). tan ɸ      and γ = 𝐸𝑖𝑛
𝑚𝑒.𝐶2 , 
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Where 𝐸𝑖𝑛 = energy of incident photon, E = energy of scattered photon, θ = scattering angle 
of scattered photon, 𝐸𝑒 = energy of recoil electron and ɸ = scattering angle of recoil electron. 
The quantity of 𝑚𝑒.𝑐2 ≈ 0.511 [MeV] is the rest of the mass energy of an electron. The 
Compton scattering provides the maximum energy to a recoil electron when the scattering 
angle of the recoil electron is ɸ = 0. The Compton edge is a term that describes the edge of 
the energy spectrum of a recoil electron with the maximum recoil energy [43].      
 
 
Figure  2-3: Process of Compton scattering effect [2]. 
 
 
2.1.2.3 Pair production  
The pair production process may occur when the photon energy that interacts with matter is 
greater than 1.02 MeV, and this energy is considered as threshold energy to create the pair 
production [2]. When the photon with high energy interacts with electromagnetic field of an 
atomic nucleus, all the photon energy is used to generate a pair consisting of a positive 
electron (𝑒+) or positron and a s negative electron (𝑒−) (Figure 2-4) [2]. The photon energy 
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excess to the threshold energy (1.02 MeV) is distributed between the two particles ( 𝑒+ and 
𝑒−) as kinetic energy [2]. The total kinetic energy of the electron and positron that results 
from the pair production process can be expressed as follows [43]: 
 
𝑬+ + 𝑬− = 𝑬𝒊𝒏 – 2 . 𝒎𝒆 . 𝒄𝟐 = 𝑬𝒊𝒏 − 𝟏.𝟎𝟐𝟐[𝑴𝒆𝑽]               ( 2-3) 
 
Where 𝐸+ is the kinetic energy of a positron, 𝐸− is the kinetic energy of an electron and the 
quantity of 𝑚𝑒 . 𝑐2 ≈ 0.511 [MeV] is the rest of mass energy of an electron [43]. When the 
energy of the incident photon is low, the kinetic energy is divided equally between the 
electron and the positron, while the energy division is unequal between the two particles 
when the energy of the incident photon is high [43]. The probability of the pair production 
process increases with the atomic number (Z) [2].     
 
 
Figure  2-4: Process of pair production [2]. 
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2.2 Lung cancer and Stereotactic Ablative 
Radiotherapy (SABR) 
Lung cancer is a disease that is described as the uncontrolled growth of cells in the lung. The 
main causes of lung cancer are smoking and air pollution. Imaging modalities, such as X-rays 
and computed tomography (CT) are commonly used in diagnostic radiology departments to 
assess the location and size of the lung lesions [51]. Treatment of lung cancer includes 
surgery, radiation therapy, immunotherapy and chemotherapy. These modalities are used 
either alone or in combination, and they depend on the stage or type of cancer and on the 
general health of the patient [51]. In addition to these techniques, there are blood tests that 
can detect proteins that may indicate disease, such as the presence of cytokeratin in the blood 
or the abnormal fluctuation of parathormone in the serum levels. Lung cancer has a reduced 
prognosis compared to other types of cancer because most cases are diagnosed after the 
metastasis has spread from its original site [51].    
 
There are two types of lung cancer cells: small-cell lung cancer cells, which account for about 
10%-20% of all cancer cases, and non-small-cell lung carcinoma (NSCLC), which account 
for the rest of lung cancer cases [51]. Small-cell lung cancer, or oat-cell carcinoma, is rarely 
found in people who have never smoked, and the cells are small, round or oval (shaped like 
oat grains). This type of lung cancer is extremely aggressive as it tends to spread quickly 
before the symptoms are recognised; the survival rate is very low. There are three types of 
NSCLC: squamous cell carcinoma, adenocarcinoma and large cell carcinoma [51]. 
Adenocarcinoma is the most common type of non-small-cell lung cancer, representing 40% 
of cases worldwide. They are columnar or cube-shaped, and they generate a structure that 
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resemble glands or are hollow. Tumours are often produced in smaller peripheral bronchi, 
and the symptoms are determined by the invasion of the lymph nodes and lungs or metastasis 
to other organs [51]. From 25% to 30% of primary lung cancers are squamous cell 
carcinomas or epidermoid carcinomas. They develop in the larger bronchi of the central 
portion of the lung, and they are scale-like cells. They are more responsive to treatment 
because they tend to remain localised longer than the other types of cancers. The last type of 
non-small cell carcinoma, or large cell carcinoma, represents 10% of lung cancer cases, tends 
to grow very quickly and emerges in any part of the lung [51].  
 
The treatment of lung cancer includes surgery, radiation therapy and chemotherapy. The 
treatment options depend on the stage or type of cancer and on the general health of the 
patient. In the surgery option, the cancerous segment is removed (segmentectomy), the whole 
lung is removed (pneumonectomy) or the lung lobe is removed (lobectomy) [51]. There can 
be complications from the surgery, such as bleeding or pneumonia. Therefore, radiation 
therapy is also used for treatment and produces good results. It can be used before surgery to 
shrink the tumours or after surgery to destroy a small number of cancerous cells. The 
chemotherapy method uses chemicals to destroy cancer cells, but it can affect normal tissues 
[51]. Recently, SABR has become more popular in the treatment of patients with lung cancer 
[52, 53].  
 
The SABR technique, also known as SBRT, is a non-invasive technique used to treat small 
and localised NSCLC instead of surgery [2]. In this thesis, the SABR and SBRT 
abbreviations will be used regularly with both representing the same technique. This 
technique is suitable for lung cancer treatment as it focuses the radiation therapy while 
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sparing the normal tissues and increases the chances of controlling the tumours [2]. This is 
achieved by a smaller radiation field and higher doses of radiation per fraction (6 to 30 Gy) 
that are delivered in a small number of fractions, generally equal to or fewer than five 
fractions [2]. The number of sessions is quite low compared to conventional radiotherapy, 
which consists of about 20 sessions over four weeks [2]. Also, SBRT can be distinguished 
from conventional radiotherapy by various features: 1) an increase in the number of beams 
used in the treatment, 2) the frequent use of non-coplanar beam arrangements and 3) the use 
of dose-painting techniques, such as intensity modulated radiation therapy (IMRT) and 
inhomogeneous dose distributions  [14]. However, the SABR technique causes a high 
biological effective dose (BED) because it delivers large doses in fewer fractions. It is 
essential to provide conformal high doses to the target volume with rapid fall-off doses away 
from the targeted volume in order to reduce normal tissue toxicity  [14]. Therefore, the 
practice of SABR requires a high level of accuracy over the entire treatment process. This 
includes the simulation process of the patient position, effective treatment planning and beam 
delivery [14]. The entire SABR technique process is illustrated in Figure 2-5 [15].  
            
Figure  2-5: Process flow of the SABR in radiation therapy [15].  
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 Patient Evaluation  
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2.2.1 Stage 1: Patient evaluation  
The patient assessment includes a review of diagnostic imaging, knowledge of the patient 
history, physical examination and laboratory tests. Based on these evaluations, the 
oncologists can determine the appropriate treatment modality [15]. Most of the patients who 
are treated with the SBRT technique are those with spinal, liver and lung tumours. The 
eligibility to treat the tumours with SBRT is limited to well-circumscribed tumours that have 
a maximum cross-sectional diameter of 5 cm [14]. However, some radiation therapy centres 
suggest that SBRT can be utilised for tumours ≤ 7 cm [54-56].  
 
2.2.2 Stage 2: Simulation/Imaging  
In this stage, the patient is immobilised and imaged in the same treatment position. The 
immobilisation devices should be comfortable and able to hold the patient in a treatment 
position for the entire SBRT session (up to one hour) [15]. Typical immobilisation devices 
are composed of extended head and neck masks or a custom-moulded cradle. These devices 
provide good correlation between the treatment machine and the targeted volume geometry 
and help in the treatment planning process and the patient setup during the treatment [15].  
 
Stereotactic body radiotherapy (SBRT) needs accurate delineation of patient anatomy, 
targeted volume and good visualisation and localisation during treatment delivery [14]. The 
data sets of three-dimensional (3D) images are acquired using different imaging modalities, 
such as CT/4D-CT to visualise the targeted area and the anatomical structures [14]. CT 
scanners are the main imaging modality for the SBRT technique when treating lung cancers 
and form the basis for many treatment planning calculations, such as those for spine and liver 
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cancer. In lung cancers, the CT can identify parenchymal diseases, pulmonary nodules and 
chest-wall involvement for superior sulcus tumours [14]. Moreover, lung tumours have 
motion due to the respiration process, and it is essential to image the target volume over the 
entire respiratory cycle. Therefore, 4D-CT imaging can be used to correlate the respiratory 
motion with the obtained CT images [15].  
 
2.2.2.1 Computed tomography (CT) 
The CT scanner is composed of a rotating X-ray tube that moves around the patient’s body 
[3]. A panel of detectors is opposing the X-ray tube, and these detectors measure the radiation 
amount exiting the patient’s body (Figure 2-6). To obtain a whole volume, multiple 
acquisitions must be performed with a short table motion in between [3]. The transmission of 
X-rays passes through different tissues, such as soft tissue, bone and air-filled cavities are 
measured and recorded during the CT rotations. Several measurements of X-ray transmission 
are obtained from varied angles of the X-ray source; then, detectors facilitate the computation 
and representation of different tissue densities inside the patient [3]. The human tissue 
represents different attenuation coefficient (µtissue) due to differing effective atomic number. 
In practice, CT number or Hounsfield units (HU) are used instead of µtissue, where HU is 
defined by [57]: 
HU = 1000 . µ 𝒕𝒊𝒔𝒔𝒖𝒆− µ 𝒘𝒂𝒕𝒆𝒓
µ 𝒘𝒂𝒕𝒆𝒓                 (  2-4) 
 
In 1989, a major step forward in CT technology was the introduction of helical or spiral CT 
[57]. The technique of slice-by-slice was replaced by volume scanning (Figure 2-6). In 
helical technique, the fan beam is continuously rotating around the patient and the patient 
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moves at constant speed along his/her body axis (the z-axis) through the gantry. This results 
in a helical track of the focal spot around the patient [57].      
 
Figure  2-6: Principle of helical CT scanners [57].  
 
For thorax cases, the CT scanner provides three different windows for viewing (Figure 2-7) 
[3]. By changing the image contrast through electronic manipulation of the CT data, the 
digital images can be processed to enhance, modify or supress some of their features. This is 
very useful when it is difficult to visualise lung details and, at the same time, evaluate the 
anatomy around the mediastinum or heart [3].     
 
Figure  2-7: Different window levels provided by CT scanner for the thorax. The left image is 
the air window, the middle image is the soft tissue window and the right image is a dual 
range that combines the two previous windows [3]. 
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2.2.2.2 Four dimensional computed tomography (4D-CT)  
Three dimensional CT refers to x, y and z axes; whereas four dimensional CT adds a time 
component to the three dimensional axes. The efficiency in detecting tumour motion 
trajectory in conventional CT scans decreases over a single breath period [16]. This causes 
artefacts which lead to blurring in the CT images, or mimic the shape of diseases or tumours. 
The main advantage of 4D-CT is that the breathing-related artefacts can be minimised. This 
is due to the acquisition process of the CT machine which takes into consideration a complete 
respiratory cycle by applying the function of breathing phase  [16]. As a result, the target or 
tumour can be imaged with high accuracy in terms of its location and volume. Data obtained 
from 4D-CT can be used to illustrate the correct position of the tumours [16]. In most 
radiotherapy departments, 4D-CT has become dominant in planning the treatment of lung 
cancer tumours. This technique provides better temporal and spatial accuracy and excellent 
dose calculation [58].  
 
2.2.2.3 Formation of four dimensional computed tomography 
(4D-CT) images 
This technique is called respiratory correlated CT, and it enables the collection of 
comprehensive temporal information, such as 3D spatial information. This information can 
be used in treatment planning and then in delivering the radiation dosages [59]. The 4D-CT 
data set includes breath-hold methods, using separate gates, and blurred or average images 
derived from slow CT [60]. In order to correlate the respiratory cycle with the acquisition of 
CT slice data, 4D-CT technology uses external surrogates, such as the pneumatic belt 
(bellows) and the real-time position management (RPM) respiratory gating system (Figure 2-
8) [25]. Applying the retrospective and prospective protocol in 4D-CT simulation can be 
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utilised to reconcile the spatial aspects and capture temporal information. The result of this 
protocol is the collection of a signal data set which represents the spatial information for one 
phase of the respiratory cycle [60]. The prospective gated-CT acquisition method is 
considered time-resolved 3D-CT imaging and is classified as 4D-CT. However, this method 
provides less optimal information on the target, and the data is acquired from one preselected 
breathing cycle window [60]. The retrospective acquisition method generates multiple 3D 
data sets and gains spatial imaging at multiple phases of the breathing cycle. This method of 
acquiring the data continuously during periodic motion utilises a very low pitch helical or an 
axial cine scanning mode [60].  
 
Figure  2-8: Overhead and side views of the pneumatic belt (bellows) (red arrow) and the 
RPM system (blue arrow) [25]. 
 
2.2.2.4 Image acquisition of 4D-CT 
The patient on the CT table must be immobilised perfectly for conventional simulated 
techniques. A device is placed in contact with the patient, and monitors the anterior and 
posterior motion of an external surrogate of the respiratory cycle [60]. Also, the technologist 
can use the same device that measures respiratory volume to produce respiratory cycle data. 
Commercial software can depict information about the length of the breathing period and 
41 
 
hence can be used in CT scan parameters. For analysing 4D-CT images using the 
retrospective method, the cine CT scan is started during free breathing; that is, several 
rotations of CT image acquisition are performed at individual couch locations for a time 
equivalent to the maximum monitored respiratory cycle added to the time required for one 
full CT tube rotation [60]. Therefore, multiple images of specific body parts are acquired at 
different times during the breathing cycle; these are completed before starting the next 
scanning slice. This process is repeated until the longitudinal section of interest is covered. 
The X-ray source is turned off between table positions. The phase and amplitude information 
is collected and measured by markers during image acquisition. This information is 
correlated to the respiration and temporal stamp from the CT scanner and indicates if the 
image is actively being acquired, for example, when the beam is on or when the beam is off 
[60]. After completing scanning, the respiratory signal information is processed. This is 
achieved by taking the sequentially and temporarily acquired reconstructed CT slice data and 
matching every slice datum with the closest corresponding phase of the acquired respiratory 
cycle [60]. The slices are classified according to the phases of the respiratory cycle. As the 
acquisition of the desired part is completed, several sets of slices are generated, such as end 
inspiration, end expiration and other phases in between (Figure 2-9) [60]. The whole 
breathing cycle consists of ten phases, so the total breathing period is divided by 1/10th [59]. 
For example, a breathing cycle of 6 seconds is sampled by 0.6 of a second. The end 
expiration is about 50% to 60% of the breathing period after inspiration, and when inspiration 
ends, it is 0% of the breathing cycle [59].  
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Figure  2-9: The sorting of 4D-CT data which illustrates the retrospective process [60].  
         
2.2.2.5 Maximum intensity projection and average intensity 
projection  
This technique is available in 4D-CT to display the voxels with maximum intensity 
projection (MIP) along the viewing ray. MIP does not need a complex transfer function; 
hence, it provides simplicity in usage [61, 62]. To determine the colour or the values of 
corresponding pixels, it utilises the maximum intensity along the viewing ray (Figure 2-10). 
Therefore, it has a great value in the medical field, for example, in the delineation of tumour 
volume during respiratory movement in lung cancer or in the extraction of vascular structures 
[61, 62]. In CT modality, the high density voxels of CT number or Hounsfield unit through 
10 data sets of CT images generate the MIP, while the average of voxels creates the average 
intensity projection (AIP) (Figure 2-11) [61, 62]. According to Tian et al., 2012 [18] , MIP is 
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suitable for tumour delineation, while AIP is useful in dose calculations. This is because the 
AIP images’ data represents the true density values that appear during the treatment [63].       
 
Figure  2-10: The diagram illustrates one of the reconstruction methods in displaying 
reformatted and 3D images. It is intended to highlight great attenuation structure, for 
example, contrast material-enhanced vasculature and bone [64].  
 
Figure  2-11: Comparison of MIP, AIP and individual respiratory phase (end of exhalation). 
A) Coronal plan of MIP images series. B) Coronal plan of AIP image series. C) End of 
exhalation image in coronal plan. The red coloured contour represents the internal target 
volume (ITV) [1].        
A B C 
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2.2.2.6 Dosimetric impact of respiratory motion and tumour 
margins  
International Commission on Radiation Unit (ICRU reports 50 and 62) recommends several 
treatment volumes or margins for treatment plan and can be described as follows (Figure 2-
12) [65]:  
1. Gross tumour volume (GTV) 
GTV is the gross palpable or visible extent and location of malignant growth [65]. 
2. Clinical target volume (CTV) 
CTV is a tissue volume that contains the GTV and sub-clinical microscopic malignant 
disease. The GTV and CTV are often considered to be identical [14]. 
3. Internal target volume (ITV) 
ITV is designed to take into account the changes in the size, shape and position of the CTV 
during treatment. This volume considers the volume of the target movement due to 
respiration [65]. 
4. Planning target volume (PTV) 
PTV is a geometrical concept and it is defined to select appropriate beam arrangement. This 
volume is designed to ensure the prescribed dose is absorbed in the CTV. Typical SABR 
margins for defining the minimal distance separating the PTV and CTV are 0.5 cm in the 
axial planes and 1 cm in the inferior/superior directions [14].   
 
According to the International Commission on Radiation Unit (ICRU 62), the margins of ITV 
are considered as an expansion of clinical target volume (CTV), and this will help in 
detecting variations in the size or shape of the target in relation to the anatomical structure 
[60]. The ITV represents the tumour measurements extracted from empirical margin 
45 
 
calculation [60]. It is difficult to determine the magnitude of tumour margins with the 
absence of respiratory-correlated CT-based treatment planning. As a result, inappropriate 
coverage of the clinical target may occur or expose healthy tissue to unnecessarily high doses 
[66]. It is vital to provide perfect coverage of the ITV margins to avoid exposing normal 
tissue to high radiation doses when planning for patient treatment. To optimise the clinical 
outcomes, a simulation system can predict the consequences and delete temporal 
miscorrelation, particularly for patients with large respiratory motion [66]. Consequential 
deviation from desired coverage can be prevented by conventional 1-2 cm of 2D gross 
tumour volume (GTV), and planning tumour volume (PTV) margins associated with normal 
breathing [67, 68]. However, patients with irregularly shaped tumours or with large 
respiratory motions are more vulnerable to the delivery of inaccurate dosages to the target 
volume [67, 68]. In fact, there are significant limitations for lung tumour coverage using 
CTV, GTV or PTV. This is found in SABR when applying an expansion by 0.5 cm axially 
and 0.5-1 cm longitudinally to the target volume margins [69]. Normal tissue can be 
irradiated when using standard margins which are not based on respiratory correlated 
imaging, especially when the time average is less than predicted for the tumour motion 
estimation [70]. Therefore, the potential for dose escalation for the patients highlight the 
importance of appropriate margins determination i.e. target volume, and this data must be 
based on respiratory correlation using 4D-CT [60]. 
  
2.2.2.7 Planning target volume (PTV) generation 
The 4D-CT can minimise the uncertainty associated with thoracic delineation and enhance 
the generation of GTV when compared to helical CT scanning  [68]. The target volumes are 
created by manual contouring on several phase data sets or by fast segmentation using mid-
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ventilation synthetic targets such as MIP. In general, it can capture approximate internal 
motion which can be used in representing ITV [68]. Rietzel et al., 2015 [59] suggests that 
PTV generation can provide safety margins to the CTV or GTV reflecting internal and setup 
uncertainty margin added in quadrature [59]. Alternatively, the ITV can be expanded with 
margins representing measured setup data for a given treatment or immobilisation system 
[71, 72]. Image guided radiation therapy (IGRT) is considered the best method for collecting 
inter-fractional and intra-fractional uncertainty data [73]. A 4D-CT can provide 
individualised and quantitative data of internal tissue, and this can be used in identifying the 
uncertainty result from targets affected by physiological motion [60].          
 
Figure  2-12: Schematic diagram demonstrates different volumes of tumours to be included in 
the treatment planning system recommended by the (ICRU reports 50 and 62)[65].  
2.2.3 Stage 3: Treatment planning  
In this process, the oncologist delineates the target volume and normal tissue structures on 
each slice of the CT images  [15]. Then, by utilising the treatment planning system (TPS), the 
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images of different CT slices are combined to form a 3D representation of the patient 
structures [15]. The process of delineating the targets and related anatomical structures is 
known as segmentation [2]. The planning software can manipulate the CT images by adding 
margins for the treatment area or helping to avoid organs at risks (OAR) like the heart and 
spinal cord. Also, it provides the setup error prior to treatment to include the target motion 
during the radiotherapy process [15]. After contouring the anatomical structures and entering 
the dose constrains, the treatment plan for the patient will be developed to meet the dose 
constrains effectively [15]. Generally, the selection of appropriate treatment planning 
depends on the prescription dose, the shape and the size of the target volume and the 
tolerance of the surrounding healthy structures [15]. 
 
2.2.3.1 Plan classification  
 Most of SBRT clinical studies of lung cancers employ three dimensional conformal 
radiotherapy (3D CRT) techniques [74]. Recently, most of the clinical radiotherapy 
institutions tend to utilise more advanced treatment technologies, such as intensity modulated 
radiation therapy (IMRT) and volumetrically modulated arc therapy (VMAT) for SBRT lung 
cancers [74]. The three techniques can be explained as follows. 
 
2.2.3.1.1 Three-dimensional conformal radiotherapy (3D CRT) 
This treatment technique is based on 3D anatomical information and utilises treatment 
radiation fields to provide a conformal dose to the target volume [2]. By using this feature, 
the 3D CRT (Figure 2-13) delivers a precise dose to the tumour and spares or reduces the 
dose to the healthy tissue. In particular, there is an option in the TPS, the beam’s-eye-view 
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(BEV) (Figure 2-14), that displays the segmented target volume and normal anatomical 
structures in a plane perpendicular to the central axis of the beam which allows for overview 
point of the radiation source [2]. To cover up the PTV dosimetrically with a high level of 
isodose, such as 99% or 95% of the prescribed dose, can be achieved by using both the field 
margins (the distance between the PTV outline and the field edge) and the BEV option [2]. 
The recommended field margin is about 2 cm, but this distance can be adjusted according to 
the presence of the critical structures around the PTV and beam profile [2]. As a part of 
radiotherapy treatment, the conformal therapy may include the use of mixed beams 
combining photons and electrons. Beams can be modified by using multi-leaf collimators 
(MLCs), wedges, shielding blocks, compensators and a bolus [20]. The delivered beams’ 
energy is varied and depends on the treated sites. For breast, head and neck treatments, the 
lower energies of 6-8 MV are preferred to treat the relative superficial target volume and 
eliminate excess skin-sparing [20]. For pelvic treatment, high beams’ energy, 10-18 MV, is 
preferable to decrease the dose to skin and increase the dose to the targeted area. Beams are 
shaped by MLCs which have several shields or leaves that can partially block the radiation 
beam [20]. Ordinarily, MLCs have 20-80 leaves organised in opposing pairs. The MLCs are 
controlled by the computer software and positioned to produce irregular beams to conform to 
tumour volume. The MLCs’ system permits a fast adjustment of shaping to match the BEV of 
the PTV (Figure 2-14) [20]. 
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Figure  2-13: Axial plan of lung case treated with the SABR technique using the 3D CRT 
technique. Ten beams fields, arrangements and orientations are indicated at the bottom of the 
image.    
 
Figure  2-14: BEV of the PTV shows the tumour volume in 3D view in Eclipse TPS utilising 
phase number 10 of 4D-CT. The yellow borders around the PTV are the jaws in two axes of 
Y and X; blue vertical lines are the MLCs. The left side icons represent the beams’ 
configuration and MLC of the treatment plan.    
 
Lung tumour 
Beam fields 
MLC 
Jaws 
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2.2.3.1.2 Intensity modulated radiation therapy (IMRT) 
The MLCs play a vital role in modern radiotherapy e.g.  IMRT plans and can do the 
following: 1) generate the desired uniform dose distribution, 2)  determine the beam intensity 
independently in varied areas of each incident beam and to shield critical structures [20]. The 
MLC leaves’ position can be different in time with a moving or fixed gantry. IMRT is 
delivered using dynamic MLC, multiple static field, dose compensation and the step-and-
shoot technique [20]. In the dynamic MLC, an automatic sequencing of beams segments 
more continuously without stopping treatment, while, in the step-and-shoot technique, there 
is a sequence of static MLC fields used with the beams being switched off when the patient 
changes position [20].  
 
There are two types of IMRT plans: forward (segmental IMRT) and inverse treatment plans. 
The first technique provides a uniform dose to the PTV and simple tissue compensation by 
shaping the BEV of the PTV and sub-segments with different MLCs [20]. The second 
technique needs a specification of prescription dose to the PTV and GTV in terms of 3D dose 
planning, fluence optimisation and dose-volume constraints [20]. The IMRT can effectively 
avoid critical structures like the spinal cord and decrease the late toxicity of the critical 
structure [20].      
       
2.2.3.1.3 Volumetrically modulated arc therapy (VMAT)     
This technique was introduced in late 2000 by the Elekta and Varian companies. They 
integrated into the Linac an option to deliver the variable dose rate rotationally [2]. The 
VMAT technique is the delivery of a rotational cone beam of a different shape and intensity. 
The gantry moves continuously for specific degrees in the VMAT treatment. This move is 
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associated with a variation in the dose rate, and the MLC leaves throughout the arc [2]. 
Multiple arcs can be used in the treatment session which is controlled by the size and location 
of the tumour. The TPS calculates the VMAT dose by sampling the delivered arcs at separate 
gantry angles. To create a good dose plan for a single arc, it is vital to optimise the beams’ 
intensities and field shapes from several gantry angles [2]. However, the optimisations of the 
fields shape are restricted because the movement of MLC leaves to their new positions must 
be done during the time that is required for the gantry to rotate between samples. As the 
numbers of sampled gantry angles are increased, the TPS optimisation becomes more 
difficult inside the MLC leaf motion constraints [2]. Otto, 2008 [75] employed a technique 
named progressive sampling to overcome this problem. This technique is based on 
subdividing the arc into a small number of gantry angles, e.g. six samples [Figure 2-15 (a)], 
the beams’ shapes and intensities are different during the initial iteration of the optimisation 
[2]. A new arc sample (after multiple iterations) is interpolated with a field shape between the 
first two samples [Figure 2-15 (b)], and the optimisation process is continuous. Another new 
arc sample (after more iteration) is interpolated in the same trend between samples 2 and 3 
[2]. This process is repeated until the required gantry angle sampling is achieved. The term 
VMAT was used initially by Otto to explain the progressive sampling technique for 
individual arc treatment delivery optimisation [2]. Varian incorporated this technique into 
their VMAT delivery and named it RapidArc (Figure 2-16). The main advantage of the 
VMAT technique is its delivery efficiency [2]. There is a significant reduction in treatment 
time and monitor units (MUs) compared with the conventional IMRT; this reduction relies on 
the protocol that is used in each radiotherapy centre [2, 76, 77].  
52 
 
 
Figure  2-15: Demonstration of progressive sample optimization technique. a) Gantry arc is 
composed of multiple evenly-spaced beams. b) Once the optimisation of beam intensities and 
shape is completed, the first new sample is introduced between the first and the second 
existing samples. c) More new samples are added to fill the gantry arc. d) This process 
resumes until the desired sampling frequency is achieved [2, 75].  
 
 
Figure  2-16: Axial plan of one full arc by VMAT for lung SABR [78].  
 
 
 
One full arc 
Lung tumour (the colour wash represents 
the delivered dose distribution)  
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2.2.3.2 Plan evaluation parameter 
 
The evaluation of the quality of planned dose distribution for the SABR technique can be 
obtained from parameters characterising target coverage, dose outside the target border, dose 
homogeneity and the lower doses that are delivered to the normal tissue volume. The most 
common method to calculate these parameters is DVH [14] (Figure 2-17). It is a histogram 
relating the tissue volumes to the radiation dose. Visual examinations of the DVH can reveal 
important clinical information such as the absorbed dose distribution  [79]. Also, it helps in 
identification of the presence of regions of low or high absorbed doses that are often difficult 
to evaluate rapidly from colour-wash or isodose presentation  [79]. The cumulative DVH in 
Figure 2-17 consists of histograms of the volume element that receive a known absorbed dose 
and which are expressed as either the volume relative to the total structure receiving a known 
absorbed dose (D) or the absolute volume  [79]. The DVH can determine values like Dmedian 
(absorbed dose received by 50% of the volume), D98% (absorbed dose near minimum value) 
and D2% (absorbed dose near maximum value) (Figure 2-17) [79].        
 
The DVH provides large amounts of data related to the dose distribution and presents the data 
as histograms and curves [80]. However, to evaluate the planned dose distribution quality, it 
is necessary to interpret these data with a simpler method/tool to assess the treatment plans 
[80]. The conformity index, homogeneity index and dose fall-off are tools that are used for 
the plan evaluation in the SABR technique and can be described below. 
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Figure  2-17: An example of differential DVH and its corresponding cumulative DVHs. This 
shows the identification of dose values for PTV such as Dmean, D50%, D98%, D95% and D2%. The 
planning organ at risk volumes (PRVs) are also indicated (yellow and green curves)[79].  
 
2.2.3.2.1 Conformity index (CI) 
The concept of the conformity index (CI) was developed as a part of the dosimetric analysis 
process and dose volume histogram. It was defined as the absolute value that results from the 
relationship between the tumour volume (or a fraction of this volume) and the delineated 
volume by an isodose (or a fraction of this volume)[81]. The CI is also defined as the ratio of 
PTV to the treated volume and demonstrates how well the PTV is covered by the treatment 
while reducing the dose to normal tissue [20]. The CI simply describes the congruence degree 
between isodose, healthy tissue contour and tumour contour by the geometric intersection 
method [81]. However, there are several indices proposed through different organisations like 
the Radiation Therapy Oncology Group (RTOG). Feuvert et al., 2006 [81] summarise a 
number of CIs by different clinical institutions (Table 2-1) [81].  
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Table  2-1: Comparison of different volume-based CIs in different clinical settings. 
Abbreviations: RTOG = Radiation Therapy Oncology Group; SALT = Saint-Anne, 
Lariboisiere, Tenon [81]. 
Proposed by CI Formulas Sample definitions 
RTOG [82, 
83] 
 
 
 
 
SALT [84, 85] 
 
 
 
 
 
Lomax and 
Scheib., 2003 
[86]   
Van’t Riest et 
al., 1997 [87]  
 
 
 
 
Baltas et al., 
1998 [88]  
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2.2.3.2.2 Homogeneity index (HI) 
The homogeneity index (HI) is a tool used to analyse the uniformity of dose distribution in 
the target volume. The development of the HI concept was as an extension of section-by-
section dosimetric analysis of treatment planning [81, 89]. The HI was introduced in 1993 by 
the RTOG which proposed guidelines for routine evaluation of the SABR technique 
including the HI. The HIRTOG = Imax/RI, where Imax is the maximum isodose in the target, and 
RI is the reference dose [81, 89]. The treatment is considered in compliance with the protocol 
if the HI ≤ 2. If the HI is 2-2.5, it is considered a minor violation; if the HI is greater than 2.5, 
the treatment plan is considered a major violation [81, 89]. Other formulas of the HI are 
described later (Table 2-2) [80].  
 
Table  2-2: Five formulae for calculating HI index [80]. 
HI formulae (proposed by) Sample definitions 
D5 /D95 
(Semenenko et al., 2008) 
[90] 
D5: Minimum dose in 5% of target volume 
D95: Minimum dose in 95% of target volume 
Dmax /Dmin 
(Kataria et al., 2012) [80] 
Dmax: Maximum point dose in the target volume 
Dmin: Minimum point dose in target volume 
D1- D98 /Dp x 100 
(Wu et al., 2003) [91] 
D1: Minimum dose in 1% of target volume 
D98: Minimum dose in 98% of target volume 
Dp: Prescribed dose to target volume 
D5- D95 /Dp x 100 
(Wu et al., 2003)[91] 
D5: Minimum dose in 5% of target volume 
D95: Minimum dose in 95% of target volume 
Dp: Prescribed dose to target volume 
Dmax /Dp 
(Van't Riet et al., 1997, 
Collins et al., 2006) [87, 92] 
Dmax: Maximum point dose 
Dp: Prescribed dose to target volume 
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According to Kataria et al., 2012 [80] the analysis of HI formulae in Table 2-2 for 99 patients 
showed a reasonable high level of agreement between these formulae that were used to 
calculate the HI [80]. 
 
2.2.3.2.3 Dose fall-off 
In the SABR technique, the high doses delivered to the volume of normal tissue located 
outside the target volume should be reduced to limit the risk of the treatment toxicity. 
Therefore, the dose fall-off outside the target volume should be sharp [14]. To improve dose 
fall-off outside the target volume, i.e. PTV, and spare the nearby OAR in SABR, the doses 
are specified to lower isodose (like 80% isodose) associated with small or no margins for 
beam penumbra at the target edges [14]. Also, applying several non-overlapping beams is 
considered as the primary method for achieving a sharp dose fall-off in SABR. This requires 
that all beams converge optimally on the target as concentrically as possible from different 
directions  [14]. Another parameter that affects dose fall-off is the beam shaping resolutions, 
such as MLC leaf width and beams’ energy. The higher beam energy in SABR leads to larger 
beam penumbra because of the lateral electron transport in the medium. In SABR lung, this 
effect is significant due to the low density medium of the lung tissue [14]. In modern 
treatment machines, a 6 MV photon beam provides a good compromise between the 
penumbra characteristics and beam penetration for SABR lung treatment. The dose fall-off 
outside the target volume is defined as follows [14]:  
 
Dose fall-off =  𝐕𝐨𝐥𝐮𝐦𝐞 𝐨𝐟 𝟓𝟎% 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐢𝐬𝐨𝐝𝐨𝐬𝐞 
𝐏𝐥𝐚𝐧𝐧𝐢𝐧𝐠 𝐭𝐚𝐫𝐠𝐞𝐭 𝐯𝐨𝐥𝐮𝐦𝐞 (𝐏𝐓𝐕)          ( 2-5) 
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2.2.3.3 Dose calculation algorithms 
The aim of dose calculation algorithms in the TPS is to predict an accurate dose deposition in 
tissues. The dose deposition occurs when photons interact with materials and release 
electrons which deposit the dose inside the tissue [1]. The variations among algorithms are 
based on different approaches used to calculate scatter dose distributions, particularly related 
to electron scatter [1]. The electron scatter mainly affects the accuracy of dose calculation 
under regions of charged particle disequilibrium (CDP). The development of dose calculation 
algorithms started with empirically-based approaches without accounting for tissue 
heterogeneities, and the dose calculation was based on measurements using a water phantom 
[1]. Later, inhomogeneity corrections were incorporated into algorithms; these corrections 
were based on scaling of the primary beams according to the radiological path length of the 
tissue encountered [1]. These methods were appropriate to calculate the primary beam 
attenuation, but they were limited in accounting for photon and electron scattering. The 
convolution method introduced by Mackie et al., in 1985 [93] is considered as having the first 
physics-based algorithms for dose calculations [93]. The dose deposition kernel is pre-
computed for different mono-energetic beams by using Monte Carlo simulation, and then the 
dose deposition is convolved with the primary dose distribution inside the patient [93]. The 
kernel is known as the dose matrix produced per unit of TERMA at the interaction site. 
TERMA is the product of the primary energy fluency and the mass attenuation coefficient 
[94].  
 
The convolution method provides accurate results for dose calculation in both conditions of 
low density tissues and electronic disequilibrium [93, 95]. To enhance the accuracy of 
accounting for the photon and electron scatter in heterogeneous media, the dose convolution 
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method was evolved and modified to incorporate the density-based scaling of both the dose 
spread arrays and primary photon fluence [96]. This modified method is called the 
convolution/superposition method [96, 97].    
 
2.2.3.3.1 The effect of the heterogeneous treatment sites on dose 
calculation algorithms 
In the clinical treatment process, the accuracy of dose calculation algorithms is of paramount 
importance, especially when treating inhomogeneous tissues such as lungs [97]. The 
American Association of Physicists in Medicine Task Group-85 (AAPM TG) report on tissue 
inhomogeneity corrections for megavoltage (MV) beams [97] showed that a 5% variation in 
dose may result in a 10% to 20% variation in tumour control probability  and also has an 
impact on the normal tissue complication probabilities (NTCP) by 20%-30%. Moreover, a 
report by AAPM TG-105 [98] and a review article by Reynaert et al., 2007 [99] provide 
several studies that document the inaccuracies related to conventional algorithms for dose 
calculation of patient-specific treatment sites such as lungs [98, 99].       
 
When treating lung cancer with SABR, the radiation dose computation is compromised due 
to the presence of low-density lung tissue surrounding the thoracic tumours. The use of small 
beam field sizes in the SABR technique with the presence of low-density in lung tissue leads 
to exacerbating the condition of CPD where the electrons increase significantly [1]. As a 
result, loss of CPD occurs in larger field sizes of lung tissue compared with water equivalent 
tissues. Despite the dose algorithms employing heterogeneity correction based on the 
radiological path length of primary electrons, they do not explicitly account for the transport 
of secondary electrons [1]. Therefore, the accuracy of dose calculation is severely limited 
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under non-equilibrium conditions. Also, in lung-equivalent tissue (low density), the range of 
the secondary electrons is involved in the dose build-down effect that forms at the edge of the 
tumour or at the lung-tumour interface [1]. The dose build-down effect is increased as the 
beam energy is increased. This effect generates a ‘ring’ of decreased dose at the tumour 
boundary. When the electron range is increased with energy, this effect becomes more severe 
and affects the dose computation [1].  
 
 
2.2.3.3.2 The types of dose calculation algorithms in radiation 
therapy  
Various types of algorithms control the quality and functionality of the treatment planning 
system (TPS) in the different stages of the planning process. Dose calculation algorithms for 
computerized TPS have been developing since the mid-1950s [2]. In broad terms, the 
algorithms fall into three main categories: A) correction-based algorithms, B) model-based 
algorithms and C) direct Monte Carlo. Most radiotherapy institutions use a commercial TPS, 
like CMS XiO-TPS (CMS Inc., St. Louis, MO) and Eclipse-TPS (Varian Medical Systems, 
Palo Alto, CA) software, which has different algorithms performance [2]. XiO-TPS includes 
various algorithms, such as superposition, fast superposition, fast Fourier transformation 
(FFT) convolution and Clarkson. Eclipse-TPS software has three algorithms: anisotropic 
analytic algorithms (AAA), pencil beam convolution (PBC) algorithms and Acuros XB 
algorithms [2]. This section reviews the main algorithm types, including examples of 
algorithms that are implemented in both XiO and Eclipse commercial TPS software for each 
category.  
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2.2.3.3.2.1 Correction-based algorithms 
These algorithms involve minimal computations and are widely used in conventional 
radiation therapy [2]. There are two steps for dose calculation by correction-based 
algorithms; these are described below.  
 
2.2.3.3.2.2.1 Establishing dose calculation data 
The basic dose distribution functions and the dose calculation parameters are measured in a 
water phantom under standard conditions, which include a normal beam incident, a fixed 
source-to-surface distance (SSD) and a flat phantom surface [100]. For complete electron 
equilibrium, the phantom must have a large volume. The following points represent the dose 
measurements under those conditions [100]: 
a) Normalise the central-axis depth doses to the maximum dose value for different square fields 
[100].  
b) Calculate lateral dose profiles at a reference depth or multiple depths that extend outside of 
the square field. The off-axial ratios of the organ at risk are obtained by normalizing those 
extend to the central-axis value [100].  
c) Beam modifier factors (f) as a function of field size and depth to calculate for the scattering 
and attenuation effects of a beam modifier, e.g. a compensator or wedge [100].  
d) Beam output factors for different square fields relative to a reference field (usually 10 × 
10 cm2). This can be decomposed into collimator scatter factors (Sc) and phantom scatter 
factors (Sp) [100].    
In clinical radiotherapy situations, the use of dose calculation parameters and standard 
distribution functions often impose some limitations [100]. Thus, different correction 
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methods have been introduced and applied to dose calculations that suffer from nonstandard 
conditions [100].  
 
2.2.3.3.2.2.2 Reconstruction of the dose distribution 
Reconstructing the dose distribution includes the correction for an irregular field, contour 
irregularities and tissue heterogeneities  [101]. 
  
2.2.3.3.2.2.2.1 Correction for an irregular field 
For calculating the dose in an irregularly shaped radiation field, the Clarkson method can be 
used by summing up the individual contributions of each decomposed small sector of the 
beam (fan beamlet) that create the irregular field [101]. The Clarkson method is based on the 
principle that the primary dose component is independent of the field size and shape, while 
the scattering dose component depends on the field size and the shape [2]. Therefore, the 
calculation of the primary and scattered dose in an irregular field at any point can be obtained 
separately utilising the effective tissue maximum ratios (TMR) as follows [100]:  
 
       TMR(r,d) = TMR(0,d) + ∑ 𝐒𝐌𝐑(𝐝, 𝐫𝐢𝐢 )                       ( 2-6) 
 
Where TMR (0, d) is the primary dose component and SMR (d,ri) is the scatter maximum 
ratio at depth (d) for a narrow fan beamlet with a radius (ri). The scatter maximum ratio is the 
scattered dose ratio at a known point in the phantom to the effective primary dose at the same 
point at the maximum dose depth [100]. 
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• Clarkson algorithms (XiO-TPS) 
The Clarkson algorithm is measurement-based algorithms which divides the dose into 
primary and scatter radiation. It resolves the irregular field into divisions of a circular beam 
generating at the point of interest in the patient [102]. The division integration method 
measures the dose as the sum of contributions of the primary radiation and the scattered 
radiation. However, it provides low accurate dose calculations with less parameterization 
compared to recent algorithms [102].  
   
2.2.3.3.2.2.2.2 Correction for contour irregularities  
The TMR method is the most convenient method for contour corrections resulting from 
surface curvature or oblique beam incidence [100]. This method is based on the principle that 
TMR relies on the prescription depth and the field size at that depth, not on the SSD [100]. 
Thus, the correction factor (CF) can be represented by the following equation (if the tissue is 
missing under the surface denoted by a dotted-dash line SS at the standard SSD) (Figures 2-
18 and 2-19) [100]: 
                              CF = 𝐓𝐌𝐑(𝐝 − 𝐭,𝐫𝐩)
𝐓𝐌𝐑(𝐝,𝐫𝐩)                                        ( 2-7) 
where rp is the field size projected at point P (i.e. at a distance of SSD + d from the surface).    
 
Therefore, the corrected dose (Dc) at point P is calculated by                     𝐃𝐜 = D × CF                               ( 2-8) 
 Where  D is the uncorrected dose [100].  
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Figure  2-18: An illustration of patient surface irregularities [100]. 
 
 
Figure  2-19:  An illustration of tissue heterogeneity correction for dose calculation algorithms 
[100]. 
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2.2.3.3.2.2.2.3 Heterogeneous correction  
There are two general approaches for accounting for the presence of tissue heterogeneities 
[103].  
1. The first approach computes the relative dose distributions inside a medium of homogeneous 
water equivalent composition [103]. These relative distributions are transformed to the 
absolute dose by means of proper calibration factors defined at a reference point in water 
[103]. This transformation is achieved by the application of inhomogeneity correction factors 
(ICFs). There are several methods for calculating ICFs, including the precent per centimetre 
method, which uses a simple one-dimensional approach, or the equivalent tissue–air ratio 
(ETAR) method, which is considered to be more sophisticated and provides better results, 
e.g. pencil beam convolution PBC algorithms  [103].  
 
2. The second approach utilizes model-based radiation transport within the heterogeneous 
medium, e.g. AAA algorithms (see section 2.2.3.3.2.2) [103].   
Each method provides a different level of accuracy, which depends on the geometrical region 
of the target [103]. 
 
• Pencil beam convolution algorithms (Eclipse-TPS) 
PBC algorithms are implemented in the Eclipse TPS (Varian Medical Systems, Palo Alto, 
CA). The pencil beam algorithms utilize the summation of the energy spread or dose kernel at 
a point along a line in a phantom to acquire the dose distribution or the pencil beam type 
[104]. The dose distribution is generated by integrating the pencil beam over the patient’s 
surface to account for variations in primary intensity and by modifying the shape of the 
pencil beam with depth and tissue density [104]. By using a convolution technique, the pencil 
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beam can calculate the dose distribution around an infinitely small beam in water [104]. 
Convolution is performed between the planner photon energy fluence distribution and 
polyenergetic pencil beams. The main disadvantage of pencil beam algorithms is that they do 
not take into account the effect of the lateral scattering [104]. 
 
The ETAR method is used by PBC algorithms for inhomogeneity correction and depends on 
tissue–air ratio measurements that are calculated under conditions approximating electron 
equilibrium [105]. Electron interactions that occur away from the primary photon interaction 
site are ignored. However, the ETAR method cannot predict the dose accurately in the build-
up regions that experience electronic disequilibrium or at points located closer to the field 
edge than the range of secondary electrons, in regions with a great electron range or in low 
density material [105]. The limitation in ETAR inhomogeneity correction also includes the 
calculation of photon transport and does not account for the transport of secondary electrons 
[105]. A number of researchers have demonstrated that the ETAR inhomogeneity correction 
method is not taking into account the secondary build-up region that occurred beyond air 
cavities in the interface region. As a result, an overestimation of the delivered dose occurs 
[106-108].  
 
2.2.3.3.2.2 Model-based algorithms  
The main feature in these algorithms is the utilization of dose kernels to model dose 
distributions that result from the primary radiation particle interactions along a ray line or at 
the point in the dose calculation geometry [93, 109-111]. A class of model-based algorithms 
named convolution-superposition methods [93, 109-111]. In general, dose kernels at different 
areas within the human body vary due to differences in tissue densities and composition  [2]. 
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Therefore, the accuracy of convolution-superposition algorithms relies on how different 
kernels can be implemented for heterogeneous geometry [2].     
2.2.3.3.2.2.1 Convolution-superposition with point dose kernels 
For a mono-energetic photon field, the dose D (r⃗) at a point (r⃗) or the vector that is composed 
of the x,y,z component ( r⃗ = xı⃗ + yȷ⃗ + zk�⃗  ) is described as follows [100]: 
𝐃(?⃗?) = ∫ µ
𝛒
 𝛙𝐩 (?⃗?′)𝐤(?⃗? −  ?⃗?′)𝐝?⃗?                       ( 2-9) 
where µ/ρ is the mass attenuation coefficient, ψp (r⃗′) is the primary photon energy fluence 
and k (r⃗′) is the point dose kernel [100]. 
 
The result of the mass attenuation coefficient and the primary energy fluence is the total 
energy released per unit mass Tp (r⃗′) [112].The dose distribution in water is represented by 
the point dose kernel resulting from both the secondary electrons set in motion and the 
scattered photons by the primary photon interactions (Figure 2-20). Point dose kernels and 
primary photon energy fluence are considered as functions of energies [112]. Thus, in the 
clinical photon beam, the total dose is provided by the combination of the point dose kernels 
and the product of total energy released per unit mass (TERMA) over the photon field for the 
energy spectrum [112]. 
 
The FFT convolution, superposition and fast superposition algorithms are implemented in 
XiO-TPS and they calculate the dose by convolving the total energy released in the patient 
with energy deposition kernels [94]. The following algorithms indicate the differences in 
three types of algorithms integrated in XiO-TPS: FFT convolution, superposition and fast 
superposition algorithms.  
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Figure  2-20: Schematic diagram demonstrates the shape of dose kernel in different situations. 
The kernel is known as the dose matrix produced per unit of TERMA at the interaction site. 
TERMA is the product of the primary energy fluency and the mass attenuation coefficient 
[43].  
 
• FFT convolution algorithms (XiO-TPS) 
According to Meckie et al., 1985 [113], to obtain FFT convolution, the kernel of deposited 
energy should be interpolated from spherical to Cartesian coordinates on a common grid with 
the TERMA. The application of interpolated and sampling of kernels from spherical to 
Cartesian coordinates by using steep kernel gradients is complicated [94]. The correct energy 
at and close to the interaction point is therefore represented in Cartesian coordinates by using 
adaptive quadrature techniques [94]. The results of calculation comparisons show that 
inaccurate doses occur if the influence of scattered kernels from the surrounding area is 
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omitted over a large enough region [94]. Therefore, the patient data must be represented in a 
three-dimensional (3D) volume because the scatter calculation at a point is related to the 
scattering medium of the 3D volume. The XiO system performs an individual low and high 
resolution FFT calculation for the scatter and primary kernels [94]. This saves about 65% of 
the time of performing an individual calculation at high resolution [94]. The accuracy for 
heterogeneous geometry by the FFT method is similar to the correction-based algorithms 
method because it completely ignores the spatial variation of the point dose kernel changes 
[100].  
 
• Superposition algorithms (XiO-TPS) 
When performing a dose calculation in heterogeneous geometry, the point dose kernels vary 
spatially [100]. The dose at these points should be summed by superposition of the different 
dose kernels, which are typically approximated by compressing or stretching the point dose 
kernel based on the electron density of the local medium. The following equation 
mathematically represents the dose at a point (i,j,k) [100]: 
 
D (i,j, k) 𝛂∑ ∑ ∑  𝐓𝐩𝐤′ 𝐣′𝐢′  (𝐢′,𝐣′,𝐤′) 𝐤𝐞 (𝐢, 𝐣,𝐤, 𝐢′, 𝐣′,𝐤′)                 ( 2-10) 
 where ke (i, j, k, i′, j′, k′) is the scaled point dose kernel based on local electron density 
[100].  
 
A Cartesian grid or discretised using collapsed cones [114] can be used for representing the 
point dose kernels. The collapsed cone method is more computationally efficient particularly 
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for density scaling and kernel tilting [100]. Moreover, it is more efficient to divide the point 
dose kernel into a primary kernel for secondary electrons and a scatter kernel for scattered 
photons with varied spatial resolution [100].  
 
The superposition dose deposition of the XiO system is an adaptation of the dose calculation 
method called ‘collapsed cone’[94]. All superposition calculations are achieved in beam 
coordinates (similar to FFT convolution), and the user-specified calculation volume is 
interpolated by the dose in the beam coordinates [94]. In this algorithm, it is possible to 
emulate the kernel calculation process directly and hence to compute the energy deposited by 
spreading energy released at the interaction point to other points in the volume of interest, 
according to the distribution implied by the kernel. This method is called ‘the interaction 
point of view’ [94]. 
 
However, the superposition algorithms’ energy deposition kernels can be altered to account 
for differences in electron density (unlike FFT convolution algorithms) [94]. In order to 
distort the kernels by finding the average density along the straight line path between the dose 
deposition site and the interaction site, this method is called density scaling and is based on 
O’Connor’s theorem [115]. The density scaling method provides a great approximation for 
scattered photons because the mass attenuation coefficient scales are linear with the material 
density (if the atomic number is assumed unchanged) [94]. Because of kernel scaling, the 
superposition method is more accurate and time consuming for the dose calculation in a 
heterogeneous media compared to FFT convolution [94]. Table 2-3 demonstrate the 
similarity and differences between Fast Fourier transform convolution algorithms and 
superposition algorithms. 
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Table  2-3 : Comparison between FFT convolution and Superposition algorithms [94].   
 
Fast Fourier Transform (FFT) 
Convolution Algorithms 
Superposition Algorithms 
Similarities 
• Both provide more accurate results than measurement-based algorithms (Clarkson 
algorithms). 
• Compute dose by convolving the total energy released in the patient (with Monte 
Carlo-generated energy) deposition kernels or ‘dose spread array’ using fundamental 
physics that describe photon and electron interactions and transport.  
• Provide more accurate dose calculations with less parameterization than measurement-
based algorithms.  
• Use similar physics principle to calculate dose. 
Differences 
Kernels are represented in 
Cartesian coordinates and 
remain invariant over the entire 
space in which they are applied.  
 
Kernels are represented in spherical coordinates that 
allow changing with the local environment in which 
they are applied. This variance allows a scatter dose in 
or near heterogeneities to be modelled more accurately 
than with FFT convolution, though this causes 
superposition to be slower than FFT convolution. 
Uses 
• Their accuracy is almost identical in water-equivalent tissues: 
1. Superposition is more accurate than FFT convolution with heterogeneous tissues, e.g. 
lung or nasopharynx cases treatment planning. 
2. FFT Convolution is faster than superposition and useful in fast calculation or dealing 
with water-equivalent tissues.  
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• Fast superposition algorithms (XiO-TPS) 
Known as dose spread arrays or spherical kernels that are cylindrically symmetrical, fast 
superposition algorithms are defined based on their rays traced along azimuth and zenith 
angles [94]. The calculation of spherical kernels is amplified with the ability to combine (sum 
and select) adjacent zenith rays in the kernel, which allows for minimising the direction and 
number of zenith rays in order to optimise the accuracy trade off. This means that the fewer 
the rays, the faster but less accurate the computation, while the more rays, the slower and 
more accurate the calculation [94]. It is possible to control the direction and number of 
azimuth rays and zenith rays. These algorithms can be increased in speed up to about a factor 
of 2.5 cm [94], which delivers a fast superposition dose calculation. Compared to the 
superposition calculation, there is a small percentage of inaccuracy [94].   
 
• Fast superposition algorithms vs. superposition algorithms 
These two types of superposition algorithms are essentially identical except for the number of 
rays traced between interaction and dose sites. 
1. Fast superposition algorithms uses about one-third of ray traced or 48 ray traces per dose 
deposition point. This doubles the speed of calculations with only a small decrease in 
accuracy.  
2. Superposition algorithms use 128 ray traces per dose deposition point. 
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2.2.3.3.2.3 Convolution superposition with pencil beam dose kernels 
The pencil beam dose kernel defines the dose distribution that results from scattered photons 
and secondary electrons set in motion by a single ray of primary photons. The dose 
distribution can be computed by [100]: 
 
D(x,y,z) = ∬ 𝐓𝐏𝐅  (𝐱′,𝐲′) 𝐤𝐏𝐁 (𝐱 − 𝐱′, 𝐲 − 𝐲′, 𝐳) 𝐝𝐱′𝐝𝐲′           (  2-11) 
 
where Tp (x′ , y′) is the energy-integrated TERMA at the patient’s surface and kPB (x′ , y′, z) 
is the pencil beam dose kernel [100]. 
 
The depth coordinate z is scaled by electron density for heterogeneous geometry. This is 
equivalent to stretching the pencil beam dose kernel longitudinally [100]. The effect of a 
lateral density variation is often ignored or approximated by the ETAR correction. From this 
perspective, the pencil beam algorithms and the correction-based dose algorithms are 
considered very similar [100].   
 
• AAA (Eclipse-TPS) 
AAAs are convolution-superposition algorithms that are implemented in the Eclipse-TPS 
[116]. AAA is defined as an improved pencil beam algorithm that uses multiple pencil beam 
dose kernels to demonstrate the dose contribution from different radiation sources of a 
clinical beam [117].  
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Pencil beam dose kernels for photon sources are divided into a lateral component and a depth 
component. AAA applies a dose summation stage for heterogeneous correction [100]. This is 
achieved by scaling the lateral component anisotropically according to the local electron 
density and depth dose component by using the equivalent path length [100]. Moreover, it 
employs spatially invariant scatter kernels extracted from Monte Carlo calculations and from 
models of three sources: contaminant electron, extra focal photons and primary photons [103, 
116]. A scatter kernel, an energy deposition density function and fluency are related to each 
source [116]. Therefore, the convolution process from the contribution of the three sources 
results in the total energy deposited by each pencil beam, while the superposition process 
generates the final dose calculation from the pencil beam contributions [116].    
 
To sum up, the AAA dose is calculated from the total of pre-calculated primary pencil beams 
extracted from a radiation source model, and the lateral scattering is scaled by electron 
density [118]. This lateral scattering measurement is derived from Monte Carlo simulations 
in water [118]. The accuracy of dose calculations for heterogeneous geometry has 
significantly improved compared to other pencil beam algorithms e.g. PBC algorithms [100]. 
 
2.2.3.3.2.4 Monte Carlo (MC) algorithms 
This technique is composed of a computer program (MC codes) that simulates the transport 
of millions of photons and particles through matter  [112]. It is composed of two independent 
components: 1) the simulation of the ‘linac phase space’ based on the geometric design of the 
treatment head and a few characteristic parameters for the electron beam; this can be used as 
input for the second component. 2) the simulation of the energy absorption and transport 
inside the patient [112]. 
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In order to determine the probability distribution of individual interactions of photons and 
particles, Monte Carlo simulation utilises a fundamental law of physics [2, 119]. The 
accuracy of predicting the dose distribution is increased as the number of simulated particles 
(histories) is increased [2, 119]. However, the increment in the number of simulated particles 
and photons result in a relatively long computational time. The calculation of the dose 
distribution is achieved by accumulating or scoring the ionizing events in bin (voxels) that 
give rise to energy deposition in the medium [2, 119]. Thus, for adequate precision in a 
radiation therapy treatment planning system, the transportation of a few hundred million to a 
billion histories of photons and particles are required [2, 119].  
 
Several MC codes have been used in radiation transport simulations and more recently in 
TPSs, such as PEREGRINE (developed at the Lawrence Livermore National Laboratory, 
Livermore, California), PENELOPE, Monte Carlo N-particle and ETRAN/ITS  [2]. Despite 
the computational time of Monte Carlo algorithms, they are the most accurate algorithms in 
calculating the dose distribution in patients, especially for heterogeneous tissues like lungs 
when incidences of particle disequilibrium happen under specific conditions  [2]. Future 
application of the Monte Carlo methodology in routine TPS is expected to be associated with 
the improvement in computer technology and computational algorithms [2].      
    
2.2.3.3.2.5 Acuros XB algorithms (Eclipse-TPS)  
Acuros XB algorithms are implemented in the Eclipse-TPS. The method of these algorithms 
is based on directly solving the linear Boltzmann transport equation (LBTE). The LBTE is 
the main equation that defines the macroscopic behaviour of ionizing particles, such as 
electrons and neurons, when they travel through and interact with matter  [120]. For a known 
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volumetric domain of matter for a subject of radiation source, the accurate description of the 
dose inside the domain can be achieved by the solution of LBTE equations [120].  
 
The following equation illustrates the transportation of a photon and an electron in a volume 
of matter (V) [118]: 
 
where ψγ and ψe are the photon and electron, respectively, that fluence everywhere in V for 
all solid angles; σt
γ and σte are the total macroscopic photon and electron cross-section, 
respectively, for all materials in V; SR  is the restricted collisional plus radiate stopping power 
for all materials; qγ  and qe  are the external photon and electron sources, respectively, from 
the treatment head;  qxx is the scattering sources in V and at all angles, and the (xx) values 
change accordingly to energies of photon–photon (xx=γ γ), electron–electron (xx=ee) and 
photon–electron (xx=γe) interactions [118]. 
 
By using the standard ray-tracing technique, the external photon and electron sources (qγ and qe , respectively) are first transported into the V [118]. A construction then occurs for all 
points in V by the first-scattered photon (qFSγγ) and first-scattered electron sources qFSγe and 
effectively replaces the qe  and qγ  in equations (2-12) and (2-13) [118]. For solving the 
resulting LBTE, a finite-element method is applied, and V is discretised spatially into voxels. 
Acuros XB utilizes an adaptive mesh refinement technique to subdivide the volume of matter 
(2-12) 
(2-13) 
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into Cartesian voxels of different dimensions (multiples of two smaller or larger than a 
reference voxel dimension) [118]. This technique permits using finer voxels inside high-dose 
and high-dose gradient areas [118].     
 
Discretization of the energy dependence of fluence (e.g. ψγ and ψe), stopping power (SR ), 
and scattering sources (qγγ , qee, qeγ, qFSγe , qFSγγ) are obtained by finite-element methods and 
standard multi-group [118]. For determining the scattering sources, a cross-sectional 
technique is used to discrete them into 25 and 49 energy groups for photons and electrons, 
respectively. Moreover, a discrete ordinate method is used for the angular dependence of 
fluence and scattering sources; this results in 32–512 discrete angles, depending on energy 
[118]. To avoid recoupling the electron and photon fluences, Bremsstrahlung production 
inside the patient must be neglected [118].  
 
The energy cut-off of 0.5 MeV (kinetic) for electrons and 0.01 MeV for photons is applied 
(which is not adjustable by the user) throughout Acuros XB coupled photon–electron 
transport. The electron fluence is solved by using discontinuous finite-element methods. The 
following equation is used to convert the electron fluence to dose D(r⃗) [118] : 
 
where σdepe   is the macroscopic energy deposition cross-section and ρ is the atomic density 
of the local voxels [118].     
(2-14) 
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The calculation of Acuros XB includes dose-to-water and dose-to-media. The transport of 
coupled photon and electron fluences in both cases occurs inside the media containing the 
calculation volume. For dose-to-water, the depositions of energy cross-sections for water are 
utilized in place of those for local media [118]. As a result, the calculation of Acuros XB 
dose-to-water is analogous to Monte Carlo simulations in media. They are then converted to 
dose-to-water through the ratio of water to media mass stoping power [118, 121]. The 
absorbed dose is represented by the dose-to-water calculations, which are provided by the 
Monte Carlo simulation and Acuros XB with great accuracy [118]. In addition, the 
calculation method of Acuros XB needs mass densities and atomic compositions to evaluate 
the macroscopic interaction cross-sections for each voxel (unlike the AAA dose calculation 
that uses relative electron density) [118].  
 
This section has discussed different categories of dose calculation algorithms and commercial 
algorithms that are used in TPS available in most radiation therapy centres. Each category 
provides varied responses to homogeneous and heterogeneous media, causing different dose 
calculation accuracies.  
 
Correction-based algorithms, including Clarkson algorithms (XiO-TPS), provide accurate 
results in homogeneous media, e.g. water [2, 100]. However, the accuracy of these algorithms 
is poor in heterogeneous media, e.g. lung tissue, even when applying an equivalent beam path 
length, which can correct for only part of the heterogeneous effect. These algorithms cannot 
take into account the accuracy of lateral scattering when a beam transports in media [2, 100]. 
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Model-based algorithms, including PBC (Eclipse-TPS), FFT convolution (XiO-TPS), 
superposition (XiO-TPS), fast superposition (XiO-TPS) and AAA (Eclipse-TPS) generally 
exhibit better accuracy than the correction-based algorithms in calculating dose. In 
homogeneous media, there are no obvious differences in the accuracy among these 
algorithms, and the algorithms provide similar results [2, 100]. In contrast, the differences in 
accuracy of dose calculations in heterogeneous media among these algorithms depend on 
how the actual scattered radiation can be simulated by the kernels of the algorithms. For 
example, the PBC inhomogeneity correction only occurs in the longitudinal direction, which 
uses the equivalent path length converted from the mass attenuation or electron density of the 
medium [2, 100]. Rana et al., 2013  [122] concluded that the accuracy of AAA is better than 
PBC in the dose calculation when treating a deep-seated tumour beyond the high-density 
heterogeneity interface [122]. Moreover, Muralidhar et al., 2009  [94] reported that 
superposition is the better algorithm for the calculation of the radiation dose in heterogeneous 
media, such as lung, compared to the FFT convolution and fast superposition algorithms and 
that it shows high accuracy [94]. Muralidhar et al., 2009  [94] reported that superposition is 
the better algorithm for the calculation of the radiation dose in heterogeneous media, such as 
lung, compared to the FFT convolution and fast superposition algorithms and that it shows 
high accuracy [94].  
 
The last category includes the Monte Carlo simulation and Acuros XB (Eclipse-TPS). These 
are currently considered to be the most accurate dose calculation algorithms compared to the 
two previous categories [118, 123, 124]. Both attempt to simulate all physical processes that 
beam particles contribute instead of producing beam particles one by one in the simulation on 
process. Acuros XB has a faster calculation process than the Monte Carlo simulation, which 
makes it less time consuming, but the two have comparable accuracy [118, 123, 124]. 
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2.2.4 Stage 4: Treatment delivery 
Most of the radiation therapy centres use Linac machines with image guidance capability, 
such as cone beam computed tomography (CBCT), for treatment delivery [14]. The patient is 
securely positioned in the immobilisation device, and he/she is positioned by using the 
markings on the patient’s skin or the table. Prior to the treatment, CBCT scans or orthogonal 
X-ray images must be taken [15]. The CBCT mounted on Linac can quickly provide (on the 
treatment table) high-resolution images in several planes with low dose deposition [125]. The 
obtained images from the CBCT are compared with the images acquired at planning, and 
then the patient position is adjusted until both data set images overlay at the exact same 
region of interest [15]. 
 
2.2.4.1 Linear accelerator (Linac) 
Linac is a device that utilises high frequency electromagnetic waves to accelerate charged 
particles like electrons (e-) to high energies through a linear tube. These high-energy electron 
beams are used to treat superficial tumours or it produce X-rays (by striking a target such as 
tungsten) to treat deep-seated tumours [2]. Figure 2-21 demonstrates the components of the 
Linac system. The direct current (DC) power is provided by the power supply to the 
modulator. The modulator includes the pulse-forming network and a switch tube called the 
hydrogen thyratron [2]. High voltage pulses that are produced by the modulator are flat 
topped DC pulses of a few micro-seconds in duration. Then, these pulses are delivered to the 
magnetron (klystron) and simultaneously to the electron gun. The magnetron generates 
pulsed microwaves and injects them into the accelerator tube (or accelerator structures) via a 
waveguide system [2]. The accelerator structure is evacuated to high vacuum and composed 
of a copper tube with its interior separated by a copper disk with a different aperture and 
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spacing. Initially, the electrons are injected into the accelerator structure with energy of about 
50 keV, and then they interact with the electromagnetic field of the microwaves [2]. These 
electrons gain energy from the sinusoidal electric field by an accelerator process analogous, 
i.e. a surf rider. The accelerator structure releases the high-energy electrons in the form of a 
pencil beam of about 3 mm in diameter [2]. For low energy Linacs (up to 6 MV), the 
accelerator tube is relatively short, and the electrons can proceed straight on and hit the target 
for X-ray production. For high energy Linacs, the accelerator structure is too long and, hence, 
is positioned horizontally or at angle with respect to the horizontal position [2].    
   
Figure  2-21: Schematic diagram of typical medical linear accelerator [2].  
 
The treatment head is made of a thick shell of high density shielding material like tungsten, 
lead or lead-tungsten alloy [2]. It consists of an X-ray target, scattering foil, flattening filter, 
ion chamber, fixed and movable collimator and light localiser system. These components will 
be explained below [2].   
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2.2.4.1.1 X-ray target and flattening filter 
The linear accelerator generates the electrons in the MV range that makes the X-ray intensity 
increase in a forward direction [2]. The function of the flattening filter is to make the beam 
intensity uniform across the field. This filter is inserted in the beam and is usually made of 
aluminium, steel, uranium, tungsten or lead [2]. Podgorsak et al., 1975 [126] have discussed 
the options of flattening filters and target materials [126].   
 
2.2.4.1.2 Beam collimation and monitoring 
Initially the treatment beams are collimated by the fixed primary collimator that is located 
directly beyond the X-ray target. After the beams’ intensities are made uniform by the 
flattening filters, they pass on the dose monitoring chambers [2]. This monitoring system is 
composed of multiple ion chambers or individual chambers with several plates. Most of 
Linac systems use a flat parallel plate chamber to cover the whole beam. The ion chamber 
function is to monitor integrated dose, field symmetry and dose rate [2]. Because ion 
chambers are in a high intensity radiation field, it is vital to evaluate the ion collection 
efficiency of an ion chamber and keep it unchanged due to the variation of dose rate. The 
designs of monitoring chambers inside the Linac treatment head are sealed to prevent the 
effect of the temperature and pressure of outside the air on the measurements [2]. Also, these 
chambers should be evaluated periodically to ensure that their responses are independent of 
the temperature and pressure [2].  
 
Beams are collimated by a continuously movable X-ray collimator after they pass through the 
ion chamber. These collimators are constructed to provide rectangular shape of field size that 
ranges from 0 x 0 to a maximum field size of 40 x 40 cm2 [2]. The collimators are made of 
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two pairs of tungsten or lead blocks (jaws) (Figure 2-14) and projected at a standard distance, 
such as 100 cm, from the X-ray source [2]. Besides the X-rays jaws, the multi-leaf 
collimators (MLCs) (Figure 2-14) are used in modern accelerators to provide irregularly 
shaped field blocking of the target tumour and modulate the beam intensity for the IMRT 
technique [2]. The field size is determined by a light localising system in the treatment head. 
This system consists of a light source and mirror that are located in the space between the 
jaws and the chambers, and the light beam is projected as if it were being emitted from the X-
ray focal spot [2]. 
 
2.2.4.1.3 Gantry  
Most of the Linac machines have the option of rotating the radiation source about the 
horizontal axis. When the gantry rotates, the collimator axis moves in a vertical plane. The 
collimator axis should be coincident with the central axis of the beam [2]. The isocentre point 
refers to the intersection point between the gantry axis, collimator axis and couch axis. For 
image guided-radiotherapy purposes, most modern accelerators are equipped with a gantry-
mounted imaging system such as CBCT [2].   
 
2.2.5 Quality assurance QA 
The term quality assurance (QA) refers to a program that is designed to control and maintain 
the standard and quality set of that program. In radiation therapy centres, the QA is 
essentially a set of procedures and policies to maintain the quality of patient care [2]. Model 
QA programs have been proposed by professional organisations, such as the American 
Association of Physicists in Medicine (AAPM), the American Society for Radiation 
Oncology (ASTRO), and the American College of Radiology (ACR) [2]. These programs 
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integrate several of the standards and criteria developed by the International Commission on 
Radiation Units and Measurements (ICRUM), the International Electrotechnical Commission 
(IEC), and the National Council of Radiation Protection and Measurements (NCRPM) [2]. In 
the SABR technique, patient-specific QA is essential to ensure that the delivered doses match 
the calculated doses. This type of QA should be developed as an integrated part of a 
comprehensive ongoing QA program in the clinic [29]. 
  
Because SABR delivers an extreme hypofractionated regime, the biological effect dose 
(BED) [127] is quite high for tumours and surrounding tissues. Thus, it is necessary to limit 
damage to normal tissue and maintain an ablative dose to the target [14, 128]. Due to the 
challenge in planning and delivering SABR, comprehensive patient-specific QA was 
established during the introduction of SABR into clinical practice [14, 128]. Patient-specific 
QA would include procedures such as validation of treatment plans [14]. This is achieved by 
comparing the dose distribution of the calculated dose by TPS with the measured dose by 
different dosimeters, like EBT films, ionisation chambers, and commercial diode detector 
arrays [40]. Comprehensive patient-specific QA requires measurements of both dose 
distribution and absolute doses. Therefore, in most radiation therapy centres, the patient-
specific QA involves two measurements using an ionisation chamber (to measure the 
absolute dose) and radiochromic films (to measure dose distribution in two-dimensional 
planar) [129]. The gamma index evaluation has become a standard technique to assess 
measured dose distribution in radiochromic films and commercial detector systems against 
the calculated dose distribution predicted by commercial treatment planning systems (TPS) 
[40]. The radiochromic films and gamma index are explained in Chapter 3, Sections 3.7 and 
3.10.
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Chapter 3 represents the general aspects 
of materials and methods utilised in this 
thesis experimental work.  
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Chapter 3 General Materials and Methods 
 
This chapter shows the material and methods utilised in the current thesis, including the 
following: 
• An illustration of the in-house custom-designed thorax dynamic phantom that was used to 
simulate the respiratory motion of the patient. It moves in two directions: 1) anterior/posterior 
and 2) superior/inferior. Also, this section explains the mechanical parts, the phantom’s 
accessories and programme source codes. 
 
• Description of the PRESAGE 3D dosimeter and dose visualisation in 3D. This is followed by 
a detailed illustration of the optical CT that was used in reading the PRESAGE data and the 
analysis software used to analyse the PRESAGE data, including PolyGevero® software and 
image J. 
 
• A 2D radiochromic film that demonstrates the dose distribution and film calibration. 
 
• A description of other phantoms that were used in this thesis, as follows: 1) IPSM phantom 
and 2) CIRS thorax phantom, both of which are used to study the dose calculation algorithms 
in SABR for lung cases (used for Chapters 6 and 7). 3) Rod phantom and 4) ArcCheck 
phantom, which are used to investigate the feasibility of using ArcCheck phantom to replace 
traditional radiochromic films (used for Chapter 9). 
 
• Devices to collect charges, such as an ion chamber and electrometer for measuring the 
ionisation charges and converting them into doses using an equation. This equation calculates 
the ion charge measurements and converts them into dose-to-water.  
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In each section, the explicit links are mentioned between the material and methods and the 
chapters in which they are used.  
 
3.1 The custom-designed thorax dynamic phantom 
A phantom is designed to simulate the motion of lung tumours in two directions: 
superior/inferior motion and anterior/posterior motion (used in Chapter 5) (Figure 3-1). The 
development of the custom-designed thorax dynamic phantom was achieved by 1) designing 
and integrating the mechanical parts, 2) developing source codes using Keil C [130] and C++ 
programs [24] to control the mechanical parts and provide the required motions, 3) the use of 
a commercial thorax phantom applicable for plain radiography and computed tomography 
scanning [131]. The phantom is an accurate life-size anatomical model of the human thorax. 
The design of the chest wall thickness is based on the clinical information [131](Figure 5-1).  
 
3.1.1 Mechanical parts of the phantom  
The mechanical parts of the custom-designed thorax dynamic phantom have different 
components. The body of the phantom is made of aluminium, which provides a solid support 
to the internal parts. This makes the phantom more efficient when performing numerous 
experiments or moving the phantom from one place to another. Figure 3-1 demonstrates the 
mechanical parts of the phantom and labels each part with a number.  
Each part of the mechanical parts is described below:  
(1) Switch mode power supply:  
It provides the required electric currents to the electrical parts, such as the stepper motor. 
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(2) Microcontroller development board:  
This part is similar to the motherboard of a personal computer. It contains a 
microcontroller with temporary memory (RAM) and flash rom for downloading codes 
that can translate the user’s orders into codes through the designed software. The code 
language used in this phantom is Keil C [130]. It can transfer the order codes to control 
the speed of both stepper motors.  
(3)  Protoboard contains resistances and capacitors: 
The main function is to discrete electronics for signal decoding. It controls the phantom 
motion in both directions using micro-switches (Figure 3-5).  
(4) DC motor:  
It is a direct current (DC) motor that moves in discrete steps. The speed of the DC motor 
is controlled by pulse width modulation (PWM). It drives the motor with a series of on–
off pulses and by varying the duty cycle. 
(5) Stepper motor controller: 
It controls both DC and stepper motors [label (4) and (6) in Figure 3-1] that control the 
phantom motion in the superior/inferior and anterior/posterior directions. 
(6) Stepper motor: 
It controls the phantom motion in the superior/inferior direction. There are multiple coils 
that are arranged in group-named phases. In sequence, the motor will rotate one step at a 
time when energising during each phase. It can achieve very precise positioning and 
speed control by using a computer controller. 
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Figure  3-1: The mechanical parts of the custom-designed thorax dynamic phantom; the labelled mechanical parts are explained as follows: (1) 
switch mode power supply; (2) a microcontroller development board; (3) protoboard that contains resistances and capacitors and 74 HC series 
logic chips for signal decoding; (4) DC motor that controls the phantom’s motion in anterior/posterior direction; (5) stepper motor controller; (6) 
stepper motor that controls the phantom motion in superior/inferior direction; (7) tooth drive belt that links the DC motor (4) with the aluminium 
bar  drive screw (8) and helps to control the anterior/posterior motion; (8) aluminium bar used to place the bellows for tracking the surrogated 
respiratory motion provided by the phantom; (9) and (10) PRESAGE holder for small PRESAGE samples with 4 cm diameter made of Perspex 
material to prevent artefacts that may occur during the 4D-CT scans; (11) PRESAGE holder for large PRESAGE samples with 8 cm diameter; 
and (12) cork material that covers the PRESAGE sample to simulate lung density. 
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(7) Tooth drive belt: 
This belt connects the DC motor in Figure 3-1(4) with the aluminium bar in Figure 3-1(8) 
and controls the vertical height of the phantom via rotation of the drive screw.  
(8) Aluminium bar:  
The bellows are placed on the aluminium bar for tracking simulated respiration during the 
anterior/posterior motion [(Figure 3-2 (A)]. The obtained amplitude from the phantom 
motion is recorded and displayed by the 4D-CT scanners [Figure 3-2 (b)]. The maximum 
peak represents the end-inspiration while the lowest peak represents the end-expiration. 
This feature would be helpful for gated studies [132].  
 
 
A 
B 
The bellows 
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Figure  3-2: (A) The bellows is placed on the aluminium bar to monitor the patient specific 
respiratory motion; (B) the phantom motion provides respiratory information in amplitude or 
wave form, and the bellows’ monitor signals and displays the information in terms of breaths 
per minute (bpm). The displayed bpm value, for example, 35 bpm, represents the simulated 
motion in the vertical direction with a stepper motor speed of 70% (PWM) [see Figure 3-6 
(A)].  
 
(9) and (10) The PRESAGE holder:  
It is made of Perspex-tissue-equivalent materials to provide strength and efficiency during the 
phantom’s motion and eliminate the metal artefacts in CT scans. The mechanical design of 
this holder allows the PRESAGE sample to move in two directions: vertically and 
horizontally. The maximum vertical motion goes up to 3.5 cm, and the maximum horizontal 
motion goes up to 1.75 cm.  
 
3.1.2 The phantom’s accessories  
(11) PRESAGE holder for large PRESAGE size 
The PRESAGE holder is made of a biodegradable plastic material called polylactic acid 
(PLA); it was created using a 3D printer and designed for the large PRESAGE sample (8 cm 
in diameter). It has two parts: the first part is connected to the PRESAGE holder with a small 
diameter of 4 cm (labelled number (10) in Figure 3-1). The second part is connected to the 
large PRESAGE that holds the sample with three screws (Figure 3-3).  
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Figure  3-3: A PRESAGE holder for a large sample size.  
 
(12) Cork material  
The cork is used as lung equivalent material because the CT numbers is almost similar to real 
lung in CT images ranged between -650 to -800 [133][Figure 3-4 (B)]. The cork was wrapped 
around the PRESAGE samples during the 4D-CT scan and irradiation process to simulate the 
real clinical condition when treating lung cancer [Figure 3-4 (B)].  
 
8 cm 
4 cm 
A 
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Figure  3-4: Cork material used in the phantom. (A) The real shape of the cork. (B) A CT 
image of the PRESAGE during the planning process using the SABR of a lung case. Here, 
the planning utilises the same beam configurations and prescription dose of the patient 
(28Gy/1 fraction). The hot spot in the middle of the PRESAGE sample represents the Dmax = 
32 Gy. The PRESAGE sample is encircled by a cork material. The point tool (the cursor and 
the small window in the right side) shows the CT value of the cork material (CT number = -
632). (C) The cork material encircles the small PRESAGE sample with a 4 cm diameter. (D) 
The cork material encircles the large PRESAGE sample with an 8 cm diameter.  
B 
C D 
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Two measurers are placed on the phantom close to the micro-switches to measure the 
displacement of the phantom’s motions in both directions: superior/inferior and 
anterior/posterior (Figure 3-5). 
 
 
 
Figure  3-5: Two measurers are placed on the phantom to measure the displacement distance 
for: (A) superior/inferior motion and (B) anterior/posterior motion. The red arrows represent 
the micro-switches that limit the motion in both directions.  
 
3.2 The written code for the phantom 
Software called real position management (RPM) was developed using C++ programming 
[24]; the goal was to control the phantom’s motion. The appendix (X) illustrates all the 
written codes and commands used in designing the software. Figure 3-6 demonstrates the 
interface of the developed software. The software can control the speed of both stepper 
motors and the direction they take.  
B 
A Micro-switches  
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Figure  3-6: The interface of the in-house software called real position movement (RPM); it 
was developed to control the motion of the custom-designed thorax dynamic phantom. This 
software was developed by C++ programming to control both stepper and DC motors in a 
vertical direction (anterior/posterior) and in a longitudinal direction (superior/inferior). The 
software has three sections: (A) It controls the speed and direction of the DC motor for 
motion in the anterior/posterior direction. The DC motor’s speed is controlled by PWM. (B) 
It controls the speed and direction of the stepper motor for motion in the superior/inferior 
direction. (C) The written codes and commands are used to control both stepper motors. (D) 
This shows a shortcut icon of the RPM software.  
 
A 
C 
B 
D 
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3.3 PRESAGE dosimeter 
The PRESAGE is a solid radiochromic 3D dosimeter that can be used across a wide range of 
clinical applications (used in Chapter 5) [134]. It is not considered a gel dosimeter, and it is 
composed of the following: a transparent polyurethane matrix (forming 90% of the total 
weight of the PRESAGE dosimeter), Triarylmathane leuco dye (radiation-sensitive reporter 
component) and halogenated carbon radical initiators [134, 135]. The halogenated carbons 
(halocarbon) are a class of organic compounds that contain a covalent bond of halogens, for 
example, iodine (I), bromine (Br) and chlorine (Cl) [134]. The bond homolysis between the 
carbon and the halogen is formed of free radicals upon irradiation. The physical properties 
(elasticity and transparency) of the PRESAGE polyurethane matrix rely on monomeric 
isocyanate and polyol, which are catalysed by metal compounds [134]. The dosimeter 
sensitivity of the PRESAGE is influenced by these metal compounds and trihalomethane 
initiators [134]. The free radicals oxidise the leuco dye, resulting in altering the PRESAGE’s 
colour (Figure 3-7) or the optical density that was caused by the radiolytic oxidisation of the 
leuco dye [135].  
 
There are many advantages when it comes to using PRESAGE, such as recording dosimetric 
data in 3D space and at a high spatial resolution. Also, it has a great degree of stability with 
respect to the diffusion of the image over time and its relative insensitivity to room light 
[136]. Because it is solid, unlike a gel dosimeter, it is easier to handle and implement with a 
clinical phantom and needs no external container that could limit optical light reflection and 
refraction at surface boundaries [137]. Moreover, the PRESAGE is capable of measuring the 
absolute value of the absorbed doses of radiation, measuring depth-dose distribution and 
isodose curves [138]. The PRESAGE’s response is suited for accurate optical CT because of 
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its low-scatter fraction [139]. Many studies demonstrate the validation of the PRESAGE as a 
practical and clinical 3D dosimeter [139, 140].  
 
Figure  3-7: Two PRESAGE samples illustrate the colour changes during irradiation. The 
original colour of the PRESAGE is clear (un-irradiated sample on the left). After the 
irradiation, the PRESAGE colour changes to green (irradiated sample on the right).  
  
3.4 Optical CT 
The readout process of the PRESAGE dosimeter is obtained by utilising the high-resolution 
optical CT scanner, which uses a charged coupled device (CCD) area detector for signal 
digitisation (Figure 3-8) [141]. To scan with the PRESAGE dosimeter, it must be placed on a 
rotating stage inside an anti-reflection coated-glass aquarium [139, 140]. In this case, the 
aquarium was filled with refraction index (RI)-matched fluids composed of a mixture of octyl 
salicylate, methoxy octyl cinnamate and a small amount of green oil-based dye (about three 
to four drops) [139, 140]. The dyes play an important role in equalising the light attenuation 
between the PRESAGE dosimeter and the fluid; hence, it optimised the dynamic range of the 
scanning system. The incident illumination was produced by a 633 nm LED array (Modus 
Un-irradiated PRESAGE Irradiated PRESAGE with 26 Gy  
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Medical Devices Inc., London, ON, Canada). The peak sensitivity of the PRESAGE 
dosimeter was matched to the light source [139, 140].  
 
Figure  3-8: Schematic diagram shows light rays through the CCD-based optical CT scanner. 
The CCD camera chip is used to focus the projection images through the PRESAGE 
dosimeter. It uses a telecentric lens system. At each rotation step, a 2D projection is acquired 
[132].  
 
The optical CT scanner was warmed up an hour before scanning. Then, a scan without the 
presence of the sample was carried out to check the light source’s stability. For each scan, a 
set of 512 light intensity transmission projections with a resolution of 1024 X 768 pixels was 
obtained over 360 degrees. The shutter speed was 32.1 ms, the gain was 10.1 dB and the 
frame rate was 7.5 frames per second (fps). When the object is placed on the rotating stage, a 
series of two-dimensional optical projections of the region of interest can be captured by the 
scanner; using this information can then provide a 3D map by utilising Feldkamp-filtered 
projection [142].  
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3.4.1 Pre- and post-scan for the PRESAGE 
The scan process of the PRESAGE sample done by the optical CT has two vital parts: pre-
scan and post-scan (Figure 3-9). The pre-scan can have three functions: 1) It permits for the 
calibration of the light field that was provided by the scanner [143]. This would not be 
typically homogenous; hence, it can show either a set of isolated imperfections or smooth 
variations. 2) It enables the removal of specific features of the PRESAGE sample from the 
image. This includes two factors: the wall effects and baseline roll caused by the mismatch of 
the residual RI. By a subtraction or modelling process, the signal-to-noise ratio (SNR) of the 
final image can be improved. The other factor is the optical artefacts that are caused by the 
sample’s imperfections. They appear as constant artefacts between the two scans and can be 
removed by subtracting the reference pre-scan. This voxel-by-voxel correction, however, 
needs an excellent reproducibility of the sample’s positioning. 3) The pre-scan can provide a 
baseline map of the optical density of the PRESAGE sample. After subtraction from the post-
scan, the resulting image represents the map of the variation in optical density that was 
induced by the radiation, indicating the quantity of the absorbed dose.  
 
Figure  3-9: (A) an example of the pre-scan sample of PRESAGE. (B) The post-scan sample 
after irradiation for the same PRESAGE sample [144].  
Pre-scan Post-scan 
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Irradiation and subsequent scanning for the PRESAGE sample must be carried out as soon as 
possible after the pre-scan process [144]. Also, the post-scan should utilise identical 
parameters to the pre-scan process of PRESAGE sample. After finalising the post-scan, the 
optical CT images come in two data sets: the reference images (without irradiation) and the 
irradiated images. Both are required for the reconstruction process [144]. The main aim of 
reconstruction is to reform the individual projections into a set of sonograms, filtering the 
sonograms and providing back projection [144]. This is described mathematically by Kak and 
Slaney., 1988 [145]. The enhancement of the image by median filtering and removing 
artefacts are typically carried out by post-processing. To convert the optical density data of 
the scanned samples into dose data, it is important to generate a calibration curve for different 
doses [144]. Currently, each vendor of the optical CT develops their own software for 
reconstructing the three-dose map. In this project, Vista 3D-reconstruction was used for post-
processing of the PRESAGE samples [144].  
 
3.5 Image J software 
Image J software was designed to process and manipulate the digital imaging (used in 
Chapter 5). It has the ability to analyse radiochromic films, gel and PRESAGE dosimeters 
(Figure 3-10). For image manipulation, the software provides a very convenient interface that 
contains a large number of different functions, allowing for efficient interaction with the 
image tools. The digital image processing offers well-documented software libraries that can 
be used to implement prototype applications or a new image-processing algorithm. Therefore, 
image J software can be extended easily by writing new codes in the available software’s 
libraries. Because it is implemented in Java, image J can be run on any operating system. 
Java’s dynamic execution model presents new plugins that can be written independently as 
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Java code. While running the software and without restarting image J software, these plugins 
can be executed, compiled and loaded on the fly. This makes the software an ideal platform 
because it is very suitable for developing and testing new image-processing techniques and 
algorithms. Also, it is available for free and needs no license for installation. Image J 
software is often used in serious applications and research development, particularly in the 
biological and medical fields. However, this software is not intuitive because it needs a strong 
orthogonal structure, such as completing multiple tasks in different ways. The main features 
of image J can be described as follows: 1) It offers a macro-language related to the 
corresponding interpreter. This allows for more implementation blocks through the 
combination of the available functions without Java’s knowledge. 2) The core functionality 
of image J can be extended by a simple plugin mechanism that is obtained by writing a small 
piece of Java code. 3) It has a set of ready-to-use tools for visualising, analysis, creating, 
editing and sorting images. It can support several different common file formats such as VFF. 
The software can provide image sequences (stacks), (deep) 16-bit integer images and 32-bit 
floating-point images [146].  
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Figure  3-10: The interface of Image J software depicts the PRESAGE’s sample analysis. The 
pointer (red arrow) is placed in the middle of the PRESAGE’s dosimeter to measure the 
pixels’ values; the software provides measurements including area, mean, minimum and 
maximum pixel values.  
 
3.6 PolyGeVero software 
PolyGeVero® software is used to calculate the dose in PRESAGE and gel dosimeters (used 
in Chapter 5). It consists of four workspaces: 1) calibration workspace; 2) calibration curve 
with summary table workspace (named CCTW); 3) gel dosimetry dose distribution 
workspace; and 4) gel dosimetry versus treatment planning system workspace (gel dosimetry 
vs. TPS) [147, 148]. The software was designed to allow the user to calculate data acquired 
by scanning the 3D dosimeters with computed tomography (CT), magnetic resonance 
imaging (MRI) and optical computed tomography (optical CT). The calculation includes two 
file formats: 1) VFF files of a VISTA cone beam optical CT (modus medical device, Canada) 
and 2) The DICOM files. Also, the software’s structure can be expanded to other file formats 
[147, 148]. The calculations can be exported to the BMP and TXT file format, for example, 
1D and 2D graphs, in the form of reports and signal and dose maps [147, 148].  
 
In the calibration workspace, the user can find tools for the computation of the calibration 
equations that are based on a few calibration options such as multi-vials (this option uses a 
few vials that are irradiated with two or three bands of varied doses); cross-beams (the 
ionising radiation beams crossed in PRESAGE or polymer gel dosimeters generating several 
bands of different absorbed doses inside one plane and one phantom); depth dose (uses a few 
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vials to observe the build-up of the absorbed dose and is reduced along the longer axis of the 
used vial) [147, 148]. In the calibration workspace, the calibration equations are stored with 
the calibration’s characteristics in the curve calibration summary table. This workspace saves 
the database of the calibration curves. The third workspace (gel dosimetry dose distribution) 
measures the 3D cube of absorbed dose distribution of the 3D dosimeters (available in .vec 
file) [147, 148].  
 
Figure  3-11: Comparison between the PRESAGE dosimeter and the DICOM image of EBT3 
film for the same delivered dose of 30 Gy.  
 
The gel dosimetry versus treatment planning system workspace is used to compare two 
datasets of dose distribution, such as the PRESAGE dosimeter and TPS (Figure 3-11). This 
comparison is based on the gamma index calculation, dose difference, gamma angle and 
correlation (Pearson coefficient) of the two datasets. The isodoses, profiles and 2D planes of 
the dose distribution can be viewed and compared in any plane in all the 3D matrixes. The 
PolyGeVero® software provides better data visualisation; it allows for displaying a single 2D 
plane and multiple planes of dose distribution into a 3D view (Figure 3-12).  
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Figure  3-12: A 3D view of the PRESAGE sample (irradiated by 10 Gy) using the 
PolyGeVero® software.  
 
3.7 Radiochromic Films 
The radiochromic films are 2D radiation detectors (used in Chapter 9). In the 1980s, these 
films were widely accepted in medical radiotherapy and ionizing radiation dosimetry [149]. 
They are composed of a thin polyester base saturated with radiation-sensitive organic 
microcrystal monomers. When the film is irradiated, the film emulsions change colour 
because of a chemical reaction called polymerisation [149]. The radiation-response signal is 
read out by calculating the optical density using a spectrometer at a specific wavelength. The 
polydiacetylene-based Gafchromic film is the most preferable radiochromic film for medical 
applications; it is designed by International Specialty Products (ISP) [149]. Varied film 
implementations of the Gafchromic films exhibit different dose responses from keV to MeV, 
which can be used in different areas of radiation therapy. For instance, by using only a 6.7-
µm thick active layer, the Gafchromic HD-810 film (Table 3-1) can be employed in high-
dose radiation measurements (up to 2500 Gy) [149]. Several studies have discussed the 
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assessment of Gafchromic films in terms of their performance and characterisation, including 
their image resolution, film stability and dose-response function (sensitivity). Gafchromic 
films are easy to handle and provide precise and accurate dose measurements [149]. The 
energy dependence of the Gafchromic EBT2 films was examined by Butson et al. 2010 [150] 
for the X-ray range of 50 kVp to 10 MVp. The study showed a 6.5 % ± 1% discrepancy in the 
optical density to absorbed dose response [150]. The environmental factors, such as UV 
exposure, humidity and temperature, must be considered because of the readout and 
irradiation process of the radiochromic films [149].  
 
Table  3-1: List of commercial Gafchromic films for radiotherapy [149].  
  
 
This thesis utilises EBT-3 films to generate gamma index for patient-specific QA (in Chapter 
9). The gamma index is explained in Chapter 3, Section 3.10. The gamma evaluation of the 
EBT3 films in this thesis were analysed by FilmQAPro® software (ISP Advanced Materials, 
New Jersey, USA) [151]. 
 
3.7.1 Film calibration  
In this thesis, film calibration followed the recommendations of the American Association of 
Physicists in Medicine (AAPM) radiation therapy committee task group 55 [152]. The 
radiochromic films were calibrated using a uniform radiation field. Films were placed on the 
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central portion of a large photon beam measuring 40 x 40 cm2. During the film calibration 
process, another dosimeter-like ionisation chamber was used to determine the characteristic 
of the calibration beam (the ionisation chamber is explained in Chapter 3, section 3.11) [152]. 
Using other dosimeters allowed for direct film calibration in terms of absolute dose within the 
required dose range e.g. 0–33 Gy. After irradiating the films, the relationship between the 
absorbed dose and film response was determined [152]. This relationship was then plotted as 
a curve called calibration curve. In general, the calibration curve aids in converting film’s 
response to dose (Figure 3-14). Also, the relationship between the dose and film’s response 
can be tabulated. The variation in the film’s response per unit absorbed can be represented as 
an individual number for a net optical density. This number can then be defined as the film-
average sensitivity for the irradiated or non-irradiated films (Figure 3-13) [152]. In this thesis, 
to generate calibration curves, EBT3 films were cut into 2 x 2 cm2 sizes and irradiated with 
different doses (0 to prescription dose [PD] in steps of 3 Gy, PD + 3 Gy) and scaled 
according to the prescription dose (Figure 3-13 and Figure 3-14). The irradiated films were 
marked on three corners with unique marks (∆, X and O) to identify the correct orientation 
during the film’s scanning (Figure 3-13).  
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Figure  3-13: Eight calibrated films demonstrate the dose-response data for irradiated films 
ranging from 0–3,300 cGy (100 cGy = 1 Gy); the size of each film is 2 x 2 cm2. The blue 
arrows head in the 0 cGy film (on the top) represent the unique marks: ∆, X and O that help 
in identifying the film’s orientation when using the scanner. The rectangle frame in the 
middle of each film is a tool used by FilmQA pro software to determine the film’s sensitivity 
for individual films at the selected area. This information is tabulated in two columns: 
absorbed dose (cGy) and film-sensitivity response.  
 
 
Film sensitivity 
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Figure  3-14: Calibration curve information (dose-response data) for EBT3 films using 
FilmQA pro software [153]. The film’s sensitivity changes during the irradiation exposure 
from 0 cGy to 3,300 cGy. The information of the curve’s calibration is obtained from the 
table in Figure 3-13.  
   
3.8 Rod phantom  
The Rod phantom is an in-house designed solid Perspex phantom (used in Chapter 5 and 
Chapter 9). The rod phantom consists of multiple Perspex slabs stacked together and has a 
dimension of 35 cm length x 20 cm height. It is designed to mimic the shape of the thorax 
and has slots for placing films in the transverse plane (Figure 3-15). The film slot has three 
pins that aid in film registration and to identify the film’s orientation. It facilitates the 
measurement of both the absolute dose (using an ionisation chamber) and dose distribution 
(film) simultaneously. 
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Figure  3-15: The rod phantom consists of several slabs. The EBT3 film was resized to 12.5 x 
20.5 cm2 to fit into the film slot. The EBT film was inserted between the slabs for measuring 
the dose distribution for patient-specific QA. The blue arrows in the EBT represent the 
metallic pin marks caused by the slab and unique marks (∆, X and O) that help in identifying 
the film’s orientation when using the scanner. The rod phantom has a port for the ion 
chamber (IC) to measure the absolute dose.  
 
3.9 ArcCheck phantom  
ArcCheck is a cylindrically shaped phantom with a 21-cm array length and 21-cm array 
diameter (used in Chapter 9) (Figure 3-16). It is composed of 1386 n-Si diodes (0.8 mm x 0.8 
mm) arranged in a helical shape at a 3-cm depth along the long axis of the phantom [40, 154]. 
The detectors are spaced 1 cm centre-to-centre and measure both the entrance and exit doses 
during irradiation [40, 154]. This phantom contains a homogenous PMMA cylinder (cavity 
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plug) with a 15 cm diameter [Figure 3-16 (B)] [40]. The cavity plug is capable of integrating 
the ion chamber (IC) or radiochromic films. The IC is explained in Chapter 3, Section 3.11. 
The SNC Patient™ software (Ver. 6.6) enables the user to compare the measured dose by the 
ArcCheck phantom and the calculated dose imported from the treatment planning system 
(Figure 3-18).  
  
Figure  3-16: (A) The ArcCheck phantom placed on the table of the Linac system. (B) The 
cavity plug is located at the rear of the phantom.  
 
This thesis also utilised the ArcCheck phantom for patient-specific QA. The gamma 
evaluations were analysed with the SNC Patient™ software (Ver. 6.6). The gamma index is 
explained in (Chapter 3, Section 3.10). 
 
3.10 Gamma index  
In radiation therapy centres, the commissioning of a treatment planning system is required to 
compare the measured and calculated dose distribution. Initially, the physicists determine a 
A B 
Cavity plug 
Head of Linac 
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set of irradiation conditions for which the treatment planning is to be assessed [155]. The 
measured dose distributions are acquired for these treatment planning, and then the 
corresponding isodose distributions are printed or displayed [155]. The qualitative assessment 
of the treatment planning system’s computation is achieved by overlaying the measured and 
the calculated isodose distributions either by hand utilising the printed isodose distributions 
and light box or by utilising software. This assessment highlights regions showing significant 
disagreement. The quantitative assessment’s methods directly compare the values between 
the measured and calculated dose distribution [155]. The QA procedures for a treatment 
planning system were descried by Van Dyk et al., 1993 [156]. They subdivided the dose 
distribution comparison into areas of low and high gradients, each with a varied acceptance 
criterion. In low-gradient areas, the doses are compared directly, with an acceptance tolerance 
placed on the variation between the measured and calculated doses [156]. The dose-
difference (DD) distribution can be displayed to determine the areas where the calculated 
dose distribution differs from the measurements [157].  
 
In high-dose gradient areas where the spatial extents of the areas are large, there is a small 
spatial error for the calculated and measured doses, resulting in large dose variation between 
them [115]. Therefore, the (DD) in high-dose gradient areas may be unimportant, and the 
concept of a distance-to-agreement (DTA) [115] is applied to identify the acceptability of the 
dose calculation. The DTA is the distance between the measured data point and the nearest 
point in the calculated dose distribution that displays the same dose. The DD (for low-dose 
gradient areas) and DTA assessments (for high-dose gradient areas) complement each other 
when they are used to determine the quality of the dose distribution calculation [155]. A 
sophisticated analysis developed by Harms et al., 1994 [158], which was based on Shiu et 
al.’s, 1992 [159] concept, and applied by Cheng et al., 1996 [160] uses a pass-fail criterion 
112 
 
for both the DD and DTA. In this analysis, each measured point is assessed to identify if both 
the dose difference and DTA exceed the selected tolerance, for example, 3% and 3 mm, 
respectively (Figure 3-17 and Figure 3-18). This analysis is known as a gamma index (γ) 
evaluation or gamma criteria [40]. The gamma index is defined as the minimum radial 
distance between the measurement point and the calculation points that are expressed as a 
surface in the dose-distance space [155]. The two gamma criteria (as these gamma criteria are 
widely accepted elsewhere) [161, 162] are: 1) 3% dose difference and 3 mm distance in 
agreement with a 95% pass rate and 2) 2% dose difference and 2 mm distance in agreement 
with a 90% pass rate [161, 162]. This thesis utilised the gamma index for PRESAGE data 
analysis in Chapter 5 and for patient-specific QA using EBT3 films and ArcCheck phantom 
in Chapter 9.    
 
Figure  3-17: Interface of the FilmQA Pro software. The first section (left) shows the case 
management tree with which uses can upload the calibrated, measured and calculated EBT 3 
films. The second section (middle) displays the selected images such as measured and 
calculated dose images. It represents two superimposed images for the measured and 
 
Measured and calculated doses are superimposed  Isodose comparison between Measured and calculated doses  
 γ passing rate 
DD 3% DTA 3% 
Controller 
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calculated doses for the lung SABR case. The controller moves the image of the calculated 
doses in different directions (up and down, right and left) until both images are overlapped. 
The third section (right) displays the calibration data or information on the images displayed 
in the second section. It illustrates the isodose of the measured and calculated doses. The 
gamma analysis tool is represented at the bottom of section three, indicating γ passing rate 
(99%) for a gamma criterion of DD = 3% and DTA 3mm.  
  
 
Figure  3-18: Interface of the SNC patient software depicts the gamma index evaluation of 3% 
DD and 3 mm DTA between the measured doses and calculated doses of an irradiated field 
size (10 x 10 cm2). This analysis was obtained by SNC patient software designed for 
ArcCheck phantom.  
 
 Measured doses  Calculated doses 
 Both measured and calculated doses are superimposed 
 Points of both measured (Set 1) and calculated doses (Set 2)  
 
DD = 3% 
DTA = 3% 
Passing rate = 100% 
Passed points = 1281 
Failed points = 0 
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3.11 Farmer chambers or ion chambers (IC) 
For measuring the exposure rate in air, condenser chambers such as the Victoreen R meter 
were used commonly for lower energy beams, for example, ≤ 2 MeV, in the early days of 
radiotherapy [2]. However, because of the stem design and its excessive leakage, these 
chambers created dosimetric problems, particularly with phantom measurements [2]. In 1955, 
Farmer designed a chamber that provided a reliable and stable secondary standard for the 𝛾 
rays and X-rays for all energies within the therapeutic range [163]. To measure the ionisation 
charges, this chamber must be connected to a specific electrometer. The original design was 
developed by Aired and Farmer to provide more consistency in the design and hence a better 
or flatter energy response [164]. Figure 3-19 shows the chamber design, including the actual 
dimension of the central electrode and thimble. The central electrode is made of pure 
aluminium, and the thimble wall is made of pure graphite. The insulator is composed of 
polytrichlorofluoroethylene (PTCFE) material. The collecting air-cavity volume of the 
chamber is about 0.6 ml (0.6 cc)[2]. This thesis utilised IC volume of 0.6 cc in Chapters 6 and 
7. 
 
Figure  3-19: Schematic diagram of the Farmer graphite or aluminium chamber [2, 164].  
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3.11.1 Farmer chamber’s components  
The Farmer chamber is composed of four parts: 1) chamber wall; 2) outer electrode; 3) 
central electrode; and 4) guard electrode.  
3.11.1.1 Chamber wall 
The thimble wall of the Farmer chamber is made of different materials, such as graphite or 
plastic, including tissue-equivalent plastic, air-equivalent plastic, nylon and PMMA (acrylic). 
For the plastic thimble, the inner surface of the wall is coated with a thin layer of graphite for 
conducting. The wall’s thickness varies among the different models, ranging from 0.04–0.09 
g/cm2.  
3.11.1.2 Outer electrode  
The thimble wall or the inner surface of the thimble wall is coated with a conducting 
material.  
3.11.1.3 Central electrode 
It is composed of a thin aluminium rod of 1 mm in diameter that delivers the ionisation 
current to the electrometer (a charge-measuring device).  
3.11.1.4 Guard electrode  
 It is a cylindrical conductor that covers the insulator around the central electrode in the stem 
of the chamber. The guard electrode is wrapped by a second insulator to separate the guard 
from the outer electrode. The main function of the guard electrode is to decrease the leakage 
of extra charges. Moreover, it enhances the signal-to-noise ratio (SNR) to the central 
electrode.  
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3.12 Electrometer  
Combining the IC and electrometer helps to measure the ionisation current and integrated 
charges (used in Chapters 6 and 7). The electrometer uses a special circuit that can measure 
small ionisation charges accurately. Negative-feedback operational amplifiers are the most 
commonly used for ion chamber dosimetry. The operational amplifier (OP AMP) is a triangle 
that has two input point (the red triangle in Figure 3-20 from A-C). The positive terminal is 
called the non-inverting position, and the negative one is the inverting terminal. This implies 
that when positive voltage is applied to the non-inverting terminal, it provides a positive 
amplified voltage, and when a negative voltage is applied to the inverting terminal, it will 
also provide a positive amplified voltage. There are three simplified circuits that are used to 
measure ionisation: 1) the integrated mode; 2) the rate mode; and 3) the direct-reading 
dosimeter mode (Figure 3-20 from A-C). 
 
In the integrated mode [Figure 3-20 (A)], the ion chamber collects the charges (Q) and 
deposits them in the feedback capacitor. A voltemeter reads the voltage (V) across (C), which 
is given by Q/C, where (C) is the capacity. This voltage measurement is essentially the 
measurment of the ionisation charge. In the rate mode [Figure 3-20 (B)], a resistance (R) 
replaces the capacitor, and the generaed voltavge (V) across the resistance is calculated by V 
= IR, where (I) is the ionisation current, and (R) is the flow through the resistance. This 
voltage measurement reflects the magnitude of the ionisation current. The application of a 
closed-loop makes a unity operational amplifier [Figure 3-20 (C)]. By using a voltage 
divider, a variable fraction of the output voltage is fed back into the input. Then, the 
electrometer can be converted into a direct-exposure reading instrument for a known chamber 
and radiation quality, and it can be calculated by (R/min), where R is the resistance.  
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Figure  3-20: Schematic diagram of the three types of simplified circuits when the ion 
chamber is connected to the negative-feedback operational amplifier. (A) Integrated mode; 
(B) Rate mode; (C) Direct-exposure reading mode.  
 
Figure  3-21: The ion chamber (0.6 cc) (the left image) and electrometer device (the right 
image). The ion chamber transfers the ionisation charge using the graphite chamber 
(explained in Figure 3-19) and is connected to the electrometer to transfer the ionisation 
charges to the electrometer. The electrometer screen displays the charges in Nano-coulombs.  
 
The graphite chamber 
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The collected charges using the IC (Figure 3-21) can be converted into dose to water (𝐷𝑤) 
with the reference point (𝑍𝑟𝑒𝑓) by using the following equation [165, 166]:  
 
𝑫𝒘 (𝒁𝒓𝒆𝒇) = 𝑴𝒄𝒐𝒓𝒓 𝑵𝑫,𝒘,𝑸′ 𝒌𝑸,𝑸′ 𝒌𝒔𝒂𝒕              ( 3-1) 
 
Where 𝑀𝑐𝑜𝑟𝑟 =  𝑀𝑘𝑝,𝑡 𝑘ℎ 𝑘𝑝𝑜𝑙 is the reading of the chamber (M) corrected for temperature or 
pressure (𝑘𝑝,𝑡), humidity  (𝑘ℎ) and polarity (𝑘𝑝𝑜𝑙). 
𝑁𝐷,𝑤,𝑄′ is the calibration factor in terms of the absorbed dose to water for the ionisation 
chamber at a reference beam quality 𝑄′. 
𝑘𝑄,𝑄′ is the correction factor for the difference between the response of an ionisation chamber 
in the reference beam quality 𝑄′ that is used for calibrating the chamber and the actual used 
beam Q. 
𝑘𝑠𝑎𝑡 is the factor to correct the response of an ionisation chamber for the lack of complete 
charge collection because of ion recombination.  
 
3.13  IPSM phantom  
In 1982, this phantom was designed by the Institute of Physical Sciences in Medicine (IPSM) 
Radiotherapy Topic Group (used in Chapter 6). It is made of epoxy-resin (water-equivalent 
material) from the Department of Medical Physics at the London Hospital [41]. It consists of 
six removable water-equivalent rods that are 3 cm in diameter and that can be substituted by 
(IC). In this thesis, the rods were substituted with the IC for all measurements [Figure 3-22 
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(E, F and G)]. The phantom also has a 9-cm water-equivalent insert that can be replaced by 
other material inserts that are equivalent to the lung, rib and dense bone [Figure 3-22 (A),(B) 
,(C) and (D)]. In Chapter 6, the dose measurements were conducted using a 0.6 cc IC. The 
IPSM phantom was used to evaluate the accuracy of the dose calculation algorithms. 
 
  
 
 
A B C D 
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Figure  3-22: (A–D) Images of different density inserts for the IPSM phantom: (A) Lung 
density insert; B) water density insert; (C) dense bone insert; and (D) rib density insert. The 
IPSM phantom is illustrated in E, F and G. (E) The IPSM phantom with the dense bone insert 
and the gantry angle of 90o. The IC is placed at the ISO point. (F) A CT image of the IPSM 
phantom with the lung density insert displayed in Eclipse-TPS; it has six points: iso, POI1, 
POI2, POI3, POI4 and POI5. The CT image demonstrates the beam field of 10 x 10 with 
gantry angle 90°. (G) A special insert inside the lung density to measure POI 6 for beam field 
of 4 x 4 with gantry angle 90°. The red arrows indicate in and out-of-field points.      
E 
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3.14  CIRS thorax phantom  
The CIRS thorax phantom is an anthropomorphic thorax phantom (IMRT phantom Model 
002LFC CIRS, Norfolk, VA, USA) (used in Chapter 7). It is made of tissue-equivalent 
materials that has the radiological properties of bone and lung as inhomogeneity [167]. The 
phantom dimension is 30 cm x 20 cm x 30 cm [168]. The thorax section of the phantom was 
drilled to accommodate the rod inserts and it was filled with solid plugs (Figure 3-23). This 
phantom was designed to measure the doses using the IC (0.6 cc), which can replace the solid 
plugs [Figure 3-23 (A) and (B)] or radiochromic films that can be inserted within the 
phantom [167]. In Australia, the Australian Clinical Dosimetry Services (ACDS) has been 
validating the CIRS thorax phantom and utilising this phantom in two audits (level II and III 
audit) for investigating the accuracy of dose calculation [167, 169, 170]. The CIRS thorax 
phantom exhibits a good performance in detecting the dose calculation discrepancies between 
the IC and TPS.  
 
 
A 
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Figure  3-23: CIRS thorax phantom placed on Linac treatment delivery table with gantry 
angle 0o. (A) An axial CT image of the CIRS thorax phantom illustrates 10 cylindrical ports 
filled with solid rods [167]. (B) Phantom setup for measurements on the Linac. The port 
number (9) was placed with the ion chamber for measurements.  
 
3.15  Statistical Analyses 
The data presented in all chapters (mean ± standard deviation) was the result of three or more 
independent measurements as indicated in each chapter. One-way analyses of variance 
(ANOVA) with repeated measures (RM one-way ANOVA) or paired t-test were used to 
determine the significance of the difference between the control and experimental group. A 
difference was considered to be statistically significant when p<0.05.  
B 
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Chapter 4 Investigation of MIP based and Phase 
Specific Planning in Lung SABR 
 
4.1 Summary 
The aim of this chapter is to investigate the dosimetric impact of tumour motion by assessing 
the tumour volumes (GTV, PTV) and the dosimetric variation (mean and maximum doses) 
between the current practice of the MIP based planning (conventional method) and the phase 
specific planning method using the 4D-CT dataset in SABR of lung tumours. The MIP based 
planning method (using MIP projections) is widely used and accepted in most radiation 
therapy centres [72]. “MIP projections represent the greatest data values encountered along 
the viewing ray for each pixel of volumetric data and they provide a full intensity display of 
the brightest objects along each ray on the projection image” [72]. Because the MIP dataset is 
used for delineating the target volumes including the PTV, it directly affects the delivered 
doses to the PTV due to the intra-fraction or respiratory motion [23]. Therefore, this chapter 
investigates planning methods that account for the tumour motion and reduce the doses to 
normal tissues.      
 
4.2 Introduction  
 
SABR is defined as the precise irradiation of an image-defined extra-cranial lesion utilising a 
small number (one to five) of high-dose fractions [18]. It is characterised by the following: 1) 
a short time period in treating the patient associated with a fewer fractions than a 
conventional course of radiation therapy [18]. This lowers the treatment cost for the patient 
and radiation therapy institution. 2) Increasing the radiation dose to the tumour per fraction 
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enhances the possibility of achieving local tumour control. 3) SABR spares a considerable 
dose-volume of the surrounding normal tissues by reducing the target margins with the 
assistance of 4D-CT (4D-CT is explained in Chapter 2, Section 2.2.2.2). 4D-CT permits the 
physicians to account for tumour motion when delineating target volumes, such as GTV, 
CTV, ITV and PTV (tumour volumes are explained in Chapter 2,  Section 2.2.2.6) [18].              
 
In the treatment planning of SABR of the lungs, the PTV is an essential component because it 
accounts for the setup variations of inter- and intra-fractional target motion. The PTV is 
derived from the delineated GTV. When treating a lung tumour using the SABR technique, 
the beams’ arrangement should be optimised specifically to the PTV location [17, 171]. 
Inaccuracies in the PTV result in under-dosing the tumour or overdosing normal tissue and 
hence increase the toxicity to the surrounding tissues [17, 171]. The ITV is generated by 4D-
CT from a set of binned CT images containing temporal and spatial information related to the 
patient’s breathing i.e. 0% to 90% of the respiratory phases [17]. In many clinical radiation 
therapy centres, the ITV delineation is based on MIP images whilst the dose calculation is 
performed in AIP images (MIP and AIP are explained in Chapter 2,  Section 2.2.2.5) [17]. 
The ITV is defined as the volume encompassing the GTV volumes in all respiratory phases in 
4D-CT images [72].                    
 
Two well-known methods are used to create tumour volumes using 4D-CT images in clinical 
practice [72]. The first method involves the two-phase planning of 4D-CT datasets: end-
expiration and end-inspiration bins (Figure 4-1). This is followed by the generation of an 
encompassing ITV volume. However, this method has two disadvantages: 1) in cases of 
small, highly mobile tumours, the extreme positions of the tumour may be so far apart, that 
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intermediate tumour positions are needed for generating a reliable ITV. 2) The use of only 
two extreme phases (end-expiration and end-inspiration) may neglect the potential of tumour 
hysteresis (the tumour mobility following varied paths during the inspiration and expiration 
process). This phenomenon was described by Seppenwoolde et al., 2002 [172]. The second 
method (or the conventional method) is based on the post-processing tool in 4D-CT called 
MIP to create a reliable ITV [173]. “MIP projections represent the greatest data values 
encountered along the viewing ray for each pixel of volumetric data and they provide a full 
intensity display of the brightest objects along each ray on the projection image” [72]. 
Because the MIP projections reflect combined images with the phase summation of different 
tumour positions during all respiratory phases, they can produce a reliable ITV [72]. This 
method (using MIP projections) is widely used and accepted in most radiation therapy centres 
[72].   
 
Because the MIP dataset is used for delineating the target volumes including the PTV, it 
directly affects the delivered doses to the PTV due to the intra-fraction or respiratory motion 
[23].  “It is often thought that the use of 4D-CT increases dose to normal lung tissue because 
of the greater gross tumour volume that is contoured” [23]. Therefore, a method that can 
reduce the PTV volume and consider the variation in tumours positions due to the respiratory 
process would be helpful in SABR of lung. The aim of this study was to investigate the 
dosimetric impact of tumours’ motion by assessing their volumes (GTV, PTV) and the 
dosimetric variation (mean and maximum doses) between the current practice of the MIP 
based planning (conventional method) and the phase specific planning method using the 4D-
CT dataset in SABR of lung tumours.   
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Figure  4-1: CT images of a lung tumour in the right lung. A) The axial plane of a CT image 
showing a lung tumour in the right lobe (pink colour). (B) and (C) coronal and sagittal planes 
of CT images show the planning target volume based on two extreme phases: end-inspiration 
(yellow colour) and end-expiration (pink colour) phases based on bins of 4D-CT images. The 
tumour showed a predominant cranio-caudal mobility [72].           
 
4.3 Material and method 
 
Fifteen patients who underwent lung SABR using the 3D CRT technique participated in this 
study. Of these patients, seven had lesions in the right lung, and eight had lesions in the 
A 
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left lung (Table 4-3). The ethics approval for this study was approved by Peter MacCullum 
Cancer Centre and the registration certificate was issued from college human ethics by RMIT 
university (See appendices I, II, III and IV). Their treatment followed the SABR protocol for 
lung cancer utilising the 3D CRT technique as follows (see section 4.3.1)[174]: 
 
4.3.1 SABR protocol for lung cancer utilising the 3D CRT 
technique  
This protocol describes in general the stages of the treatment planning for SABR of the lungs 
using the 3D CRT technique. It follows the guidelines of the Trans-Tasman Radiation 
Oncology Group (TROG Cancer Research)[174].  
Patient positioning: The patients were instructed to lie in the supine position in a Bodyfix® 
bluebag on a table for the 4D-CT. The arms are usually raised above head and where this is 
difficult to achieve, the contralateral arm placed by the side [174].   
4D-CT: All patients were scanned using 4D-CT performed on a Philips BrillianceTM CT   
scanner (Koninklijke Philips Electronics, Amsterdam, The Netherlands) utilising the Philips 
Bellows system to acquire a breathing trace during the scan acquisition. The bellows were 
strapped around each patient either in the area with the most movement of breathing or 
approximately 5 cm below thorax. The breathing trace of each patient was reviewed by two 
radiation therapists. The pulmonary wave trace was edited to ensure the tags were located 
at the peak of each wave before reconstructing the scan (Figure 4-2). 
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Figure  4-2: The breathing trace box. The black arrow is pointed to a tag incorrectly located, 
after the editing the tag is moved to the peak of the wave.  
 
The standard parameters of the 4D-CT scanning: The scan protocol was pulmonary 4D 
using the helical mode, 140 KV and 300 mAs, a slice thickness and an increment = 3 mm, 
field of view (FOV) = 600, pitch (table feed per rotation) = 0.68, rotation time = 0.5 seconds 
and matrix size = 512 with standard resolution. The image reconstruction was performed 
utilising a slice thickness and an increment = 5 mm.  
 
 The 4D-CT scans were reviewed by a radiation oncology medical physicist during the 
reconstruction process to create the MIP and AIP dataset. For image reconstruction, the 
default software provided by the CT scanner manufacture was used. The reconstruction 
process was obtained for 10 respiratory phases from the 0% phase to the 90% phase. After 
the 4D-CT reconstruction was completed, the 4D-CT dataset (MIP dataset and AIP dataset) 
was available in a picture archiving and communicating system (PACS). These datasets were 
transferred to the treatment planning system (TPS) for the contouring process. The CT 
DICOM datasets were transferred to Eclipse for contouring and treatment planning.   
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Contouring process: This process was divided into target volume and OARs contouring. 
1) Target volume contouring: The 4D-CT images were loaded to the TPS for contouring; the 
AIP images were loaded as a primary dataset, and the MIP images were loaded as a 
secondary dataset. The tumour volume was visualised clearly in MIP images and could be 
adjusted by using the window level option in the TPS. Visible gross tumours also known as 
GTV was contoured, whilst the clinical target volume (CTV) including the visible tumour 
(GTV) and areas of potential tumour growth. The MIP dataset represents a composite of all 
tumour positions along the respiratory cycle. Therefore, the ITV volume was marked for the 
tumour volume obtained from MIP images. The PTV volume was created from the expansion 
of the ITV as follows: Expansion for SAFRON Trial (26 Gy/1 fraction): 5 mm radial margin; 
expansion for CHISEL trial (48Gy/4 fractions and 54 Gy/3 fractions): 5 mm axial margin and 
10 mm cranio-caudal margin.      
   
2) OAR contouring: All OARs were contoured in the AIP dataset. In addition to thorax, the 
following structures were also contoured: heart, brachial plexus, oesophagus and bifurcation 
of the lobar bronchi (this was viewed to avoid overlap with the ITV). The radiation therapist 
contoured the following structures: bony spinal canal, lungs, liver and ribs/chest wall. As part 
of the contouring process, the internal skin or rind skin of the OAR was defined as a 5-mm 
rim of tissues inside the body contour. Because the MIP images displayed the range of the 
tumour motion, they were mainly used for contouring the target volume, like ITV and PTV. 
Moreover, the target volumes were attached to the AIP dataset and the treatment plan was 
calculated in the AIP dataset.      
 
Beam arrangements: The beam arrangements were separated to ensure maximum 
conformity of the high dose distribution to the tumours and reduce OAR doses. The beams 
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were separated evenly by sufficient angles (approximately 30–40 degree) to avoid overlap on 
the chest wall. A minimum of eight beams are used for 3D CRT; generally, the delivered 
numbers of beams ranged from 8–12 beams and all fields used 6MV. The minimum field size 
for all fields must be 3 cm x 3 cm, as defined by jaws, and they can further shaped by MLC 
(Figure 2-14). Non-coplanar beams may be required in the planning to ensure a centrally 
peaked dose distribution associated with rapid dose fall-off outside the target volume and to 
avoid overlapping with other fields over the chest wall [129]. The beam arrangement was 
optimised specifically to the PTV location.  
 
MLC margins: The MLCs were conformed on each field to zero margins on PTV using the 
outbound method of leaf positioning. In Eclipse TPS, the MLC set option is under fit MLC to 
structure. The MLC leaf position was optimised and individually adjusted to provide better 
conformal dose distribution to the target, and the MLC portal had to be at least 3 cm x 3 cm.  
 
Jaws settings: In addition to MLC, asymmetric jaws (in X and Y directions) were used to 
cover the peripheral target volume (Figure 2-14). The jaws minimised the interleaf leakage 
between adjacent MLC leaf pairs, and the Y jaws were used to define the field width.     
 
Prescription dose: Two patient trials were used in this thesis: SAFRON and CHISEL [175, 
176]. SAFRON delivered 26 Gy in one fraction [175, 177], while CHISEL [176] delivered 54 
Gy in three fractions, or 48 Gy in four fractions. It is important to consider the protocol for 
the PTV as follows: SAFRON: D99% = 100%, which means 99% of the PTV was covered 
by 100% of the prescribed dose. CHISEL: 100% of the PTV had to be covered by 95% of the 
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prescribed dose [129, 175-177]. These two trials run by Trans-Tasman Radiation Oncology 
Group (TROG Cancer Research)[174]. 
 
Organs at risk (OARs) dose constraints: The OARs dose constraints followed the Trans-
Tasman Radiation Oncology Group (TROG Cancer Research) protocol. The dose constraints 
are explained in the following tables for SAFRON and CHISEL [175, 176].  
 
Dose constraints for SAFRON:  
Table  4-1: Planning dose constraints used for SABR of the lungs with a dose prescription of 
26 Gy/1 fraction. D20%: the delivered dose to 20% of the lung volume. D66%: the delivered 
dose to 66% of the lung volume [177].   
Organ Dose Constraints 
Heart Maximum dose < 15 Gy 
Lung D20% < 20 Gy 
Lung D66% < 5 Gy 
Oesophagus Maximum dose < 15.4 Gy 
Brachial plexus Maximum dose < 15 Gy 
Chest wall Maximum dose to 30 cm3 < 24 Gy 
Skin Maximum dose < 12 Gy 
Spinal cord Maximum dose < 12 Gy 
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Dose constraints for CHISEL:  
Table  4-2: Planning dose constraints used for SABR of the lungs with dose prescriptions of 
48 Gy/4 fractions and 54 Gy/3 fractions. D20%: the delivered dose to 20% of the lung 
volume.  
Organ Dose Constraints 
Heart Maximum dose < 30 Gy 
Lung D20% < 15 Gy 
Oesophagus Maximum dose < 27 Gy 
Brachial plexus Maximum dose < 24 Gy 
Chest wall Maximum dose to 30 cm3 < 30 Gy 
Skin Maximum dose to 30 cm3 < 30 Gy 
    
4.3.2 MIP based planning and phase specific planning methods 
Two methods were used for the treatment planning of the tumour volume in this study: 1) 
MIP based planning (or the conventional method) and 2) phase specific planning (Figure 4-
3). Both methods followed the SABR protocol of 3D CRT (section 4.3.1). However, the main 
differences between the two methods were in the contouring process and the delivery of the 
prescription dose.  
 
The MIP based planning method is based on the reconstruction feature available in 4D-CT to 
create the volume of the tumour target for 10 respiratory phases (the MIP formation by 4D-
CT is explained in Chapter 2, sections 2.2.2.4 and 2.2.2.5). Initially, the tumour volume in 
this method is formed automatically by reconstructing the 10 respiratory phases into an 
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individual dataset called the MIP dataset (Figure 4-3). This dataset represents the maximum 
pixels of the tumours for all respiratory phases. The tumour volume was contoured from the 
reconstructed MIP images followed the SABR protocol of 3D CRT to create the PTV1. For 
the treatment plan, all beams were focused on the PTV1 volume. The prescription dose e.g. 
28 Gy was delivered in one set (Figure 4-4).                 
 
The phase specific planning method tracked the tumour volume manually on each respiratory 
phase (from the 0% phase to the 90% phase); then, the tumour volume in each phase was 
contoured separately for each phase and labelled GTV2. The GTV2 volume was contoured 
using the same window and level setting without reference to the previously contoured 
volume. After the contouring process was completed in each phase, the PTV2 was created 
according to the SABR protocol of 3D CRT. The delivery of the prescription dose was 
divided into 10 plans (each plan represented an individual respiratory phase from 0% to 90%) 
(Figure 4-5). For example, the prescription dose of 28 Gy was divided by 10, and hence each 
phase received 2.8 Gy (Figure 4-5). Using a feature available in TPS that allows multiple 
treatment plans to be combined, the 10 treatment plans were merged to form an individual 
plan (Figure 4-6). 
 
134 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure  4-3: Schematic illustration of tumour volumes: GTV (red circle), CTV (blue circle 
outlined GTV), ITV (green dashed line) and PTV (orange outline) of the two methods: MIP 
based planning and phase specific planning. In the MIP based planning method (the left 
volumes), the ITV was generated from the GTV volume by the MIP tool automatically. In the 
second method (the right volumes), the ITV was produced from the summation of GTV for 
each phase (the GTV manually tracked and contoured in each phase). 
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The prescription doses (Gy/fraction/s) of SABR of the lungs for the 15 patients were varied 
from 20 Gy to 54 Gy delivered in one to four fractions (Table 4-3).  
 
The statistical analyses were performed by Graph Pad PRISM 6 software, v. 6.03. A paired t-
test was used to investigate the statistical significances (p <0.05) and mean differences 
between the two methods (MIP based planning and phase specific planning methods). 
    
    
Figure  4-4: The MIP based planning method (conventional method) indicating GTV1 and 
PTV1 contours. The GTV1 represents the tumour volume in 10 phases, and it was created 
from the MIP dataset by automated reconstruction in 4D-CT. In this method, the tumour was 
irradiated by 28 Gy in one set. 
GTV1 
PTV1 
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Figure  4-5: Phase specific planning method indicating the manual contours for GTV2 and PTV2 (violet coloured contours) used for patient 
number 4 (28 Gy/1frction). The 0% phase showed the differences between the contours of the MIP based planning method (GTV1, PTV1) and 
the phase specific planning method (GTV2, PTV2). In each respiratory phase, the tumour volume was tracked and contoured manually in the 
4D-CT dataset. The treatment plans were generated in each phase and irradiated by 2.8 Gy.    
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Figure  4-6: The delivery of the prescription doses for the MIP based planning (upper image) 
and phase specific planning (lower image) methods for patient number 4 (28Gy/1frction). In 
the first method, the beam configurations were created from one treatment plan of 28 Gy. In 
the second method, the beam configurations were produced from 10 treatment plans of 10 
respiratory phases (from 0% to 90%), and each phase received 2.8 Gy. The beam 
arrangements were optimised specifically to the PTV1 and PTV2 locations.  
  
MIP based planning method 
Lung tumour  
Beam 
configurations 
Max dose  
 
 
Phase specific planning 
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Table  4-3: The prescription doses (Gy) for the 15 patients who underwent SABR of the lungs.     
Patients Prescription doses (Gy), fraction(s) Lesion location 
1 20.1 Left lower lobe 
2 20.1 Left upper lobe 
3 20.1 Left middle lobe 
4 28.1 Right upper lobe 
5 28.1 Right upper lobe 
6 28.1 Right upper lobe 
7 28.1 Left lower lobe 
8 28.1 Left upper lobe 
9 28.1 Right lower lobe 
10 28.1 Left lower lobe 
11 28.1 Left upper lobe 
12 48.4 Left middle lobe 
13 48.4 Right upper lobe 
14 54.3 Right lower lobe 
15 54.3 Right middle lobe 
 
 
4.4 Results  
 
The results of this study were analysed according to the tumour volume GTV and PTV and 
can be divided into two sections as follows: 
4.4.1 Comparison between GTV1 of the MIP based planning 
method and GTV2 of the phase specific planning method  
Figure 4-7 demonstrates the variation between the GTV1 and GTV2 volumes for the MIP 
based planning and phase specific planning methods for 15 lung patients. The line graph 
showed that the GTV1 volume for the first method was higher than the GTV2 for the second 
method. This trend was dominant for GTV1 with larger volumes 35.6, 9.60, 7.40, 14.10, 18 
and 24.60 cm3 for patients 5, 8, 9, 13, 14 and 15, respectively. As the volume was increased, 
the differences between the GTV1 and GTV2 increased. The mean volume of the GTV1 for 
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MIP based planning was significantly higher than GTV2 for phase specific planning (Table 
4-4). The dosimetric variation (mean and maximum doses in Gy) between the two methods 
was demonstrated in Figure 4-8 and Figure 4-9, respectively. The MIP based planning 
method showed higher dosimetric values for mean and maximum doses compared with the 
phase specific planning method, especially for prescription doses of 48Gy/4 fractions and 54 
Gy/3 fractions (patient numbers 12–15). The mean and maximum doses were (39.37 Gy, 
42.09 Gy) and (38 Gy, 41.36 Gy) for GTV1 and GTV2, respectively (Table 4-4). The mean 
and maximum doses were significantly higher for the MIP based planning method compared 
with the phase specific planning method. 
 
 
Figure  4-7: Line graphs illustrating the differences between the GTV1 and GTV2 volumes 
for the two methods.  
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Figure  4-8: Line graphs illustrating the difference between the GTV1 and GTV2 mean doses 
(Gy) for the two methods.   
 
  
Figure  4-9: Line graphs illustrating the difference between the GTV1 and GTV2 maximum 
doses (Gy) for the two methods.   
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Table  4-4: The mean values of the GTV1, GTV2 volumes (cm3), mean dose (Gy) and 
maximum dose (Gy) for the two methods. The data presented in this table was the result of 
three independent measurements (n=3). The mean volume, mean dose (Gy) and max dose 
(Gy) values (mean values ± standard deviation) of GTV1 are significantly different from the 
GTV2 volumes (*P<0.05, paired t-test).    
 
 
4.4.2 Comparison between PTV1 of the MIP based planning 
method and PTV2 of the phase specific planning method 
 
The differences between PTV1 and PTV2 volumes were illustrated in Figure 4-10. The visual 
analysis of the line graph indicates significant distance between the PTV1 (the blue line) and 
PTV2 (the red line). The PTV1 volumes of the first method were higher than the PTV2 of the 
second method, particularly in larger volumes of patients 5, 8, 9, 13, 14 and 15, respectively. 
Table 4-5 summarises the mean values of PTV1 and PTV2 volumes and the mean and 
maximum doses of the two planning methods. The mean values of PTV1 volumes were 
significantly higher than the PTV2 volumes by 39.60%. The dosimetric analysis between the 
two planning methods showed that the mean doses were significantly higher for the MIP 
based planning method than the phase specific planning method in the line graph of Figure 4-
11. This was noticeable at the higher prescription doses for patients 12, 13, 14 and 15 who 
were treated with higher doses per fractions (48/4 fractions and 54/3 fractions). Furthermore, 
the mean values of the mean and maximum doses of the PTV1 of the MIP based planning 
 GTV1 (MIP based Planning) 
Mean±Stdev 
GTV2 (Phase specific Planning) 
Mean±Stdev 
Volume (cm3) 8.51±5.07* 6.05±4.91 
Mean Dose (Gy) 39.37±7.34* 38±6.76 
Max Dose (Gy) 42.09±9.11* 41.36±8.65 
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method were significantly higher than the PTV2 of the phase specific planning method 
(Table 4-5).               
 
 
 
 
Figure  4-10: Line graphs illustrating the differences between the PTV1 and PTV2 volumes 
for the two methods. 
 
 
Figure  4-11: Line graphs illustrating the difference between the PTV1 and PTV2 mean doses 
(Gy) for the two methods.   
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Figure  4-12: Line graphs illustrating the differences between the PTV1 and PTV2 maximum 
doses (Gy) for the two methods.    
 
Table  4-5: The mean values of the PTV1, PTV2 volumes (cm3), mean dose (Gy) and 
maximum dose (Gy) for the two methods. The data presented in this table was the result of 
three independent measurements (n=3). The mean volume, mean dose (Gy) and max dose 
(Gy) values (mean values ± standard deviation) of PTV1 are significantly different from the 
PTV2 volumes (*P<0.05, paired t-test).   
 
 
4.5 Discussion  
 
This study investigated the dosimetric impact of the tumour motion by assessing the tumour 
volumes (GTV, PTV) and the dosimetric variation (mean and maximum doses) between the 
 PTV1 (MIP based Planning) 
Mean±Stdev 
PTV2 (Phase specific Planning) 
Mean±Stdev 
Volume (cm3) 30.74±9.79* 22.02±8.43 
Mean Dose (Gy) 37.17±7.73* 34.44±6.87 
Max Dose (Gy) 42.48±9.83* 41.39±8.1 
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MIP based planning method (conventional method) and the phase specific planning method 
using a 4D-CT dataset. The PTV definition in the MIP based planning method (conventional 
method) in SABR of the lungs was based on an MIP dataset of 4D-CT images that represent 
the visible tumour volume, which was enlarged by individual isotropic margins to create the 
tumour volumes (i.e. the PTV is formed by expanding of 0.5 mm of ITV margin).  
 
Rietzel et al., 2006 [178] compared PTVs with margins of 15 mm on composite 4D target 
volumes to PTVs with 20 mm margins using a free-breathing helical CT scan [178]. For the 
10 patients in their study, the PTV size was decreased by 23% on average [178]. Another 
study by Hof et al., 2009 [179] investigated the tumour volume definitions between the two 
extrema target positions of respiratory phases (end-inspiration and end-expiration) and the 
conventional method of 4D-CT. They also founded that there was a PTV reduction of 31% 
compared to the conventional method. In this chapter, the results showed that the phase 
specific planning method can provide a significant reduction in the PTV definition using 
individual margins like in the conventional method by tracking and contouring the tumour 
volume manually in each phase. The reduction between the conventional method and phase 
specific planning method was 39.60% for the PTV on average.     
 
It could be argued that the reduction in the PTV2 (the phase specific planning method) may 
be due to inadequate target coverage of manual contouring. This argument was justified by a 
study published by Rietzel et al., 2006 [178]. They compared 4D-CT based PTV that is 
created by two methods: 1) using all respiratory phases (free breathing patient data) and 2) 
using just extreme positions i.e. end-expiration and end-inspiration. They concluded that the 
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variation between the two methods were marginal and not a result of the differences in 
manual contouring non-linear tumour trajectories [178, 179].         
 
Reports concerning the normal tissue toxicity associated with high-dose radiotherapy 
following are limited [179]. In general, most indicate very few patients developing 
pulmonary side effects [180-182]. However, some patients have been reported with high-
grade lung toxicity [183]. In terms of assessing the factors that can predict the lung damage 
induced by radiation, the mean lung dose (MLD) is appropriate for the prediction of normal 
tissue complication probabilities (NTCPs) [184]. Hof et al., 2009 [179] reported a reduction 
from 3.2 Gy in MLD using two-phase planning of 4D-CT datasets (end-expiration and end-
inspiration bins) compared with  2.6 Gy in MLD obtained by the MIP based planning method 
[179]. Although this amount of Gy seems negligible, SABR of the lungs delivers 
hypofractionated or single doses to patients, and hence the biological effect doses can be 
increased accordingly. Moreover, the lung doses are increased as the tumour volume is 
increased [179].          
 
In this chapter, the mean and maximum doses delivered to PTV1 in the MIP based planning 
method were significantly higher than the phase specific planning method by 7.92% and 
2.63%, respectively. This increase is proportional to the prescription doses and fractions i.e. 
48 Gy/4 fractions and 54Gy/3 fractions, respectively (Figure 4-11 and Figure 4-12). As 
mentioned earlier, inaccuracies in the PTV result in under-dosing the tumour or overdosing 
normal lung tissue and hence increase the toxicity to the surrounding tissues [17, 171]. The 
phase specific planning method benefitted from the full use of the 4D-CT dataset, including 
the contouring of 10 GTVs per patient, which may not feasible for routine clinical use, as it 
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depends on manually tracking the tumour position and contouring it in each respiratory phase 
[178]. However, the reduction in PTV volume and doses using the phase specific planning 
method corroborates the usefulness of 4D-CT in the target volume definition to reduce the 
irradiation to the normal lung tissue, particularly by tracking the tumour in each respiratory 
phase.  
 
4.6 Conclusion   
 
The phase specific planning method had several advantages over the conventional method, 
such as a significant reduction in the target volume (PTV), mean and maximum doses 
delivered to the PTV. Moreover, tracking the tumour manually in each phase make it 
independent from the absolute amount of tumour motion, and it avoids missing the target 
particularly for tumours associated with a large amount of motion [179]. This chapter 
indicated that the current practice of MIP based planning method using 4D-CT images may 
result in a significant increase in the tumour volume definition, especially to the PTV, which 
may increase the radiation doses to the normal lung tissue.  
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Chapter 5  Dosimetric Impact of Organ Motion in 
Static and Dynamic Conditions for Three SABR 
Techniques: 3D CRT, IMRT, and VMAT by Using 
PRESAGE 3D Dosimeters 
 
 
5.1 Summary  
The previous chapter clearly demonstrated that the MIP based planning method (the 
conventional method) may provide larger PTV and irradiates normal lung tissue to 
compensate for the tumour motion induced by respiration. This chapter further investigates 
the use of PRESAGE 3D dosimeters to quantify the dosimetric variation between the static 
and dynamic conditions utilising a retrospective clinical case of lung SABR. An in-house 
custom-designed thorax dynamic phantom was designed to simulate the tumour motion in 
two directions (i.e., superior/inferior (Z-axis) and anterior/posterior (Y-axis). The PRESAGE 
dosimeter was attached to the moving arm of the phantom and irradiated in two scenarios 
(static and dynamic) using three SABR techniques: 3D CRT, IMRT, and VMAT. This 
chapter attempts to quantify the dosimetric variation results from the tumour motion. 
 
5.2 Introduction 
 
SABR for lung cancer has shown promising results compared to the conventional 
radiotherapy treatment, with tumour control rates of up to 90% over 3 years [185-187]. The 
SABR technique is characterised by the precise delivery of few high dose fractions (typically 
3–5) and up to 60 Gy to a small target volume [17]. SABR for lung cancer can be 
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compromised by tumour motion, resulting in irradiation to normal tissue and decrease in the 
local control to the targeted tumour [67]. To quantify the dosimetric variation due to tumour 
motion, several dynamic, high-resolution devices have been proposed [17, 188, 189]. 
However, these devices offer two-dimensional analysis of the three-dimensional dose 
distribution [132]. Three-dimensional analysis of the dose distribution is preferable because 
the two-dimensional plane is not a representative of the entire dose distribution [132].  
 
To study the dose distribution in three-dimensional planes, PRESAGE 3D dosimeters have 
shown promising results for analysing the dose distributions. The application of PRESAGE 
as 3D-dosimter has several advantages: 1) it exhibits “robustness to laboratory environment, 
i.e., no O2 sensitivity” [132]; 2) it has very low scatter due to the absorption medium [132]; 3) 
it can be prepared in any external container allowing better dosimeter edge resolution through 
improved refractive index (RI) matching [140]. Dynamic thorax phantoms that can be 
integrated with the PRESAGE 3D dosimeters are limited to specific small PRESAGE sizes, 
thus allowing for dosimetric studies in a small field size, e.g., 2 × 2 cm2 [132]. For example, a 
commercial CIRS dynamic thorax phantom accommodates PRESAGE with a length less than 
5 cm and diameter of 5 cm [132, 190]. Large PRESAGE sizes are preferable to visualise the 
dose distribution of the planned dose or the static condition and compare it with the dynamic 
condition [190]. To date, no commercial phantom is available to measure the dose in a large 
PRESAGE dosimeter.      
 
The aim of this chapter was 1) to design an in-house custom-designed thorax dynamic 
phantom to accommodate a large PRESAGE 3D dosimeter and also 2) to propose a method 
to quantify the dosimetric impact of organ motion (such as tumours in the lung) using the 
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above phantom and PRESAGE 3D dosimeters. The investigation of the dosimetric variation 
includes a retrospective clinical case of patients that underwent SABR of the lung using 3D 
CRT technique, and it was replanned for IMRT and VMAT. Before the static and dynamic 
studies were conducted, the designed phantom and PRESAGE dosimeters were first tested.      
      
5.3 Materials and methods  
Before the investigation of the dosimetric variation using PRESAGE 3D dosimeters and the 
in-house custom-designed thorax dynamic phantom in static and dynamic conditions, the 
movement distance of the phantom was assessed to ensure that the phantom provides good 
motion simulation. PRESAGE dosimeters were also evaluated to confirm that the dose 
distributions of the planned and delivered doses matched. Therefore, the materials and 
methods section in this chapter is divided into the three following sub-sections. 
 
5.3.1 Validation of movement distance of in-house custom-
designed thorax dynamic phantom  
 
The phantom motion was validated by setting a known movement distance of 1 cm and 2 cm, 
in both directions: A/P (Y axis) and S/I (Z axis) (the phantom motion in both directions is 
described in Chapter 3, Section 3.1). The phantom was scanned for the above movements, 
followed by a reconstruction process to create MIP images.  
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 CT scanning procedure 
The in-house custom-designed thorax dynamic phantom, including the PRESAGE 3D 
dosimeter, was CT scanned in the static condition using a Philips BrillianceTM CT scanner 
(Koninklijke Philips Electronics, Amsterdam, The Netherlands). The CT scan protocol for the 
static condition was as follows: helical mode, 140 KV and 300 mAs, slice thickness and 
increment = 3 mm, field of view (FOV) = 600, pitch (table feed per rotation) = 0.68, rotation 
time = 0.5 second, and matrix size = 512 with standard resolution. The image reconstruction 
was performed with a slice thickness and increment of 5 mm. The CT DICOM datasets were 
transferred to the treatment planning system for contouring.  
 
Two objects were monitored in MIP images owing to the motion: 1) the PRESAGE body 
(diameter = 4.25 cm) and a small rounded object implemented inside the PRESAGE 
(diameter = 0.5 cm) [Figure 5-1 (A)]. The PRESAGE diameter is 4 cm, but the contoured 
body of the PRESAGE has a diameter of 4.25 cm. The object diameter and movement 
distance of the two objects were monitored using MIP images.      
 
5.3.2 PRESAGE 3D dosimeters  
The PRESAGE 3D dosimeter is described in Chapter 3, Section 3.3. The PRESAGE 3D 
dosimeters were prepared at Alfred Hospital, Melbourne, Victoria. The fabrication process 
utilised of four different compounds: 1) polyurethane resin precursors, Crystal Clear® 204 
part A and part B (Smooth-On, Inc., Easton, PA, USA). 2) Luecomalachite green (LMG) 
(Sigma-Aldrich®), which “acts as a dye when oxidised by free radicals created by the 
irradiation of the radical initiator chloroform” [191]. 3) Chloroform (Chem-Supply). 4) The 
catalyst dibutyltin dilaurate (DBTDL) (Merck KGaAC, Darmstadt, Germany) [191]. The 
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catalyst increases the post response stability and sensitivity. It also changes the effective 
atomic number (Zeff) to be radiological equivalent to that of water [135, 192]. 
 
The PRESAGE fabrication process for 100 g is summarised as follows:    
1. Prepare part (A) = 48.9 g in one container.  
2. Prepare chloroform (5 g) + LMG (2 g) solution.  
3. Mix 44 g of part (B) with the solution prepared in step 2. 
4. Add the solution prepared in step 3 to part (A) prepared in step 1. 
5. Add DTDBL = 0.05 ml to the solution prepared in step 4. 
6. The final mixture is placed inside a pressure cooker under 60 psi for 48 h (the 
recommended time for curing the PRESAGE dosimeters).   
 
Two sizes of PRESAGE 3D dosimeters were used in this study, a small size with the 4 cm 
length × 4 cm diameter and a larger size with 8 cm length × 8 cm diameter [Figure 5-2 (C) 
and (D)]. The small PRESAGE was used to generate the calibration curve for the PRESAGE 
dosimeters. The larger PRESAGE was utilised to demonstrate the dose distribution and the 
penumbra of the retrospective lung SABR for static and dynamic conditions (specified in 
sections 5.3.2.2 and 5.3.3). Both PRESAGE sizes were prepared from the same batch. The 
PRESAGE dosimeters were kept at a temperature of 4 °C before and after the irradiation. 
Furthermore, before the irradiation and optical CT readout, the PRESAGE dosimeters were 
allowed to reacclimatise to room temperature (22 °C). After irradiation, the PRESAGE was 
given 12 h for the post-irradiation polymerisation reaction to stabilise before the optical CT 
readout (the optical CT, including pre- and post-scans and the scanning parameters, are described 
in Chapter 3, Section 3.4.1).  
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Figure  5-1: A) a PRESAGE dosimeter (4 cm length × 4 cm diameter) covered by cork 
material: the white circle indicates the small rounded object inside the PRESAGE dosimeters 
with 0.5 cm diameter. B) The setup position of the in-house custom-designed thorax dynamic 
phantom on the 4D-CT table. C) A MIP image of the in-house custom-designed thorax 
dynamic phantom showing the small object inside the PRESAGE with 0.5 cm diameter.     
 
5.3.2.1 Calibration curve of PRESAGE 3D dosimeters 
 
To create the calibration curve, a rod phantom and 10 small-sized PRESAGE dosimeters 
were irradiated for various doses. The rod phantom is described in Chapter 3, Section 3.8. 
The rod phantom, including the PRESAGE 3D dosimeter, was CT scanned using the CT 
A 
B 
C 
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parameters described in section 5.3.1. The CT DICOM datasets were transferred to the 
Eclipse treatment planning system for contouring and treatment planning.  
 
Two slabs in the middle of the rod phantom were drilled to the same diameter as that of the 
PRESAGE dosimeters. To eliminate the air gap or the PRESAGE motion due to the phantom 
setup, the PRESAGE dosimeter was tightened with a help of ring made of Perspex fitted to 
the slabs [(Figure 5-2 (B)]. The irradiation of the 10 PRESAGE dosimeters ranged from 5 Gy 
to 50 Gy, and Figure 5-2 (D) shows the irradiated dosimeters from 10 Gy to 30 Gy. Each 
dosimeter was irradiated to a specific dose, e.g., 30 Gy, using 2 × 2 field size (box technique) 
with gantry angles: 0°, 90°, 180°, and 270° (Figure 5-3). When the PRESAGE is irradiated, 
free radicals are produced due to radiolysis of the radical initiator, i.e., chloroform. Then, the 
free radicals oxidise the leuco dye causing an alteration in the optical density or the 
absorbance, i.e., colour. Thus, the change in the optical density (ΔOD) can be measured at a 
particular wavelength when dealing with such dosimeters [193]. To ensure that the ΔOD of the 
PRESAGE dosimeters are obtained owing to the absorbance of the radiation dose only, the ΔOD 
values are measured by subtracting the ΔOD value of the irradiated dosimeters from the reference 
or blank (radiation dose = 0) by using an optical CT scanner [135, 138]. The pixel values and the 
doses were recorded and plotted a chart relating these values for 10 PRESAGE dosimeters using 
image J software (Table 5-1) (Figure 5-4) (image J software is described in Chapter 3, Section 
3.5).               
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Figure  5-2: Process of irradiating small PRESAGE dosimeters (4 cm length × 4 cm diameter) 
inside the rod phantom to obtain the calibration curve. A) Rod phantom composed of several 
slabs. B) Two drilled slabs of the rod phantom to place the PRESAGE within the phantom; 
the small PRESAGE is tightened by the Perspex shaped in ring (red arrow) and then placed 
within the slabs in the centre of the rod phantom. C) An irradiated large PRESAGE dosimeter 
(8 cm length × 8 cm diameter). D) Five PRESAGE dosimeters irradiated by 10 Gy, 15 Gy, 20 
Gy, 25 Gy, and 30 Gy.            
A C 
B 
D 
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Figure  5-3: Axial CT image of the rod phantom showing the planned dose distribution of an 
irradiated field size of 2 × 2 cm2 (box technique) by 30 Gy in TPS.   
 
 
Table  5-1: Correlation between doses and pixel values of 10 small-sized PRESAGE 
dosimeters.   
 
 
 
 
 
 
 
Dose (Gy) Pixel values 
5 0.07 
10 0.15 
15 0.27 
20 0.33 
25 0.41 
30 0.44 
35 0.55 
40 0.58 
45 0.6 
50 0.63 
Dose distribution 
of 2 × 2 cm2 field 
size 
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Figure  5-4: Relationship between optical attenuation per pixel and dose. The correlation 
coefficient parameters of fitted line are shown in the inset of the graph.  
 
5.3.2.2 Validation of dose distribution of PRESAGE 3D 
dosimeter  
The PRESAGE dose distribution was validated by comparing the planned dose in the TPS 
and the dose distribution in the PRESAGE dosimeters. For this section, the dose distribution 
was assessed for both PRESAGE dosimeters sizes (small and large dosimeters sizes). The in-
house custom-designed thorax dynamic phantom, including the PRESAGE 3D dosimeter, 
was CT scanned in static condition using a Philips BrillianceTM CT scanner (Koninklijke 
Philips Electronics, Amsterdam, The Netherlands). The CT scan protocol for the static 
condition is described in section 5.3.1. The CT DICOM datasets were transferred to the 
Eclipse for contouring and treatment planning. The treatment plans were developed to 
deliver the static and dynamic treatment conditions.  
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A small PRESAGE dosimeter irradiated by 30 Gy used in the calibration curve was 
compared with the planned dose. Also, a large PRESAGE dosimeter was irradiated in the 
static condition with  a clinical lung SABR plan (Patient 1 who was treated by 3D CRT with 
a prescription dose of 28 Gy) (Figure 5-5) (3D CRT protocol for SABR of the lung, including 
the 4D-CT scanning parameters, is described in Chapter 4, Section 4.3.1). Table 5-2 presents 
the beam configurations related to Patient 1.  
  Data analysis 
The dose distribution for the SABR plan (3D CRT) was calculated by The PolyGeVero® 
software [147] (The PolyGeVero® software is described in Chapter 3, Section 3.6). The 
calibration curve information in Table 5-1 was imported to the PolyGeVero® to calculate the 
dose distribution for the PRESAGE dosimeters.  
 
Figure  5-5: Process of irradiating large PRESAGE dosimeters for the static and dynamic 
conditions using in-house custom-designed thorax dynamic phantom. A) setup position of the 
in-house custom-designed thorax dynamic phantom on Linac treatment table; the phantom 
motion was controlled by the designed software using a laptop. B) Irradiated large PRESAGE 
B A 
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dosimeter surrounded by cork material (equivalent to lung density) showing the tumour field 
in the 90° gantry angle.         
 
Table  5-2: Beam configurations and monitor units in the original treatment plan of patient 1 
treated by SABR with 3DCRT technique. OBL = oblique.  
 
Beams 
Number 
Patient 1 
(Tumour is located in the right lung) 
PTV = 31.78 cm3 
Beam Configurations Monitor Unit (MU) 
1 
OBL 
Gantry rotation 40° 
Couch rotation 0° 
Collimation rotation 90° 
550 
2 
OBL 
Gantry rotation 15° 
Couch rotation 0° 
Collimation rotation 90° 
742 
3 
OBL 
Gantry rotation 335° 
Couch rotation 0° 
Collimation rotation 90° 
857 
4 
OBL 
Gantry rotation 295° 
Couch rotation 0° 
Collimation rotation 90° 
881 
5 
OBL 
Gantry rotation 265° 
Couch rotation 0° 
Collimation rotation 90° 
763 
6 
OBL 
Gantry rotation 233° 
Couch rotation 0° 
Collimation rotation 90° 
811 
7 
OBL 
Gantry rotation 345° 
Couch rotation 90° 
Collimation rotation 0° 
612 
8 
OBL 
Gantry rotation 197° 
Couch rotation 90° 
Collimation rotation 0° 
530 
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5.3.3 Static and motion conditions for three techniques of lung 
SABR: 3D CRT, IMRT, and VMAT  
To study the dosimetric impact of organ motion, a treatment plan of a retrospective clinical 
case of a patient who underwent SABR for the lung, i.e., Patient 2 who was treated by 3D 
CRT with a prescription dose of 28 Gy (GTV= 3.4 cm3, PTV = 14 cm3), was used for the 
static and dynamic conditions (the 3D CRT protocol for SABR of the lung, including the 4D-
CT scanning parameters, is described in Chapter 4, Section 4.3.1).  Table 5-3 presents the 
beam configurations for Patient 2.  
   
 PRESAGE 3-D dosimeter and in-house custom-designed thorax dynamic phantom 
Six identical large PRESAGE dosimeters (8 cm length × 8 cm diameter) were used to 
investigate three treatment plans that include 3D CRT, IMRT, and VMAT under the static 
and dynamic conditions. The PRESAGE dosimeters were fit into the PRESAGE holder 
attached to the in-house custom-designed thorax dynamic phantom (the phantom parts, 
including the mechanical and software information, are described in Chapter 3, Sections 3.1, 
3.1.1 and 3.1.2). 
 
As described earlier (Chapter 3, Section 3.1), the phantom is capable of simulating the tumour 
motion in two directions: A/P (Y axis) and S/I (Z axis). The tumour motion or the movement 
distance in Patient 2 was recorded to be 2 mm in the A/P direction, 13 mm in the S/I direction, 
and 0 mm in the R/L (X-axis) direction. The 4D-CT monitored the trace of the tumour motion for 
Patient 2. Figure 5-5 shows the position of the phantom, including the PRESAGE dosimeter in 
Linac system, for the static condition. In the dynamic condition, the phantom simulated the 
motion in both directions with the same movement distance of the tumour motion, as in the case 
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of Patient 2, by using PRESAGE dosimeters. The parameters of the phantom movement are 
illustrated in Figure 3-6.   
 
 CT scanning procedure 
The in-house custom-designed thorax dynamic phantom, including the PRESAGE 3D 
dosimeter, was CT scanned in the static condition by using the same parameters listed in 
section 5.3.1. 
 
 Treatment plan and delivery  
Three SABR techniques were used in this study for the static and dynamic conditions. The 
treatment plan of patient 2 using 3D CRT was replanned for IMRT and VMAT for the same 
patient (The planning for 3D CRT followed the SABR protocol described in Chapter 4, 
Section 4.3.1). Then, the three plans were copied to the CT PRESAGE images in Eclipse-
TPS (Figure 5-6). The beam orientations were optimized according to the location of the 
PTV in all three plans. The beam configurations with the MU for 3D CRT and IMRT plans 
are summarised in Table 5-3. 
  
The IMRT and VMAT plans utilised dose constraints in the SABR protocol described in 
Chapter 4, Section 4.3.1. As a starting point, the multileaf collimator (MLC) was conformed 
with zero margins to the PTV using the outbound method of leaf positioning, and the 
MLC leaf positions were individually adjusted to provide adequate target coverage. The C-
VMAT plans were composed of two arcs. The first arc was defined with the gantry start 
angle at 181° and stop angle at 0° clockwise for right-sided lesions. For left-sided lesions, 
the start angle was 0°, and the stop angle was 179°. The second arc was defined with the 
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gantry start angle at 0° and stop angle at 181° counter clockwise for right- sided lesions. 
For left-sided lesions, the start angle was 179°, and the stop angle was 0°. The 
collimator angles were 30° and 330° for arc 1 and arc 2, respectively. The MUs for arc 1 
and arc 2 were 4279. The maximum gantry speed was 4.8°/s, and the maximum dose rate 
was 600 MU/min. All the plans were planned using 6 MV X-rays.   
 
 Data analysis 
The dosimetric variation between the static and dynamic conditions for the three SABR plans 
3D CRT, IMRT, and VMAT was calculated by the PolyGeVero® software [147]. The 
calibration curve information in Table 5-1 was imported to the PolyGeVero® to calculate the 
dose distribution for the PRESAGE dosimeters. The data analysis for this study includes 
gamma index and dosimetric volumes of the three plans in two conditions (the gamma index 
is described in Chapter 3, Section 3.10).   
 
 Statistical  analyses 
The statistical analyses were performed by Graph Pad PRISM 6 software, v. 6.03. A paired t-
test was used to investigate the statistical significances (p <0.05) and mean differences 
between the two conditions (static and dynamic). 
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Table  5-3: Beam configurations and monitor units in the original treatment plan of patient 2 
treated by SABR with 3D CRT technique. OBL = oblique, ANT = anterior, LT=lateral. 
Beams 
Number 
Patient 2 
(Tumour is located in the left lung) 
PTV = 14 cm3 
Beam Configurations Monitor Unit (MU) 
1 
ANT 
Gantry rotation 0° 
Couch rotation 0° 
Collimation rotation 90° 
456 
2 
OBL 
Gantry rotation 30° 
Couch rotation 0° 
Collimation rotation 90° 
408 
3 
OBL 
Gantry rotation 60° 
Couch rotation 0° 
Collimation rotation 90° 
791 
4 
LT 
Gantry rotation 90° 
Couch rotation 0° 
Collimation rotation 90° 
759 
5 
OBL 
Gantry rotation 120° 
Couch rotation 0° 
Collimation rotation 90° 
764 
6 
OBL 
Gantry rotation 150° 
Couch rotation 0° 
Collimation rotation 90° 
382 
7 
OBL 
Gantry rotation 210° 
Couch rotation 0° 
Collimation rotation 90° 
432 
8 
OBL 
Gantry rotation 195° 
Couch rotation 90° 
Collimation rotation 0° 
403 
9 
OBL 
Gantry rotation 
155°Couch rotation 90° 
Collimation rotation 0° 
354 
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Figure  5-6: CT images of three SABR techniques in TPS: 3D CRT, IMRT, and VMAT. The 
planning process was applied to large PRESAGE dosimeters to study the static and dynamic 
conditions.      
 
5.4 Results 
This section is divided into three parts, which state the findings for each section in the 
materials and methods section as follows:    
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5.4.1 Validation of the movement distance of the in-house 
custom-designed thorax dynamic phantom  
The movement distance of 1 cm and 2 cm given by the dynamic phantom agreed well with 
the measurements of the movement distances (Figures 5-7 and 5-8). In Figure 5-7 (A), the 
MIP image shows the PRESAGE body with diameter of 4.26 cm. With the phantom 
displacement of 1 cm, the PRESAGE body moved for 1 cm, as shown in Figure 5-7 (B), and 
the measurement increased to 5.26 cm.  
 
In Figure 5-8 (A), the same experiment was repeated using 2 cm displacement of the phantom 
for small object (0.5 cm length × 0.5 cm diameter). The measurements of the movement 
distance in the MIP images agreed well with the movement setting of the phantom. The small 
object moved gradually in the MIP images from the bottom to the top inside the PRESAGE. 
The measurement of the movement distance in Figure 5-8 (A-E) indicated the displacement 
of the small object by 2 cm as the motion gradually increased in the MIP images from 0.5 cm, 
including the object, to 2.5 cm.      
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Figure  5-7: Two CT images of small PRESAGE dosimeters surrounded by cork illustrating 
the movement distance in the A/P direction by 1 cm [see Figure 5-1 (A)]. A) Measurement of 
PRESAGE body (light brown coloured contour) is 4.26 cm in the static condition. B) The 
same PRESAGE body moved by 1 cm in the A/P direction, and MIP images of the contoured 
PRESAGE body showed the amplitude of the motion.      
 
     
A B 
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Figure  5-8: MIP images showed the movement distance of the small object (0.5 cm length × 0.5 cm 
diameter) inside the thorax phantom (see Figure 5-1). A) A MIP image shows the object 
measurements and the movement distance in the A/P direction. MIP images from B–E illustrating 
the object motion for 2 cm in the A/P direction.     
A B 
C 
E 
D 
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5.4.2 Validation of dose distribution of PRESAGE 3D 
dosimeters  
The PRESAGE dosimeters exhibited excellent dose distribution for both sizes (small and 
large PRESAGE) using the calibration curve shown in Figure 5-4. In the small PRESAGE, 
the shape and measurements of the planned dose in TPS using the 2 cm × 2 cm field size (box 
technique) for 30 Gy, shown in Figure 5-3, agreed with the dose distribution of the 
PRESAGE dosimeter shown in Figure 5-9. Moreover, the shape and the measurements of the 
dose distribution obtained from the planned dose in TPS of Patient 1 and those in the large 
PRESAGE dosimeter were almost equal, particularly for the 50 Gy isodose line, with 
measurements of 3.81 cm and 3 cm for the Z-axis and X-axis, respectively (Figure 5-10).          
 
 
Figure  5-9: A small PRESAGE dosimeter with dose distribution of 2 × 2 cm2 field size (box 
technique) irradiated by 30 Gy. 
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Figure  5-10: Isodose line distribution of the PRESAGE 3D dosimeter and the planned dose in 
TPS using retrospective clinical cases of patients who underwent SABR of the lung (Patient 
1) treated by 3D CRT with a prescription dose of 28 Gy. 
  
5.4.3 Static and motion conditions for three techniques of lung 
SABR: 3D CRT, IMRT, and VMAT  
Figures 5-11 and 5-12 show the dose distribution of the static and dynamic conditions for the 
three SABR techniques: 3D CRT, IMRT, and VMAT in the ZX and YZ planes. The images 
in dynamic mode exhibited broadening of the penumbra compared with the images acquired 
in static mode, especially in the (Y and Z directions) for the three SABR techniques. The 
dose distributions in the three-dimensions (X, Y, and Z) are illustrated in Figure 5-13. Owing 
to the movement, the dose distributions were varied between the static and dynamic 
conditions. For the known movement distance of the phantom in the Y- and Z-axes, the dose 
distribution showed an elongation and shortening in the former and later axes for the 3D CRT 
technique [Figure 5-14 (A)]. This elongation was also visualised in the X-axis [Figure 5-14 
(B)]. This trend was consistent for the three SABR techniques with the prescription dose of 
28 Gy. Table 5-4 summarised the isodose line volumes for the static and dynamic conditions 
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using the three SABR techniques with 28 Gy isodose line. The highest differences in the 
mean volume measurements between the two conditions were noticed in IMRT (0.14 cm3) 
and 3D CRT (0.13 cm3). The mean volume measurements of the VMAT showed the lowest 
difference between the static and dynamic conditions of 0.10 cm3 (Table 5-4). The gamma 
analysis for 3%, 3-mm criterion showed passing rates of <1 for 3D CRT (Figure 5-15), 
IMRT, and VMAT. This suggested a good agreement between the two sets of data (static and 
dynamic) for the three SABR techniques. Also, the statistical analysis showed no significant 
difference between the static and dynamic conditions. 
 
 
Table  5-4: Mean volume measurements of the TPS, static and dynamic conditions for the 
three SABR techniques: 3D CRT, IMRT, and VMAT. The data presented in this table was 
the result of three independent measurements (n=3).    
SABR 
Techniques 
Volume of 28 Gy 
isodose line (cm3) 
using TPS 
Mean volume of 28 
Gy isodose line 
(cm3) Static 
condition 
using PRESAGE 
Mean±Stdev 
Mean volume of 
28 Gy isodose 
line (cm3) 
Dynamic 
condition 
using PRESAGE 
Mean±Stdev 
Differences 
(Dynamic - 
Static 
volume) 
(cm3) 
3D CRT 32.7 31.56±0.83 31.69±0.81 0.13 
IMRT 26 25.61±0.38 25.75±0.35 0.14 
VMAT 21 20.43±0.42 20.53±0.46 0.10 
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Figure  5-11: Coloured wash dose distribution of six large PRESAGE dosimeters irradiated in 
two conditions (static and dynamic) for three SABR techniques: 3D CRT, IMRT and VMAT 
in the ZX plane. 
 
171 
 
 YZ 
Plane 
                Static condition     Dynamic condition 
 
3D
C
R
T
 
 
IM
R
T 
V
M
A
T 
        
Figure  5-12: Coloured wash dose distribution of six large PRESAGE dosimeters irradiated in 
two conditions (static and dynamic) for three SABR techniques: 3D CRT, IMRT, and VMAT 
in the YZ plane.    
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Figure  5-13: Three-dimensional image of the irradiated PRESAGE dosimeters in dynamic 
condition using IMRT technique for patient 2. The three axes were assigned as follows: X 
(red colour), Y (yellow colour), and Z (green colour).  
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Figure  5-14: Dosimetric variation between the static and dynamic conditions for individual 
plane/layer of SABR technique using 3D CRT for the 28 Gy isodose line in: A) YZ axes and 
B) ZX axes. The displacement measurements (in millimetres) between the static and dynamic 
conditions are displayed in (B) for ZX axes.     
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Figure  5-15: Gamma index analysis using 3%, 3 mm criterion for 3D CRT technique 
demonstrating that most of the PRESAGE dosimeter was <1 in the YZ plane (top image) and 
ZX plane in the (bottom image). The red cursor in the box tool shows the gamma index value 
of 0.135.      
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5.5 Discussion 
 
This study investigated the impact of tumour motion using PRESAGE 3D dosimeters and in-
house custom-designed thorax dynamic phantom in three SABR techniques: 3D CRT, IMRT, 
and VMAT. Before the experiment, the phantom movement distance and the PRESAGE 
dosimeters were assessed. The results of the motion assessment for the phantom exhibited 
very good agreement between the simulated movement distances and the CT images. 
Furthermore, the results of the PRESAGE dosimeters showed excellent dose distribution 
compared to the planned dose for regular field size (2 cm × 2 cm) and a retrospective clinical 
case (patient 1). These results emphasised that both the phantom motion and the PRESAGE 
dosimeters used in this study can produce reliable measurements for the static and dynamic 
conditions.         
 
Studies related to the investigation of the motion using PRESAGE 3D dosimeter are very 
limited [132, 190]. Brady et al., 2010 [132], irradiated the PRESAGE  (<5 cm length × 5 cm 
diameter)  with small field sizes (∼2 cm) in three scenarios: static, motion, and gated, by 
using the commercial CIRS dynamic thorax phantom [132]. They recorded an elongation in 
the axis directions that were parallel and perpendicular to the edge of the MLC leaf [132]. 
The gamma analysis results showed that the passing rates were 84.7%, 84.5%, and 100% for 
the static, motion, and gated treatment scenarios, respectively [132]. Another study by 
Thomas et al., 2013 [190], used the same commercial CIRS dynamic thorax phantom to 
assess the differences in the PTV and CTV for the IMRT and rapid arc plans using 
PRESAGE in the static and dynamic states. They found that the isodose distributions were 
varied between the static and dynamic on the order of millimetres, and the dynamic isodoses 
provided significant deviations in the form of shifting and stretching in the motion directions 
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[190]. Our results agreed with those of Brady et al., 2010 [132]. The observed elongations in 
the three SABR techniques were consistent in the X- and Y-axes. Moreover, the gamma 
analysis showed good agreement between the static and dynamic condition for the 3D CRT, 
IMRT, and VMAT, i.e., (< 1). The differences between the static and dynamic conditions 
were quantified in this chapter, and the recoded variations were small (<0.5%) among the 
three plans (Table 5-4).       
 
From the two previous studies [132, 190], it was clear that the isodose distributions during 
the motion were exhibited by elongation or stretching and shifting compared to the static 
plans [132, 190], leading to the under-dosing of the PTV [190]. The elongation of the dose 
distribution can be attributed to the X-ray beams passing though the rounded end of the 
Varian MLC leaf, which has been exhibited to increase penumbral blurring by approximately 
2 mm [132, 194]. Apart from the elongation of the isodose distribution, the results in this 
chapter monitored shortening isodose distribution on the Z-axis. The shortening  phenomenon 
by the motion was proposed by Clements et al., 2013 [195]. They compared the ITV between 
the 4D-CT and CBCT images obtained during the phantom motions using QUASAR 
phantom for small, medium, and large lesions moved by 0, 1 cm, 2 cm, and 4 cm. They found 
that when the motion was present, the ITV in 4D-CT and CBCT were shortened by 7 mm to 
11 mm [195].  
 
The  main aspects of this study are summarised as follows: 1) the use of larger size 
PRESAGE samples allows for better demonstration of the dose distribution, especially for the 
penumbra area (Figures 5-11 and 5-12) of a retrospective clinical case of lung SABR; 2) 
analysis of the PRESAGE data by the PolyGeVero ® software [147] to quantify the 
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dosimetric variation between the two conditions; 3) simulation of the target motion by 
designing an in-house custom-designed thorax dynamic phantom that featured larger 
PRESAGE sizes, unlike the commercial CIRS dynamic thorax phantom that is limited to a 
specific PRESAGE size (<5 cm in diameter). The limitation of this work was the lack of 
motion in the X-direction (R/L) for the designed phantom, which may occur in some lung 
cases during the tumour motion [178]. Therefore, the current phantom design was suitable for 
evaluating the tumour motion in two directions, and as an example, patient 2 was considered 
in this chapter. Also, this study was specified for patients with regular breathing with a small 
tumour displacement of < 2 cm.       
 
5.6 Conclusion  
The trend of the dose distribution results during the tumour motion cannot be predicted to 
cause over- or under-dosing to the targeted volume. This study proposed a method to quantify 
the dosimetric impact of organ motion by using an in-house custom-designed thorax dynamic 
phantom and PRESAGE 3D dosimeters in the static and dynamic conditions for a known 
distance motion in two directions. In the SABR of the lung for QA purposes, this could help 
in identifying the prescription dose coverage due to tumour movement and correlate with the 
planned dose.  
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Chapter 6   A Study of Dose Calculation Algorithms 
Using IPSM Phantom with Different Density 
Materials for in-field and out-of-field Conditions 
 
6.1 Summary 
The two previous chapters investigated the dosimetric impact of tumour motion in lung 
SABR. This chapter investigates the performances of dose calculation algorithms used in 
treatment planning of lung SABR. The accuracy of the dose calculation is vital in the SABR 
technique to achieve clinically effective dose distribution for better tumour control. Multiple 
commercial radiotherapy treatment planning systems (TPS) were implemented with different 
algorithms, such as Acuros XB in Eclipse and Superposition in XiO. In this chapter, the 
IPSM phantom was used to investigate the dose calculation algorithm performances in four 
different densities (water, lung, ribs, and dense bone) using different beam configurations, 
including small beam fields utilised in lung SABR. Five commercial algorithms implemented 
in two TPS (Eclipse and XiO) and one plan check (M3D) system were used in this study.  
6.2 Introduction 
Dose calculation algorithms play an important role in delivering the precise dose to the target 
volume. Prior to clinical use, the accuracy of dose calculation algorithm needs to be validated 
against measurements for different inhomogeneous conditions. The ideal dose calculation 
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algorithms should perfectly reflect the actual dose distribution in the patient to help assess 
treatment plans with low uncertainty. According to the ICRU recommendations, the delivered 
dose should have an error of less than 5% [196], which suggests that every step of dose 
calculation and patient positioning, among others, should be performed far better than this 
percentage. Moreover, the required accuracy for the dose calculation step should be in the 
range of 2%–3% [197].  
 
At present, Monte Carlo (MC) simulations are considered the most accurate algorithms by 
simulating large numbers of primary photon histories [198]. However, the main disadvantage 
of such algorithms is their relatively long processing time, which makes them less attractive 
in daily clinical applications [199]. Consequently, many treatment planning system (TPS) 
vendors have attempted to develop clinical algorithms that can calculate the dose distribution 
with a reasonable processing time. Semi-analytical algorithms for the dose calculation of 
photon beams, including pencil beam convolution (PBC) [117], anisotropic analytical 
algorithms (AAA) [117] and superposition/convolution algorithms such as superposition 
[199] and collapsed cone convolution [177], are widely used in radiation therapy centres. 
These algorithms can provide relatively accurate measurements of the dose distribution of the 
target volume with less processing time [200]. Several previous studies investigated the 
performances and limitations of these algorithms in phantoms composed of water or water–
air interfaces (large inhomogeneities) to mimic lung cases [200-204]. According to the 
existing literature, no study has yet examined the performances of different algorithms using 
four different densities in a phantom using a number of beam geometries with different field 
sizes, including symmetric and asymmetric fields.                      
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This study investigated five different dose calculation algorithms, namely, PBC, Acuros XB, 
AAA implemented in an Eclipse system, collapsed cone convolution algorithm (CCC) 
implemented in Mobius3D and superposition algorithms implemented in the XiO system, and 
then validated the results against measurements using an IPSM phantom for different density 
inserts.  
 
6.3 Materials and Methods 
A phantom designed by the Institute of Physical Sciences in Medicine (IPSM) Radiotherapy 
Topic Group in 1982 [41] was used to study the accuracy of dose calculation algorithms with 
the following density inserts: water-equivalent, lung, rib and dense bone inserts (Figure 3-
22). The IPSM phantom including special lung insert is described in Chapter 3, Section 3.13. 
Each density insert simulates real clinical densities with a similar CT number. The CT 
number was assigned as follows: water insert (CT number = 0), lung insert (CT number = 
−740 to −770), rib insert (CT number = 400) and dense bone insert (CT number = 1,000). In 
this study, the measurements were conducted by using a 0.6 cc IC. The IC converts the ions 
into doses by using equation 3-1 (the IC is described in Chapter 3, Section 3.11). The IC was 
placed at six different positions, and three different field sizes of 3 × 5, 5 × 5 and 10 × 10 
were defined to provide both in-field and out-of-field measurements. The in-field 
measurements were represented by the calculated point (iso), and the out-of-field 
measurements were allocated for (POI5) for beams 1–12. These measurements were 
performed for different beam configurations as follows: open, physical wedge (Phy) and 
enhanced dynamic wedge (EDW) fields at 90° and 270° gantry angles with a collimator angle 
of 90o. The applied monitor unit (MU) for all points and beams geometries was 100 MU. All 
calculations were performed for Varian 21iX linear accelerator 6 MV photons (Varian 
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Medical System, Palo Alto, CA). The beam configurations of the gantry, collimation and MU 
were consistent in all calculations.      
 
The clinical treatment plans were initially created using the Eclipse treatment planning 
system (v13.6, Varian Medical Systems) with the same beam configurations utilised in the IC 
measurements. In the Eclipse system, the doses were recalculated by AAA (v13.6.23), PBC 
(v11.0.31) and Acuros XB (v13.6.23) algorithms. The AAA algorithm utilises pencil-beam 
energy deposition kernels produced from the MC simulation [117, 177]. These algorithms 
represent the kernels analytically and adopt a scaling based on local density variations using 
specific analytic kernels for build-up or down effects at density interfaces [117, 177]. In the 
PBC algorithms, the dose kernels at a point are summed up along a line in a phantom to 
acquire a pencil-type beam (or dose distribution) [104]. Using a convolution method, the 
pencil beam computes the dose distribution around an infinitely small beam in water. Unlike 
the AAA, the PBC algorithms cannot consider the variation of lateral scattering effects [104]. 
The Acuros XB algorithm has been implemented recently in the Eclipse system [205]. They 
are based on the explicit solution of linear Boltzman transport equations (LBTEs) to 
demonstrate the dose calculations [205]. The main difference between the MC simulation and 
the Acuros XB is that the former method solves the coupled system of LBTEs stochastically 
using the histories of the photon and electron transportation, whereas the latter uses grid-
based LBTE solutions to separate the photon and electron influences in energy, space and 
angle and determines a solution for the radiation transport through matter [118]. The Acuros 
XB algorithms have a relatively less processing period when calculating the dose than the 
MC simulation, and their results are comparable with those of the MC [206].     
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The DICOM RT plans and CT images of the IPSM phantom were imported into the XiO 
treatment planning system (v5.0, Elekta AB, Stockholm, Sweden) and Mobius Medical 
System (M3D; v2.0.1, Mobius Medical system) to recalculate the measured points using 
superposition and CCC algorithms respectively. The M3D uses the CCC algorithm, which 
adopts the convolution of a total energy released per unit mass (TERMA) volume with MC-
derived point spread kernels implemented in a graphic processing unit [177, 207]. The 
superposition algorithm implemented in the XiO-TPS involves the convolution of the 
TERMA volume with MC-measured point energy deposition kernels [177]. It is characterised 
by density scaling of the energy deposition kernels to consider the local density heterogeneity 
[177].         
 
The measured dose by the IC (the actual dose) was compared with the dose calculation 
derived from the TPS for the AAA, PBC, Acuros XB, superposition and CCC algorithms. To 
evaluate the performance of the algorithms, the actual dose by the IC was used as the 
reference dose. The differences in percentages for all calculated points by the five algorithms 
were normalised to the reference dose. All calculated points were defined as follows: [(the 
measured dose calculated by the algorithms – the measured dose by the IC/the measured 
dose by the IC)]. 
  
The statistical analyses were performed by Graph Pad PRISM 6 software, v. 6.03. A one-way 
ANOVA, with repeated measures utilising multiple comparisons was used to investigate 
the statistical significances (p <0.05) and mean differences among the five algorithms in 
four different densities (water, lung, ribs, and dense bone). 
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6.3 Results 
The measurement points for the measured dose by IC and the five algorithms for water, lung 
and dense bone density–IPSM inserts are shown in Table 6-1. The measurement points for 
special lung and rib density inserts are shown in Tables 6-2 and 6-3 respectively. Theses 
tables include the beam configurations, field size, gantry angle and wedge application. The 
results can be divided into in-field and out-of-field results as follows:   
 
6.3.1 In-field condition 
The water density results showed a maximum percentage of ±1% for all algorithms [Figure 6-
1 (A)]. The Acuros XB and superposition algorithms represented the lowest mean values of 
0.2 and 0.31, respectively (Table 6-4). In the rib density material, the calculation differences 
in the algorithms ranged from −1.27% to 1.91% [Figure 6-1 (B)], and the mean differences 
did not exceed 0.58% (Table 6-4). 
  
The performance of the algorithms in dense bone density showed significant differences 
between the 90o and 270o gantry angles. In 90o gantry angle, the PBC, superposition and CCC 
algorithms experienced maximum error percentages in the following points of beam 1: POI2 
= 3.55% in PBC, POI1 = 4.88% in Superposition and POI1 = 5.3% in CCC, respectively 
[Figure 6-2 (A)]. These maximum error percentages were associated with high mean 
differences of 1.57±1.15, 3.2±1.44 and 3.01±1.51 for the PBC, superposition and CCC 
algorithms, respectively (Table 6-4). By contrast, the AAA and Acuros XB algorithms 
provided better performance in dense bone density with maximum error differences only in 
particular points of beam 1 as follows: POI1=2.32% and POI2 = 1.45%, respectively [Figure 
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6-2 (A)]. At 270o gantry angle, the five measured points of all algorithms except for the PBC 
algorithm showed maximum differences of (< ±1.83%) that ranged between −0.9% and 
1.83% [Figure 6-2 (B)]. The performance of the PBC algorithm at a 270o angle was an 
underestimated dose compared with the measured dose by the farmer chamber with a 
maximum percentage of −2.87% [Figure 6-2 (B)].                    
 
In the lung density measurements, the differences in percentages of the five algorithms were 
within ±2%. However, some points of the AAA and PBC measured points downstream from 
the measured dose were beyond 2%. Four points of the AAA assigned to POI1 and POI2 of 
beams 1 and 2 experienced high errors at 2.13%, 3%, 2.82% and 3.65%, respectively. The 
PBC had two points 2.13% and 2.99% related to POI1 for beams 1 and 2, respectively that 
exceeded 2% [Figure 6-3 (A)]. Moreover, the special insert (POI6) of lung density showed 
different measurements among the three algorithms of AAA, PBC and Acuros XB. The AAA 
measurements at points (POI6) were higher for beams 2 and 3 than the PBC and Acuros XB 
measurements [Figure 6-3 (B)]. As shown in [Figures 6-3 (A) and (B)], the calculations of 
Acuros XB were close to the measured dose by the IC and associated with the lowest mean 
values 0.22 and −0.46 for both types of lung densities with and without special inserts, 
respectively (Table 6-4 and Table 6-5).                 
 
          
 
 
185 
 
Table  6-1: Measurement points for the measured dose by IC and the five algorithms (AAA, 
PBC, Acuros XB, Superposition and CCC) using water, lung, and dense bone density inserts 
in IPSM phantom for different beam configurations. The collimator is set to 90o for all 
beams. Phy = physical wedge, EDW= enhanced dynamic wedge.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beams Gantry Field size Wedge Measurement points 
Beam 1 90o 
10 x 10 cm2 
SSD = 100 cm 
 
None 
ISO 
POI1 
POI2 
POI3 
POI4 
Beam 2 90o 10 x 10 cm2 EDW 25o OUT 
ISO 
POI1 
POI2 
POI3 
POI4 
Beam 3 90o 5 x 5 cm2 None ISO 
Beam 4 90o 5 x 5 cm2 EDW 25o  OUT ISO 
Beam 5 90o 5 x 5 cm2 45
o OUT 
(Phy) ISO 
Beam 6 270o 5 x 5 cm2 None ISO 
Beam 7 270o 5 x 5 cm2 EDW 25o IN ISO 
Beam 8 270o 5 x 5 cm2 45o IN (Phy) ISO 
Beam 9 90o 3Y x 5X cm2 None ISO 
Beam 10 90o 3Y x 5X cm2 45o OUT (Phy) ISO 
 
Beam 11 
 
270o 
 
3Y x 5X cm2 
 
None 
 
ISO 
Beam 12 270o 3Y x 5X cm2 45o IN (Phy) ISO 
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Table  6-2: Measurement points for the measured dose by IC and the three algorithms (AAA, 
PBC and Acuros XB) using a lung insert–IPSM phantom with a special insert at POI6 for 
different beam configurations. The collimator set to 90o for all beams. Phy = physical wedge, 
EDW= enhanced dynamic wedge.  
 
 
 
 
 
 
 
Table  6-3: Measurement points for the measured dose by IC and the five algorithms (AAA, 
PBC, Acuros XB, Superposition and CCC) using a rib insert–IPSM phantom for different 
beam configurations. The collimator set to 90o for all beams. Phy = physical wedge, EDW= 
enhanced dynamic wedge.  
Beams Gantry Field size Wedge Measurement points 
Beam 1 90o 
10 x 10 cm2 
SSD = 100 cm 
 
None 
ISO 
POI1 
POI2 
POI3 
POI4 
POI6 
Beam 2 270o 10 x 10 cm2 None 
ISO 
POI1 
POI2 
POI3 
POI4 
POI6 
Beam 3 270o 4 x 4 cm2 None ISO POI6 
Beam 4 90o 15 x 15 cm2 None ISO 
Beams Gantry Field size Wedge Measurement points 
Beam 1 90o 
10x10 cm2 
SSD=100 cm 
 
None 
ISO 
POI1 
POI2 
POI3 
POI4 
Beam 2 90o 10 x 10 cm2 EDW 25o OUT 
ISO 
POI1 
POI2 
POI3 
POI4 
Beam 3 90o 5 x 5 cm2 None ISO 
Beam 4 90o 5 x 5 cm2 EDW 25o  OUT ISO 
Beam 5 90o 5 x 5 cm2 45o OUT (Phy) ISO 
Beam 9 90o 3Y x 5X cm2 None ISO 
Beam 10 90o 3Y x 5X cm2 45o OUT(Phy) ISO 
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Figure  6-1: Percentages differences of the calculated points for five algorithms compared 
with the measured dose from the ion chamber for A) water and B) rib density inserts.  
 
 A 
 B 
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Figure  6-2: Percentages differences of the calculated points for five algorithms compared to 
the measured dose from the ion chamber for dense bone density at A) 90o and B) 270o. 
B 
A 
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Figure  6-3: Percentages differences of the calculated points for:  A) five algorithms compared 
to the measured dose from the ion chamber for lung density and  B) three algorithms using a 
special insert in the lung density for POI6 compared to the measured dose.
B 
A 
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6.3.2 Out-of-field condition  
The differences in percentages for the five algorithms measurements in out-of-field condition 
for four different densities were shown in [Figure 6-4 (A-D)]. The results of eclipse system: 
AAA, PBC and Acuros XB algorithms demonstrated underdose point’s measurements by -
40% for all densities except for AAA calculations in lung density (overdose by 40%). The 
measured points of the superposition algorithms were overestimated to the actual dose less 
than 30% in water, lung and dense bone [Figure 6-4 (A, B and D)]. At the same densities, the 
CCC algorithms showed relatively the lowest differences in percentage compared to the 
superposition algorithms. Compared to the actual dose, most of the measured points by CCC 
were less than 25% in water and lung density while the dense bone results showed most of 
the measured doses were close to the actual dose results except for four points were beyond -
20% [Figure 6-4 (A, B and D)]. In the rib density, the calculated points of the superposition 
and CCC algorithms were underestimated to the actual dose by less than -30 % except for 
two points in superposition calculation were overestimated by 25 % and 30 % respectively. 
Similarly to the dense bone results of the CCC, most of the measured points of the CCC 
calculation in the rib density were close to the actual dose [Figure 6-4 (C and D)]. The 
highest discrepancies (-71%) were allocated for beam 12 representing small field (Y=3, X=5) 
using physical wedges (45oIN) in the dense bone density for all calculated algorithms except 
superposition algorithms [Figure 6-4 (D)].          
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Figure  6-4: Percentages differences of the calculated points for five algorithms in out-of-field 
condition of four different densities: A) water density, B) lung density, C) rib density and D) 
dense bone density.          
 
Table 6-4 summarises the mean values of the five algorithms with four different densities 
inserts: water, lung, ribs and dense bone. The calculation of the three algorithms by a special 
insert within the lung density are summarised at the Table 6-5. The statistical analysis was 
significant for the mean differences among the four densities with p<0.05 (Table 6-4 and 
Table 6-5). 
 
Table  6-4: Mean differences in percentage of different densities: water, lung, rib and dense 
bone for gantry angles of 90° and 270°.   The data presented in this table was the result of 
three independent measurements (n=3). The mean values (mean values ± standard deviation) 
are significantly different among the five algorithms (P<0.05, One-way analyses of variance 
(ANOVA) with repeated measures). 
 
 
AAA 
Mean±Stdev 
 
 
PBC 
Mean±Stdev 
 
 
Acuros XB 
Mean±Stdev 
 
 
Superposition 
Mean±Stdev 
 
 
CCC 
Mean±Stdev 
 
P value 
Water Density 0.39±0.49 0.43±0.32 0.2±0.36 0.31±0.33 0.36±0.39 0.0010 
Lung Density 1.12±1.23 0.38±1.06 0.22±0.91 0.36±0.87 0.49±0.69 0.0003 
Rib Density 0.42±0.52 0.39±1.14 0.11±0.43 0.58±0.48 0.52±0.68 0.0163 
Dense Bone 
Density 
(90o beams) 
0.41±0.93 1.57±1.15 0.24±0.88 3.2±1.44 3.01±1.51 
 
< 0.0001 
 
Dense Bone 
Density (270o 
beams) 
-0.44±0.32 -1.68±0.77 -0.21±0.23 0.08±0.36 1.34±0.33 
 
0.0243 
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Table  6-5: Mean differences in percentage for the special insert in the lung density for POI6 
and calculated by three different algorithms: AAA, PBC and Acuros XB. The data presented 
in this table was the result of three independent measurements (n=3). The mean values (mean 
values ± standard deviation) are significantly different among the three algorithms (P<0.05, 
One-way analyses of variance (ANOVA) with repeated measures).  
 
 
AAA 
Mean±Stdev 
 
PBC 
Mean±Stdev 
 
Acuros XB 
Mean±Stdev 
 
P value 
Lung Density 
(With POI6) 0.89±2.98 1.07±1.34 -0.46±1.63 
 
0.0263 
 
 
 
6.4 Discussion  
This study investigated the performances of five algorithms, namely, AAA, PBC and Acuros 
XB in Eclipse, Superposition in XiO treatment planning system and CCC implemented in 
plan-checking software (Mobius3D). The comparison between the absolute doses from the IC 
(the measured dose) and the calculated doses by the five algorithms showed a significant 
variation for the different densities of water, lung, rib and dense bone.    
 
6.4.1 In-field condition  
In water density, the measurements of the five algorithms demonstrated almost similar 
performances as predicted in a homogenous medium. PBC and AAA are considered semi-
analytical algorithms [208] that can provide a lower uncertainty (within ±1%) in homogenous 
tissues than in heterogeneous tissues [199]. The calculations of the five algorithms for rib 
density were within ± 2%. Both water and rib densities showed relatively small mean 
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differences for all calculations including in-field measurements. By contrast, the dose 
calculation performances demonstrated a significant variation in calculating dose for the lung 
and dense bone densities. In the lung density, the AAA and PBC algorithms recorded the 
largest differences compared with the measured dose and exceeded 2% for beams 1 and 2, 
respectively. Acuros XB, superposition and CCC provided better performances than AAA 
and PBC in the calculation of lung densities with differences less than 2%. Another 
investigation on AAA, PBC and Acuros XB in special inserts inside the lung phantom (POI6) 
showed that Acuros XB and PBC had better calculations than AAA [(Figure 6-3 (B)]. The 
measurement of the point inside the lung density (POI6) is difficult to perform, and thus a 
potential deviation may occur from the absolute dose value for both the IC and the algorithms 
calculations. The largest value recorded for the AAA in POI6 with a small field of 4 × 4 was 
−6.13 %.   
 
The dense bone density for the beams with a 90o gantry angle showed the largest 
discrepancies for PBC, superposition and CCC. As the measured doses were located after the 
dense bone, these discrepancies of the algorithms could be explained as a limitation in the 
accuracy of the mass attenuation data utilised in the TERMA calculations for these 
algorithms. The calculation of all algorithms provided better performances for beams with a 
270o gantry angle because of the absence of the high attenuation of the dense bone. However, 
the PBC calculations of small fields, namely, beam 6 (5 × 5) and beam 11 (3 × 5), for the 
same gantry angle under-predicted the absolute dose and exceeded −2%. AAA, Acuros XB 
and PBC showed almost the same mean difference in percentage in the 90o and 270o gantry 
angles. For example, the mean difference of the PBC results with a 90o (1.57%) was almost 
the same as the mean difference of those with a 270o (−1.68%), but the downstream points 
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were in the opposite direction. This result demonstrated that PBC provided high 
discrepancies within (±1.7%) in both gantry angles compared with AAA and Acuros XB.    
 
Hardcastle et al., 2016 [177] compared the AAA and CCC algorithms for 10 lung cancer 
patients, used the in-house MC algorithm as a reference calculation, and showed that CCC 
closely agreed with the MC algorithms [177]. For the 10 patients, the calculated doses were 
at the centre of the ITV [177]. The maximum differences in AAA and CCC compared with 
MC were −11.3% and 7.5%, respectively [177]. The results from our study were consistent 
with those of Hardcastle et al., 2016 [177]. CCC provided lower mean differences in absolute 
dose by (0.49%) compared with AAA (1.12%) in the lung density. Moreover, Tan et al., 2014 
[200] investigated the accuracy of six algorithms (i.e., AAA, PBC, Acuros XB, FFT 
convolution, superposition and MC algorithms) in calculating the entrance and exit doses for 
6 MV in a water phantom [200]. They found that the entrance dose measurements agreed 
within 2% of the measured dose by the IC [200]. These results were consistent with those of 
our investigation using water density, as the measurements of 20 points were close to the IC 
measurements and the differences were within ±1%. However, the performances of the six 
algorithms varied when computing the exit doses in the same phantom. The exit doses 
computed by the FFT convolution, superposition, Acuros XB and MC algorithms were close 
to the measured dose, and their percentages ranged from 2% to 3% [200]. By contrast, the 
exit doses computed by AAA and PBC were higher than the measured dose (IC) by up to 
4.8% and 5.3%, respectively [200]. The reason for this outcome is that AAA and PBC 
assumed that the full backscatter existed even at the exit level, thus resulting in the over-
prediction of exit doses [200]. Our results agreed with the good performance results of 
Acuros XB and superposition in Tan et al., 2014 [200]. Despite the high mean difference in 
the superposition algorithm when calculating the dense bone with 90o beams, superposition 
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and Acuros XB provided the lowest mean difference and thus produced close values to the 
actual dose by IC for all densities. Another study compared superposition and AAA for four 
different cancer sites, namely, brain, nasopharynx, lung and prostate, and found that the mean 
dose deviation of superposition was within 3% and was relatively more accurate than that of 
AAA, especially in a heterogeneous medium [199]. Moreover, this study agreed with our 
results in that AAA had relatively high mean differences (1.12%) compared with the other 
algorithms in a lung density–IPSM phantom. According to Stathakis et al., 2012 [206] the 
dose prediction accuracy of Acuros XB in bone and lung heterogeneities is better than those 
of AAA and CCC and is in good agreement with the MC measurements [206].                 
 
6.4.2 Out-of-field condition       
In the out-of-field condition, superposition and CCC provided lower discrepancies than 
AAA, PBC and Acuros XB. The calculated doses of AAA, PBC and Acuros XB were 
underestimated by less than −40% for most of the calculated points compared with the actual 
dose in the out-of-field condition for all densities. Our results agreed with those of Rebecca et 
al., 2010 [209]. They quantified the accuracy of the out-of-field condition using the AAA 
algorithms and the results showed an underestimation (about 40%) of the measured dose 
compared with the actual dose [209]. The same research group suggested that the 
underestimation of the dose increased with the increasing distance from the field edge [209]. 
The results from our study showed that the beam configurations affected the measured doses 
for all densities. Beams with a larger field size without using enhanced or physical wedges 
provide fewer discrepancies in percentages than beams with a small field size using wedges. 
Moreover, these percentages increased with the physical wedges associated with an 
asymmetric small field size (Y=3, X=5) in dense bone density [Figure 6-4 (D)]. The out-of-
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field results for the previous algorithm calculations can be used in low doses outside the 
irradiation target, which can cause acute toxicities [209]. The low-dose information can be 
used for the assessment of late effects, such as second cancers. According to Kry et al., 2007 
[210] a 50% change in low dose is sufficient to cause a significant variation in second cancer 
risk [210].  
 
Our study showed the calculation variations among the five algorithms in four different 
densities. The Acuros XB algorithm had lower mean differences than the measured dose by 
the IC ranging from –0.46 to 0.24 for all the densities. In the lung density, AAA over-
predicted the absolute dose compared with the other algorithms. In the dense bone density, 
despite the limitation in the accuracy of the mass attenuation, superposition provided the 
lowest mean difference in percentage at 0.08%.           
 
6.5 Conclusion 
Our results show that the Acuros XB and superposition algorithms are closer to the actual 
measured dose than AAA, PBC and CCC for majority of the field conditions for water-
equivalent, lung, rib and dense bone densities. The CCC algorithm resulted in a better 
agreement with the measurement of the out-of-field points compared with the other 
algorithms.  
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Chapter 7 Evaluation of Dose Calculation 
Algorithms for Lung Cancer Patients Undergoing 
Stereotactic Ablative Radiotherapy (SABR) using 
3D CRT technique 
 
 
7.1 Summary 
 
The previous chapter investigated the accuracy of five different algorithms using IPSM 
phantom. This chapter further evaluates the dosimetry of seven different dose calculation 
algorithms on 21 retrospective of lung cancer cases treated by 3D CRT technique. Also, this 
chapter investigates the accuracy of four algorithms (AAA, PBC, Acuros XB and 
Superposition) using CIRS thorax phantom. Stereotactic ablative radiotherapy (SABR) is a 
high precision image guided radiation therapy (IGRT). Such an advanced cancer treatment 
technique like SABR requires high accurate dose calculation algorithms to deliver conformal 
dose to the tumour and spare healthy tissues. The aim of this study was to investigate and 
quantify the dosimetric variation in small field of lung cancer radiotherapy using seven 
different dose calculation algorithms. This study was performed for twenty one lung cancer 
patients who underwent stereotactic ablative radiotherapy (SABR) using 3D CRT technique. 
Moreover, the CIRS thorax phantom was used to validate the algorithms measurements of 
four algorithms (AAA, PBC, Acuros XB and Superposition) for the lung material. In the 
clinical study, two methods were applied as follows: The same dose coverage to the target 
volume and the same monitor unit method. The comparison among the different algorithms 
was achieved by utilising different dosimetric parameters such as conformity index (CI), 
homogeneity index (HI) and dose fall-off. In the same dose coverage method, the calculated 
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mean dose of the CI for the four algorithms: superposition, fast-superposition, FFT 
convolution and Clarkson were: 1.24, 1.3, 1.37 and 1.45 respectively while the CI values for 
the same monitor unit method were: 1.25, 1.3, 1.66 and 2.2 respectively. For the Eclipse 
system, the mean dose of the CI values for the same dose coverage method for AAA, PBC 
and Acuros XB were 1.31, 1.39 and 1.22 while for the same monitor unit method for AAA, 
PBC and Acuros XB were 1.35, 1.9 and 1.28 respectively. The Superposition and Acuros XB 
algorithms were provided better performance in calculating the dose associated with low 
discrepancies compared to the IC measurement in thorax phantom study, and lowest dose 
fall-off with good conformity to the PTV for lung cancer cases in the clinical study.     
 
7.2 Introduction  
Stereotactic ablative radiotherapy (SABR) is a high precision image guided radiation therapy 
(IGRT). The SABR technique is characterised by hypofractionated ablative doses of radiation 
typically less than five fractions with great conformal dose distribution. Typical multi-
fraction dose systems include 48 to 60 Gy which delivered in three to five fractions. The 
biologically effect dose (BED) [211] is quite high to both normal tissue and tumours because 
of the used of hypofractionated doses [211]. Such an advanced cancer treatment technique 
like SABR needs high accurate dose calculation algorithms to deliver conformal dose to the 
tumour and spare healthy tissues [123].   
 
Dose calculation algorithm for the SABR poses great challenge due to respiratory 
movements and the heterogeneous medium characterisation of the lungs. The use of small 
field in the presence low densities  present inside lungs causes electronic disequilibrium at 
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the air/tissue interface because of the lateral range of the secondary electrons become longer 
than the width of the small field segments [212, 213]. Various types of algorithms control the 
quality and functionality of the treatment planning system (TPS) at different stages of the 
planning process. Some of the common TPS used for external beam dose calculation include 
XiO, Monaco (CMS/Elekta), Pinnacle (Philips Medical systems), Oncentra and Eclipse, 
which have multiple algorithms that provide different dose calculation performance on 
heterogeneous medium. XiO includes algorithms, such as superposition, fast superposition, 
fast Fourier transformation (FFT) convolution and Clarkson. Eclipse has three algorithms: 
anisotropic analytic algorithms (AAA), pencil beam convolution (PBC) algorithms and 
Acuros XB algorithms.  
 
The aim of this study was to investigate and quantify the dosimetric variation in small field 
of SABR lung cancer using seven different dose calculation algorithms in clinical study. 
Also, to investigate the accuracy of four algorithms (AAA, PBC, Acuros XB and 
Superposition) using CIRS thorax phantom.    
 
7.3 Material and Methods  
This study investigated the dose calculation algorithms by using a well-known CIRS thorax 
phantom (phantom study). In addition, the planning dosimetry using different dose 
calculation algorithms for 21 lung cancer patients treated by SABR with 3D CRT technique 
(clinical study). The ethics approval for this study was approved by Peter MacCullum Cancer 
Centre and the registration certificate was issued from college human ethics by RMIT 
university (See appendices I, II, III and IV). The SABR protocol for lung cancer using 3D 
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CRT is described in Chapter 4, Section 4.3.1. The materials and methods section in this 
chapter is divided into the two following sub-sections.   
 
7.3.1 CIRS thorax phantom (phantom study) 
This study uses CIRS thorax phantom as described in Chapter 3, Section 3.14. In this study, 
two treatment plans for lung cancer patients treated by SABR with 3D CRT were selected. 
These treatment plans were simulated by using the CIRS thorax phantom and the IC was 
inserted at the same location of the tumour to measure the absolute doses (Figure 7-1). The 
simulated plans were identical to the original plans in terms of total number of beams, beam 
configurations and the monitor units that used in the treatment. Table 7-1 shows the beam 
configurations and the monitor units for each beam that used in both treatment plans (the 
simulated and the original plans). The IC converts the ions into doses by using equation 3-1 
(the IC is described in Chapter 3, Section 3.11). The DICOM images of the CIRS thorax 
phantom were transferred to the XiO treatment planning system (v5.0, Elekta AB, 
Stockholm, Sweden) and Eclipse treatment planning system (v13.6, Varian Medical Systems) 
and calculated using superposition, PBC, AAA and Acuros XB algorithms. To evaluate the 
performance of the algorithms, the actual dose by the IC was used as the reference dose. The 
differences in percentages for all calculated points by the four algorithms were normalised to 
the reference dose. All calculated points were defined as follows: [(the measured dose 
calculated by the algorithms – the measured dose by the IC/the measured dose by the IC)]. 
The statistical analyses were performed by Graph Pad PRISM 6 software, v. 6.03. A one-way 
ANOVA, with repeated measures utilising multiple comparisons was used to investigate 
the statistical significances (p <0.05) and mean differences among the four algorithms in 
CIRS thorax phantom.  
202 
 
Table  7-1: Beam configurations and monitor units in the original treatment plans of two lung 
cancer patients who treated by SABR with 3D CRT techniqe. OBL = oblique. Post=posterior. 
LT= lateral. RT= right.   
Beams 
Number 
Patient 1 
(Tumour is located in the left lung) 
Patient 2 
(Tumour is located in the right lung) 
Beam configurations Monitor Unit (MU) Beam configurations 
Monitor 
Unit (MU) 
1 
OBL 
Gantry rotation 130o 
Couch rotation 20o 
Collimation rotation 90o 
441 
OBL 
Gantry rotation 30o 
Couch rotation 0o 
Collimation rotation 90o 
590 
2 
OBL 
Gantry rotation 220o 
Couch rotation 0o 
Collimation rotation 90o 
473 
OBL 
Gantry rotation 330o 
Couch rotation 0o 
Collimation rotation 90o 
475 
3 
Post 
Gantry rotation 180o 
Couch rotation 0o 
Collimation rotation 90o 
399 
OBL 
Gantry rotation 300o 
Couch rotation 0o 
Collimation rotation 90o 
453 
4 
OBL 
Gantry rotation 150o 
Couch rotation 0o 
Collimation rotation 90o 
426 
RT 
Gantry rotation 270o 
Couch rotation 0o 
Collimation rotation 90o 
474 
5 
LT 
Gantry rotation 90o 
Couch rotation 0o 
Collimation rotation 90o 
617 
OBL 
Gantry rotation 230o 
Couch rotation 0o 
Collimation rotation 90o 
519 
6 
OBL 
Gantry rotation 50o 
Couch rotation 20o 
Collimation rotation 90o 
656 
OBL 
Gantry rotation 200o 
Couch rotation 0o 
Collimation rotation 90o 
507 
7 
OBL 
Gantry rotation 15o 
Couch rotation 0o 
Collimation rotation 90o 
672 
POST 
Gantry rotation 180o 
Couch rotation 0o 
Collimation rotation 90o 
541 
8 
OBL 
Gantry rotation 110o 
Couch rotation 340o 
Collimation rotation 90o 
454 
OBL 
Gantry rotation 330o 
Couch rotation 90o 
Collimation rotation 0o 
546 
9 
OBL 
Gantry rotation 70o 
Couch rotation 340o 
Collimation rotation 90o 
459 
OBL 
Gantry rotation 30o 
Couch rotation 90o 
Collimation rotation 0o 
497 
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Patient 1 
 
  
 
Patient 2 
 
  
 
Figure  7-1: Two different plans for two lung cancer patients treated by SABR using 3D CRT 
technique. The left column: CIRS phantom and the right column: lung cancer cases. The CT 
images in the left column shows the CIRS thorax phantom for patient 1 and 2 including ion 
chamber that is placed in port number (9) in patient 1 and port number (6) in patient 2 [see 
Figure 3-23 (A)]. The CT images in the right column shows CT images of lung cancer 
patients (patient 1 and 2) and demonstrates the lung tumours on each patient image. The 
location of the ion chamber in CIRS phantom simulates the tumour location in lung cancer 
patients and both (the phantom and lung cancer patient) are using the same beam 
configurations and doses.    
CIRS Thorax Phantom 
CIRS Thorax Phantom SABR Case (3D CRT) 
SABR Case (3D CRT) 
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7.3.2 Twenty one lung cancer cases using 3D CRT technique 
(clinical study)  
The clinical study was conducted for 21 lung cancer patients who underwent Stereotactic 
Ablative Radiotherapy (SABR). The PTV volume and location of all studied patients are 
shown in Table 7-2. The tumour sizes varied between 4.9 cm3 - 77.57 cm3 and 12 patients 
had lesion in the right side and 9 were left sided tumours. Two different methods were 
applied: (I) same dose coverage to the target volume, i.e. 99 percent of planning target 
volume (PTV) volume is covered by 100 percent of the prescribed dose (termed same dose 
coverage method), (II) same monitor units in all algorithms for studying the performance of 
seven different dose calculation algorithms in XiO and Eclipse treatment planning systems. 
For both methods, the Superposition algorithm was used as the reference algorithm. All 21 
patients were treated by the three dimensional conformal radiotherapy (3D CRT) with a 
prescription dose of 26 Gy. The patients were positioned with arms above head in a 
Bodyfix® blue bag. All patients underwent 4D-CT scanning using the bellows system on the 
Philips BrillianceTM CT scanner (Koninklijke Philips Electronics, Amsterdam, The 
Netherlands) utilising the Philips Bellows system to acquire a breathing trace during the scan 
acquisition.  The pulmonary wave trace was edited to ensure the tags are located at their crest 
and through of each wave corresponding to inhale and exhale phases prior to reconstruction. 
The ITV was delineated on the Maximum Intensity Projection MIP studyset and then 
expanded by a 5 mm radially to create the PTV. Beam arrangements were individualised to 
ensure maximum conformity of the high dose distribution to the target and reducing OAR 
doses. The numbers of beams were ranged from 8 to 12 for all patient plans. Both the 
commercially available XiO treatment planning system (v5.0, Elekta AB, Stockholm, 
Sweden) and Eclipse treatment planning system (v13.6, Varian Medical Systems) were used 
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for planning and measuring purposes. All the plans were planned using a 21iX linear 
accelerator for 6 MV X-rays.   
 
Table  7-2: PTV volume and tumour location for 21 patients treated by the 3D CRT technique. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The Tumour Location PTV (cm3) 
1 Right lung 25.122 
2 Left  lung 4.9 
3 Left  lung 22.33 
4 Right  lung 20.763 
5 Left  lung 19.87 
6 Right  lung 34.05 
7 Right  lung 21.65 
8 Left  lung 8.69 
9 Left  lung 19.09 
10 Right  lung 26.64 
11 Right  lung 5.15 
12 Left  lung 11.33 
13 Right  lung 35.09 
14 Right  lung 13.44 
15 Left  lung 77.57 
16 Right  lung 33.53 
17 Left  lung 47.39 
18 Right  lung 29.54 
19 Left  lung 17.61 
20 Right  lung 27.74 
21 Right  lung 38.06 
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The tumour dosimetry was evaluated using the conformity index (CI), dose fall-off index and 
homogeneity index (HI).  The CI indirectly indicates the prescription dose spillage outside 
the target volume, and ideally it should be close to 1 [20]. The dose conformity to the 
target volume was assessed using the CI as described below [27]: 
 
CI =  𝐓𝐡𝐞 𝐯𝐨𝐥𝐮𝐦𝐞 𝐩𝐞𝐫𝐜𝐞𝐧𝐭𝐚𝐠𝐞 𝐨𝐟 𝐛𝐨𝐝𝐲 𝐫𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐝𝐨𝐬𝐞  
𝐓𝐡𝐞 𝐯𝐨𝐥𝐮𝐦𝐞 𝐩𝐞𝐫𝐜𝐞𝐧𝐭𝐚𝐠𝐞 𝐨𝐟 𝐏𝐓𝐕 𝐫𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐝𝐨𝐬𝐞       ( 7-1) 
 
The dose fall-off index and HI, as recommended by the American Association of Physicists 
in Medicine (AAPM) Task Group 101 protocol [14], were used to assess the dose 
gradient around the tumour and dose inhomogeneity inside the tumour volume. 
 
The dose fall-off index was defined as follows [14]: 
 
Dose fall-off =  𝐓𝐡𝐞 𝐕𝐨𝐥𝐮𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝟓𝟎% 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐢𝐬𝐨𝐝𝐨𝐬𝐞 
𝐏𝐓𝐕 𝐕𝐨𝐥𝐮𝐦𝐞         ( 7-2) 
        
The HI was defined as follows [28]: 
      
HI =     𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝐝𝐨𝐬𝐞 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐛𝐲  𝟓% 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐓𝐕 ( 𝐃𝟓)   
𝐋𝐨𝐰𝐞𝐬𝐭 𝐝𝐨𝐬𝐞 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐛𝐲 𝟗𝟓% 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐓𝐕 (𝐃𝟗𝟓)        ( 7-3) 
 
The dose fall-off index explains the dose spillage around the PTV, and therefore a lower dose 
fall-off index indicates less dose spillage outside the PTV [214]. When the HI is close to 1, 
there is better dose homogeneity inside the PTV, and hence a high index represents 
higher dose heterogeneity of the PTV [28]. The maximum doses (Dmax) of OAR were 
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recorded for the heart, oesophagus and spinal cord. In addition, the percentage volume of the 
right, left and whole lung that received 5 Gy (V5) and 20 Gy (V20) were recorded for all 
studied cases. Right lung V5 and V20 were calculated for right lung tumours and Left 
lung V5 and V20 were calculated for left lung tumours. 
  
The clinical study utilised seven dose calculation algorithms from two planning systems. The 
XiO treatment planning system (v5.0, Elekta AB, Stockholm, Sweden) utilised Superposition 
[100] [94], Fast superposition [94], Fast Fourier Transform (FFT) Convolution [113] [94] and 
Clarkson [102] while in Eclipse treatment planning system (v13.6, Varian Medical Systems) 
AAA (v13.6.23)[103, 105, 122], PBC (v11.0.31) algorithms [102, 104] and Acuros XB 
(v13.6.23) [120],[118],[121] were included in this study. 
 
The statistical analyses were performed by Graph Pad PRISM 6 software, v. 6.03. A one-way 
ANOVA, with repeated measures utilising multiple comparisons was used to investigate 
the statistical significances (p <0.05) and mean differences among the seven algorithms in 
all parameters for two different methods: same dose coverage and same monitor unit study. 
   
7.4 Results 
This section is divided into two parts, which present the findings of the phantom study 
(Section 7.3.1) and clinical study (Section 7.3.2). 
208 
 
7.4.1 CIRS thorax phantom (phantom study) 
The calculated doses using the superposition and Acuros XB algorithms were close to those 
of the IC measurements for patient 1 and patient 2. In both patients, the discrepancies 
between the IC measurements and dose calculated by both algorithms (superposition and 
Acuros XB) were low for beams 1–9 (Figure 7-2). The highest discrepancies were obtained 
using the AAA and PBC algorithm. The mean differences in the AAA and PBC were 1.78 ± 
1.86 and 1.49 ± 1.68 for patient 1 and 2.6 ± 0.48 and 2.41 ± 0.43 for patient 2, respectively. 
The discrepancy between the measured dose by the IC and the dose calculated by the 
superposition and Acuros XB algorithms was less than 3% for any of the beams (Figure 7-2). 
In both patients, the statistical analyses revealed a significant variation among the four 
algorithms (Table 7-3). 
 
Table  7-3: Mean differences in percentage of the following algorithms: Superposition, 
Acuros XB, PBC and AAA for patient 1 and patient 2 by using CIRS thorax phantom. The 
data presented in this table was the result of three independent measurements (n=3). The 
mean values (mean values ± standard deviation) are significantly different among the four 
algorithms (P<0.05, One-way analyses of variance (ANOVA) with repeated measures). 
 
 
 Superposition 
Mean±Stdev 
Acuros XB 
Mean±Stdev 
PBC 
Mean±Stdev 
AAA 
Mean±Stdev 
P value 
< 0.05 
Patient 1 0.92±1.3 0.94±1.29 1.49±1.68 1.78±1.86 0.0235 
Patient 2 1.79±0.38 1.8±0.47 2.41±0.43 2.6±0.48 <0.0001 
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Figure  7-2: Discrepancies of four different algorithms Acuros XB, Superposition, PBC and 
AAA algorithms for patient 1 and 2 by using CIRS thorax phantom. The beam configurations 
from beam 1-9 are described in table 7-1 for both patients.     
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7.4.2 Twenty one lung cancer cases using 3D CRT technique 
(clinical study)  
The CI, HI and dose fall-off for the two methods are shown in Table 7-4. The table also 
presents the results of statistical analyses of the seven algorithms. With both methods, the P 
value of all the algorithms was < 0.05.  
At the same dose coverage and same monitor unit methods, the highest mean CI, HI and dose 
fall-off values were for the Clarkson algorithm (1.45 ± 0.14, 1.22 ± 0.08 and 6.04 ± 1.57), 
(2.2 ± 0.7, 2.2 ± 0.7 and 6.58 ± 1.19) and PBC algorithm (1.39 ± 0.13, 1.21 ± 0.06, 5.98 ± 
1.45), (1.9 ± 0.34, 1.31 ± 0.16, 6.23 ± 1.04), respectively. These results point to the poor 
performance of these algorithms with respect to treatment planning. In contrast, the results 
obtained using the AAA and FFT convolution algorithms were relatively better than those 
achieved using the Clarkson and PBC algorithms. The Clarkson and PBC algorithms revealed 
high mean values for V5 and V20 in the right, left and whole lungs for both methods (Table 
7-5). At the same dose coverage method, the mean values for V5 and V20 for whole lungs 
using the Clarkson algorithm were 16.51 ± 2.32 and 2.07 ± 0.72, respectively, whereas the 
mean values for V5 and V20 using the PBC algorithm were 16.02 ± 2.18 and 1.97 ± 0.71, 
respectively. At the same monitor unit method, the mean value for V5 and V20 for whole 
lungs using the Clarkson algorithm was 15.43 ± 2.86 and 4.14 ± 0.98, respectively, whereas it 
was 14.76 ± 2.06 and 3.39 ± 0.95, respectively, for the PBC algorithm. Table 7-6 shows the 
mean Dmax values for the heart, oesophagus and spinal cord for the seven algorithms.  
Figures 7-3 and 7-4 depict the dose distribution in coloured wash and isodose lines for the 
three algorithms and the two methods. Using the AAA and Acuros XB algorithm in the same 
dose coverage methods, the isodose lines of the 28 Gy covered the PTV (white colour 
contoured) perfectly as compared to the PBC algorithm, which uncovered a small part of the 
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left area of the PTV (Figure 7-3). The poor dose distribution inside the PTV for the PBC 
algorithm was illustrated in the same monitor unit method (Figure 7-4). The dose coverage of 
28 and 32 Gy were located outside the PTV contour, increasing the possibility of radiation 
into the healthy tissues. The dose coverage of the AAA and Acuros XB algorithm was almost 
the same for both methods, although the dose coverage of the Acuros XB algorithm was 
superior to that of the AAA at a focused dose (32 Gy) in the middle of the target tumour. An 
individual patient’s DVH of the OAR, including the right lung, left lung, whole lung, 
oesophagus, heart, internal skin (inner skin) and spinal cord of AAA, in addition to the PTV 
curves of the three algorithms (AAA, PBC and Acuros XB) for both methods are illustrated 
in Figure 7-5. Figure 7-6 shows the DVH of the PTV for the superposition, fast-
superposition, FFT convolution and Clarkson algorithms for the two methods at the same 
dose coverage and same monitor unit methods. 
Figures 7-7 and 7-8 depict the isodose lines obtained for the four algorithms using both 
methods. At the same dose coverage (Figure 7-7), the PTV (light blue coloured contour) in 
superposition and fast superposition was tightened by a prescription dose of 28 Gy as 
compared with the FFT convolution and Clarkson algorithms, which showed an expanded 
dose beyond the PTV border for the same dose. Moreover, with the superposition and fast 
superposition algorithms, the isodose at 31 Gy (red coloured) was contained in the target 
tumour, whereas the isodose showed a shift in location with the FFT convolution algorithm. 
With Clarkson algorithm, the isodose lines were larger than the PTV volume. In Figure 7-8, 
for the same monitor unit method, the isodose of 32 Gy (dark brown coloured) resulted in a 
large shift from the centre of the PTV with the FFT convolution algorithm, and misplacement 
occurred for the 32 Gy isodose with the Clarkson algorithm for the same method. 
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Figure  7-3: Dose coloured wash (top row) and isodose lines (bottom row) of 3D CRT technique for the dose distribution of three 
algorithms: AAA, Acuros XB and PBC for same dose coverage method. The white coloured contour represents the PTV 
Same Dose Coverage Method 
AAA Acuros XB PBC 
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Same Monitor Unit Method 
AAA Acuros XB PBC 
 
 
Figure  7-4: Dose coloured wash (top row) and isodose lines (bottom row) of 3D CRT technique images for the dose distribution of 
three algorithms: AAA, Acuros XB and PBC for same monitor unit method. The white coloured contour represents the PTV. 
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OAR curves of AAA and the PTV curves for the three alorithms:AAA, PBC and  
Acuros XB for Same Dose Coverage Method 
 
 
 
OAR curves of AAA and the PTV curves for the three alorithms:AAA, PBC and  
Acuros XB for Same Monitor Unit Method 
 
 
 
Figure  7-5: OAR curves of AAA and the PTV curves for the three algorithms:AAA, PBC and 
Acuros XB for both methods.   
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Table  7-4: Mean values for the conformity index, homogeneity index and dose fall-off for the 
seven different algorithms. The data presented in this table was the result of three independent 
measurements (n=3). The mean values (mean values ± standard deviation) are significantly 
different among the seven algorithms (P<0.05, One-way analyses of variance (ANOVA) with 
repeated measures). 
Mean values of the plan evaluation parameters for same dose coverage Method 
 Superposition 
Mean±Stdev 
Acuros 
XB 
Mean±Stdev 
Fast- 
superposition 
Mean±Stdev 
AAA 
Mean±Stdev 
FFT 
Convolution 
Mean±Stdev 
PBC 
Mean±Stdev 
Clarkson 
Mean±Stdev 
P 
value 
Conformity 
index 1.24±0.08 1.22±0.08 1.3±0.09 1.31±0.13 1.37±0.14 1.39±0.13 1.45±0.14 
P value 
< 
0.0001 
 
Homogeneity  
index 1.13±0.04 1.12±0.05 1.13±0.04 1.19±0.05 1.19±0.05 1.21±0.06 1.22±0.08 
P 
value< 
0.0001 
 
Dose fall-off 5.31±1.01 5.2±1.03 5.57±1.04 5.65±1.1 5.7±1.15 5.98±1.45 6.04±1.57 
P value 
< 
0.0077 
 
Mean values of the plan evaluation parameters for same monitor unit Method 
Conformity 
index 1.25±0.08 1.28±0.09 1.3±0.13 1.35±0.23 1.66±0.27 1.9±0.34 2.2±0.7 
P value 
< 
0.0001 
Homogeneity 
index 1.13±0.05 1.18±0.05 1.21±0.05 1.19±0.06 1.22±0.07 1.31±0.16 2.2±0.7 
P 
value< 
0.0001 
Dose fall-off 5.28±0.54 5.43±0.61 5.65±0.82 5.79±0.92 5.96±1.05 6.23±1.04 6.58±1.19 
P value 
< 
0.0009 
216 
 
 
 
Figure  7-6: The internal skin and the PTV curves for four algorithms calculation by using two 
different methods: same dose coverage and same monitor unit. The red arrows are pointed to 
Clarkson algorithm curves.  
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Figure  7-7: Isodose line images of the same dose coverage method for four different algorithms’ 
calculation: superposition, Fast superposition, FFT convolution and Clarkson. The light blue 
coloured contour represents the PTV. 
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Figure  7-8: Isodose line images of the same monitor unit method for four different algorithms’ 
calculation: superposition, Fast superposition, FFT convolution and Clarkson. The light blue 
coloured contour represents the PTV.  
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Table  7-5: Mean values for V5 and V20 for right, left and whole lung for the seven different 
algorithms. The data presented in this table was the result of three independent measurements 
(n=3). The mean values (mean values ± standard deviation) are significantly different among the 
seven algorithms (P<0.05, One-way analyses of variance (ANOVA) with repeated measures). 
 
Mean values of V5 and V20 of the lungs for same Dose Coverage Method 
 
Super-
poition 
Mean±Stdev 
Acuros 
XB 
Mean±Stdev 
Fast super-
position 
Mean±Stdev 
AAA 
Mean±Stdev 
 
FFT 
Convolution 
Mean±Stdev 
PBC 
Mean±Stdev 
Clarkson 
Mean±Stdev P value 
Whole 
lung V5 
(%) 
 
14.84±1.64 
 
14.73±1.71 
 
15.6±1.91 
 
15.68±2 
 
15.8±2.02 
 
16.02±2.18 
 
16.51±2.32 
P value < 
0.0039 
 
Whole 
lung V20 
(%) 
 
1.79±0.52 
 
1.72±0.52 
 
1.86±0.56 
 
1.86±0.6 
 
1.9±0.63 
 
1.97±0.71 
 
2.07±0.72 
P value < 
0.0114 
 
Right lung 
V5 (%) 
 
23.92±1.8 
 
23.98±1.63 
 
24.5±1.95 
 
24.97±2 
 
25.02±2.14 
 
25.91±2.93 
 
25.98±2.94 
P value < 
0.0201 
Right lung 
V20 (%) 
 
3.71±1.6 
 
3.7±1.51 
 
3.76±1.66 
 
3.88±1.75 
 
3.94±1.87 
 
4.55±2.49 
 
4.81±2.52 
P value < 
0.0459 
 
Left lung 
V5 (%) 
 
12.69±1.38 
 
12.01±1.39 
 
12.78±1.89 
 
13.71±1.96 
 
13.89±1.99 
 
13.94±2.08 
 
13.97±2.25 
P value < 
0.0026 
 
Left lung 
V20 (%) 
 
2.98±1.89 
 
2.85±1.92 
 
3.01±1.94 
 
3.32±2.13 
 
3.34±2.36 
 
3.65±2.38 
 
3.73±2.37 
P value < 
0.0158 
 
Mean values of   V5 and V20 of the lungs for same monitor unit Method 
Whole lung 
V5 (%) 
 
10.92±1.89 
 
10.58±1.83 
 
12.26±1.91 
 
12.61±1.92 
 
13.43±1.91 
 
14.76±2.06 
 
15.43±2.86 
P value < 
0.0001 
 
Whole lung 
V20 (%) 
 
 
1.5±0.36 
 
 
1.53±0.36 
 
 
1.65±0.35 
 
 
1.86±0.37 
 
 
1.89±0.45 
 
 
3.39±0.95 
 
 
4.14±0.98 
 
P value < 
0.0001 
 
Right lung 
V5 (%) 
 
23.32±1.83 
 
23.3±1.76 
 
23.89±1.98 
 
24.14±2.07 
 
25.05±2.23 
 
25.25±2.56 
 
25.43±2.72 
P value < 
0.0451 
 
Right lung 
V20 (%) 
 
3.4±1.59 
 
3.43±1.59 
 
3.65±1.63 
 
4.11±1.7 
 
4.47±1.73 
 
4.75±1.83 
 
5.15±1.93 
P value < 
0.0011 
 
Left lung 
V5 (%) 
 
12.2±1.4 
 
12.31±1.36 
 
12.34±1.44 
 
12.58±1.53 
 
12.77±1.68 
 
12.96±1.92 
 
13.27±2.19 
P value < 
0.0466 
 
Left lung 
V20 (%) 
 
2.49±1.06 
 
2.54±1.07 
 
2.78±1.06 
 
2.93±1.1 
 
3.32±1.18 
 
3.34±1.42 
 
4.04±1.47 
P value < 
0.0024 
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Table  7-6: Mean values for Dmax of the heart, oesophagus and spinal cord for the seven 
different algorithms. The data presented in this table was the result of three independent 
measurements (n=3). The mean values (mean values ± standard deviation) are significantly 
different among the seven algorithms (P<0.05, One-way analyses of variance (ANOVA) with 
repeated measures). 
 
 
 
Mean values of Dmax OAR for same dose coverage Method 
 Superposition Mean±Stdev 
Acuros 
XB 
Mean±Stdev 
Fast super-
position 
Mean±Stdev 
AAA 
Mean±Stdev 
FFT 
Convolution 
Mean±Stdev 
PBC 
Mean±Stdev 
Clarkson 
Mean±Stdev P value 
 
Heart 
(Dmax) 
(Gy) 
8.46±6.84 9.04±7.27 9.1±7.11 9.4±7.28 9.5±7.33 9.61±7.4 9.8±7.69 
P value< 
0.0023 
 
 
Oesophagus 
(Dmax) 
(Gy) 
5.79±3.75 6.2±3.88 6.25±3.89 6.34±3.24 6.62±3.46 7.03±3.51 7.16±3.49 
 
P value< 
0.0001 
 
 
Spinal  cord 
(Dmax) 
(Gy) 
5.05±3.43 5.3±3.6 5.35±3.33 5.64±3.62 5.76±3.9 5.96±3.48 5.98±3.47 
 
 
P value< 
0.0001 
 
Mean values of  Dmax  OAR for same monitor unit Method 
 
Heart 
(Dmax) 
(Gy) 
9.17±7.24 9.15±7.24 9.28±7.93 9.33±7.34 9.55±7.94 9.78±8.33 9.85±8.31 
P value< 
0.0034 
 
 
Oesophagus 
(Dmax) 
(Gy) 
6.34±3.92 6.23±3.85 6.51±3.98 7.03±3.51 7.1±3.48 7.17±3.35 7.41±3.56 
P value< 
0.0025 
 
 
Spinal  cord 
(Dmax) 
(Gy) 
5.94±3.46 5.9±3.95 5.96±3.48 5.97±3.97 6.02±3.69 6.04±3.97 6.14±3.58 P value< 0.0111 
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7.5 Discussion 
This study investigated the dose calculation performance of various algorithms in phantom and 
clinical studies. The CIRS thorax phantom was used to calculate the dose in two treatment plans 
of two lung cancer patients treated with SABR using the 3D CRT technique. Several studies 
have demonstrated the efficacy of the CIRS thorax phantom in calculating dose calculation 
algorithms using the IC [167, 168, 215]. However, most recent CIRS thorax phantom studies 
utilised algorithms other than superposition algorithms [167, 168, 215]. Thus, there are 
insufficient data on dose calculation using superposition algorithms and the CIRS thorax 
phantom. The present study examined the dose calculation performance of a superposition 
algorithm compared with that of the Acuros XB algorithm, AAA and PBC algorithm in lung 
material. The results revealed significant variation among the dose calculations of the four 
algorithms. The dose calculation of both the Acuros XB and superposition algorithms was very 
close to that of the IC measurement, with low discrepancies rates for both patients compared 
with that of the PBC algorithm and AAA. The AAA over-estimated the dose in both SABR 
patients (3.3% in patient 2), showing the highest discrepancy among the algorithms. These 
results are in agreement with those of a study by Dunn et al., 2015 [215] who suggested that the 
AAA consistently calculated a higher dose than that measured by the IC using the CIRS thorax 
phantom [215]. The difference in the AAA calculation as compared to the calculations of the 
other algorithms was approximately 3%, when the calculated points were downstream from lung 
inhomogeneities in tissue equivalent material [215].  
 
In the clinical study, the performance of seven algorithms was investigated using XiO and 
Eclipse. The results revealed significant variation among the dose calculation of the algorithms at 
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the same dose coverage and same monitor unit methods. The comparison of the three algorithms 
available in Eclipse (Acuros XB, AAA and PBC) showed that the performance of the Acuros XB 
algorithm was better than that of the AAA or PBC algorithm, with low mean values in plan 
evaluation parameters and OAR (Tables 7-4, 7-5 and 7-6). As shown by the dose coloured wash 
for the Acuros XB algorithm in Figures 7-3 and 7-4, it appeared to show high conformability, 
with low spillage outside the PTV as compared with that of the AAA and PBC algorithm. The 
Acuros XB algorithm is based on directly solving the linear Boltzmann transport equation 
(LBTE) [118, 123, 124]. It attempts to simulate all physical processes that beam particles 
contribute to; instead of producing beam particles one by one in a simulation process [118, 123, 
124]. Therefore, the calculation process is faster than that of the Monte Carlo simulation, making 
it less time consuming [118, 123, 124]. According to the results shown in Tables 7-4, 7-5 and 7-
6, for both methods, the AAA provided the second-best conformity, with low dose fall-off in 
Eclipse as compared with the performance of the PBC algorithm (Figures 7-3 and 7-4). The 
AAA is an improved pencil beam algorithm, which uses multiple pencil beam dose kernels to 
demonstrate the dose contribution from different radiation sources of a clinical beam [117].  
 
The clinical results in the present study are in accordance with those of a study conducted by 
Amankwaa-Frempong et al., 2014 [216]. They demonstrated that the PBC algorithm over-
estimated the dose calculation to lungs PTV by 10.5% higher than the AAA dose calculation 
[216]. Thus, the AAA provides an improvement in dose accuracy of the Eclipse system 
compared to that of single pencil beam models. The improvements offered by the AAA include 
modelling of the penumbra, low-dose regions and field profiles (symmetric and asymmetric) of 
both open and wedged fields [215]. However, in research conducted by the Australian Clinical 
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Dosimetry Service (ACDS), Dunn et al., 2015 [215] presented the findings of an ACDS level II 
audit of a rectilinear slab phantom and an ACDS level III audit of an anthropomorphic phantom 
[215]. Their results showed that when the AAA was implemented in regions distal from lung-
tissue interfaces, it resulted in systematic under-dosing, with an average discrepancy of 2.9 ± 
1.2% [215]. Based on an ACDS level III audit, they concluded that the Acuros XB algorithm 
provided more accurate results than the AAA [215]. The results obtained from the CIRS thorax 
phantom used in the present study are in agreement with those of Dunn et al., 2015 [215]. Our 
findings pointed to relatively high discrepancies in mean differences in percentage between the 
AAA and other algorithms (PBC, Acuros XB and superposition).  
 
The superposition and fast superposition algorithms provided better CI, HI and dose fall-off 
compared with the FFT convolution and Clarkson algorithms (Tables 7-4, 7-5 and 7-6). 
Although, the dose calculation of the Clarkson algorithm is accurate in homogeneous media, 
(e.g. water), its performance is considered the worst among all the algorithms in heterogeneous 
media [102]. The accuracy of the Clarkson algorithms is poor in heterogeneous media (e.g. lung 
tissue), even when an equivalent beam path length is applied, as this can correct for only part of 
the heterogeneous effect [102]. The inaccuracy is due to the inability of the algorithms to take 
account of lateral scattering when a beam transports in media [102]. As they are measurement-
based algorithms, they are the most inaccurate and least reliable of all the algorithms, especially 
when applied to lung cases [102]. In the present study, the performance of the FFT convolution 
algorithm was better than that of the Clarkson algorithm.  
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A dosimetric study by Muralidhar et al., 2009 [94] of the application of convolution, 
superposition and fast superposition algorithms to four lung cancer cases demonstrated that the 
performance of the fast superposition algorithm was better than that of the other two algorithms 
[94]. The mean relative difference was 0.91% for the convolution and superposition algorithms 
and 0.55% for the fast superposition algorithm. When they compared the mean relative 
differences with the prescribed dose in the three algorithms, the fast superposition algorithm 
indicated the best correspondence inside the target structures. In contrast, our clinical results for 
21 lung cancer cases treated with SABR showed that the treatment plan (CI, HI and dose fall-off) 
evaluation obtained using the superposition algorithm was better than that of the fast 
superposition and convolution algorithms. Kry et al., 2013 [217] attempted to determine the 
accuracy of dose calculation algorithms in a heterogeneous medium [217]. They used the 
radiological physics centre (RPC) thorax phantom to compare PBC, AAA, 
convolution/superposition and Monte Carlo algorithms. They found that the PBC, AAA and 
convolution/superposition algorithms over-estimated the delivered dose to the centre of the target 
by 4.9%, 3.7% and 3.7%, respectively [217]. In the present study, the PBC algorithm over-
estimated the delivered dose to the PTV in lung SABR cases, resulting in high doses to the OAR, 
as compared to the other algorithms.  
 
The main focus of the present study was to investigate the performance of different algorithms 
(seven algorithms) in heterogeneous media using 21 cases of lung SABR. The results obtained 
using the Acuros XB and superposition algorithms in the CIRS thorax phantom study agreed 
with the findings of the clinical study, and the dose calculation of both algorithms was accurate. 
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7.6 Conclusion 
This study demonstrated that there were significant variations among the calculations of seven 
different algorithms in lung SABR. The dose-calculation performance of the superposition and 
Acuros XB algorithms in a heterogeneous medium was good in both the CIRS thorax phantom 
and clinical studies. In the phantom study, the AAA overestimated the dose by 3%, showing the 
maximum dose discrepancy as compared with that of the other algorithms. In the clinical study, 
the mean values for CI, HI, dose fall-off and Dmax of the OAR obtained using the Clarkson and 
PBC algorithms were relatively high as compared with those obtained using the superposition 
and Acuros XB algorithms. Based on this study, superposition and Acuros XB algorithms are 
recommended as the first choice in lung SABR involving small fields. 
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Chapter 8 Investigation of AAA and Acuros XB 
Algorithms for Three Different Stereotactic Ablative 
Radiotherapy techniques (SABR): Volumetric 
Modulated Arc Therapy (VMAT), Intensity 
Modulated Radiation Therapy (IMRT) and 3D 
Conformal Radiotherapy (3D CRT)  
 
8.1 Summary 
The previous chapter clearly demonstrated the variation in the dose calculation algorithms using 
phantom and clinical lung SABR using 3D CRT technique. This chapter further investigates the 
dosimetric characteristics of three stereotactic ablative radiotherapy (SABR) techniques using 
two common dose calculation algorithms: an anisotropic analytical algorithm (AAA) and Acuros 
XB algorithm. The three SABR techniques include coplanar volumetric modulated arc therapy 
(C-VMAT), non-coplanar intensity modulated radiation therapy (NC-IMRT) and non-coplanar 
three-dimensional conformal radiotherapy (NC-3D CRT). Stereotactic Ablative Radiotherapy 
(SABR) is a special type of radiotherapy where a high dose of radiation is delivered over a short 
time. The treatment outcome and accuracy of dose delivered to cancer patients highly depend on 
the dose calculation algorithm and treatment technique. Twelve lung cancer patients underwent 
4D-CT scanning and three different treatment plans were generated:  C-VMAT, NC-IMRT and 
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NC-3D CRT. Dose calculation was performed using the AAA and Acuros XB algorithm in the 
Eclipse treatment planning system. The following dosimetric indices were used to compare the 
treatment plans: conformity index (CI), homogeneity index (HI), dose fall-off index and doses 
received by organs at risk (OAR) and planning target volume (PTV). The CIs for C-VMAT, NC-
IMRT and NC-3D CRT were 1.21, 1.28 and 1.38 for the AAA respectively, and 1.17, 1.26 and 
1.36 for the Acuros XB algorithm, respectively. Using the Acuros XB calculation, the HIs were 
1.05±0.04, 1.09±0.03 and 1.1±0.04 for C-VMAT, NC-IMRT and NC-3D CRT, respectively. 
This study showed that the treatment planning results obtained using the Acuros XB algorithm 
was better than those achieved using the AAA for all the studied treatment techniques in a 
heterogeneous medium, such as lung. 
 
8.2 Introduction  
Stereotactic  ablative  body  radiotherapy  (SABR)  is  a  specialised  form  of     radiotherapy 
treatment, which delivers a high radiation dose using a small number of fractions, generally 
equal to or fewer than five fractions [78, 218].  SABR is becoming more popular for the 
treatment of patients with lung cancer [52, 53].  In  recent  years,  the  incidence  rates  of  lung  
cancers have increased  worldwide [133]. For  early-stage  inoperable  non-small  cell  lung  
cancer [219, 220],  SABR generally involves the use of different treatments, which are 
delivered via various methods,  such  as  three-dimensional  conformal  radiotherapy  (3D 
CRT)[221],  intensity  modulated radiation therapy (IMRT)[222]  and volumetric modulated arc 
therapy (VMAT) [223].  VMAT is an arc-based IMRT technique, which has the ability to 
modulate the beam intensity as it rotates around the patient [28].  In VMAT, fewer monitor 
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units (MU) are generated, and it offers faster  delivery  times  and  superior  dose  distributions  
as  compared  to  conventional  3D CRT/IMRT treatment plans [224]. 
 
SABR  is  typically  applied  to  small  tumours  and  hence  employs  small  radiation  fields. 
However,  air  cavities  present in  such small  fields can  cause  electronic  disequilibrium  at 
tissue-air interfaces [123, 212, 213]. Consequently, when treating heterogeneous media, dose 
calculation algorithms have to be able to account for tissue heterogeneities and provide an 
accurate computation of electron transport close to the tissue-air interface. One of the most 
common algorithms used in the EclipseTM   treatment planning system (Varian Medical Systems, 
Palo Alto, CA) is the anisotropic analytical algorithm (AAA). 
 
The AAA, a convolution/superposition-based algorithm is an improved pencil beam algorithm, 
which uses multiple pencil beam dose kernels to determine the dose contribution from different 
radiation sources of a clinical beam [116, 117]. The limitations and the performance of the 
AAA have been well documented elsewhere [117, 122, 215].  The AAA offers significant 
improvements in dose accuracy compared to single pencil beam models.  These include 
modelling of penumbra, low-dose regions and field profiles (symmetric and asymmetric) in 
both open and wedged fields [117].  However, the AAA also has weaknesses, as demonstrated 
by the findings of Dunn et al., 2015 [215] who showed that when the AAA was implemented 
in regions distal from lung tissue interfaces, resulted in systematic under-dosing, with an 
average discrepancy of 2.9 ± 1.2% [215]. 
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Recently, Varian introduced the Acuros XB dose calculation algorithm for external beam 
treatment planning. This algorithm utilises the linear Boltzmann transport equation (LBTE) to 
solve and describe the macroscopic behaviour of radiation particles, such as electrons and 
neutrons, numerically as they travel and interact with matter [120].  For matter with a 
known volume in a given domain, the LBTE can be used to accurately describe the dose inside 
this domain [118, 120]. 
 
Several studies have shown that the Acuros XB algorithm is comparable to the Monte Carlo 
method and that both these methods are convergent and provide solutions closer to the 
measurements [118, 120, 225]. These  studies  also  showed  that  the  Acuros  XB  algorithm  
was  more applicable to inhomogeneous media (i.e. it performed better) than was the AAA. 
Moreover, Acuros XB was reported to provide a faster calculation time compared to the 
Monte Carlo method and a relatively shorter computation time compared to the AAA for 
treatment plans involving a large number of fields [226]. 
 
According to our review of the literature, there have been no dosimetric assessments of 
different SABR techniques using AAA and Acuros XB dose calculation algorithms.  Hence, the 
aims of this study were to: 1) investigate the dosimetric variation among three different SABR  
techniques:  coplanar  volumetric  modulated  arc  therapy  (C-VMAT), non-coplanar intensity 
modulated radiation therapy (NC-IMRT) and non-coplanar three-dimensional conformal  
radiotherapy (NC-3D CRT)  and  2) to  compare the results computed  using the Acuros XB and 
AAA dose calculation algorithms for the three SABR plans. 
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8.3 Methods and Materials 
Twelve lung cancer patients treated by SABR were selected for this study. Of these patients, 
seven had lesions in the right lung, and five had lesions in the left lung (Table 8-1). The ethics 
approval for this study was approved by Peter MacCullum Cancer Centre and the registration 
certificate was issued from college human ethics by RMIT university (See appendices I, II, III 
and IV). The prescription dose was 26 Gy in one fraction, and the plans were normalised to 
deliver the prescription dose to 99% of the PTV.  The patients were positioned  in  a  Bodyfix®  
blue  bag,  with  their  arms  above  their  heads.  All the patients underwent 4D-CT scanning on 
a Philips BrillianceTM CT scanner (Koninklijke Philips Electronics, Amsterdam, The 
Netherlands) utilising the Philips Bellows system to acquire a breathing trace during the scan 
acquisition. The pulmonary wave trace was edited to ensure the tags were located at the peak 
of each wave before reconstructing the scan.  Maximum  intensity  projection  (MIP)  images  
and average intensity projection (AIP) images were generated from multiple respiratory 
phases  acquired  during  4D  imaging  for  contouring  and  dose  calculation,  respectively.  The 
CT DICOM datasets were transferred to the Eclipse treatment planning system (v13.6, Varian 
Medical Systems) for contouring and treatment planning. In Eclipse, both the AIP and MIP 
images were used for treatment planning.  The internal target volume (ITV) was delineated on 
the MIP images. A planning target volume (PTV) was generated from the ITV by applying a 5 
mm margin to account for patient setup error. OAR, such as lungs, heart, oesophagus, spinal cord 
and liver, were delineated on the AIP images. The AIP images were also used for dose 
calculation. As part of the contouring process, internal skin or rind skin of OAR was defined as a 
5-mm rim of tissues inside the body contour. 
231 
 
Table  8-1: PTV volume and tumour location for 12 patients computed using AAA and Acuros 
XB algorithms for C-VMAT, NC-IMRT and NC-3D CRT techniques. 
 
 The Tumour Location       PTV (𝐜𝐦
𝟑) 
 
1 Right lower lung 
 
34.05 
2             Left Upper lung 8.69 
3             Left lower lung 19.09 
4             Right Middle lung 5.15 
5             Left lower lung 11.33 
6             Right upper lung 35.09 
7             Right middle lung 13.44 
8             Right middle lung 33.53 
9              Left middle lung 47.39 
10              Right middle lung 29.54 
11              Left upper lung 17.61 
12              Right upper lung 27.74 
 
For each SABR patient, three different types of plans were created: 1) C-VMAT, 2) NC- 
IMRT and 3) NC-3D CRT. In the NC-3D CRT plans, a minimum of nine beams were used, 
and care was taken to ensure the field size was no less than 3 cm × 3 cm, as defined by the  X 
and Y jaws. Of these nine beams, two were non-coplanar, with a couch angle of 90° and 270° to 
reduce the dose to the chest wall; six were placed ipsilateral, and one (ninth beam) entered from 
the contralateral side to compensate for the dose gradient. The beam orientations were optimized 
according to the location of the PTV. As a starting point, the multileaf collimator (MLC) were 
conformed to zero margins on the PTV using the outbound method of leaf positioning, and 
the MLC leaf positions were individually adjusted to provide adequate target coverage.  
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Two plans were generated using the AAA (v13.6.23) and Acuros XB (v13.6.23) algorithms. NC-
IMRT plans were generated by maintaining the same beam angle arrangements defined for 3D 
CRT for both the AAA and Acuros XB algorithm. Similarly, C-VMAT plans were generated 
for both the AAA and Acuros XB algorithm using the same dose constraints employed for 
NC-IMRT. The C-VMAT plans were composed of two arcs. The first arc was defined with 
the gantry start angle at 181° and the stop angle at 0° clockwise for right-sided lesions. For 
left-sided lesions, the start angle was 0°, and the stop angle was 179°. The second arc was 
defined with the gantry start angle at 0° and the stop angle at 181° counter clockwise for 
right sided lesions. For left-sided lesions, the start angle was 179°, and the stop angle was 
0°. The collimator angles were 30° and 330° for arc 1 and arc 2, respectively. The maximum 
gantry speed was 4.8°/sec, and the maximum dose rate was 600 MU/min. All the plans were 
planned using 6 MV X-rays.  A cumulative dose volume histogram was used to quantify the 
dosimetric variations among the three SABR systems. 
 
The tumour dosimetry was evaluated using the conformity index (CI), dose fall-off index and 
homogeneity index (HI).  The CI indirectly indicates the prescription dose spillage outside the 
target volume, and ideally it should be close to 1 [20]. The dose conformity to the target 
volume was assessed using the CI as described below [27]: 
 
CI =  𝐓𝐡𝐞 𝐯𝐨𝐥𝐮𝐦𝐞 𝐩𝐞𝐫𝐜𝐞𝐧𝐭𝐚𝐠𝐞 𝐨𝐟 𝐛𝐨𝐝𝐲 𝐫𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐝𝐨𝐬𝐞  
𝐓𝐡𝐞 𝐯𝐨𝐥𝐮𝐦𝐞 𝐩𝐞𝐫𝐜𝐞𝐧𝐭𝐚𝐠𝐞 𝐨𝐟 𝐏𝐓𝐕 𝐫𝐞𝐜𝐞𝐢𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐝𝐨𝐬𝐞       ( 8-1) 
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The dose fall-off index and HI, as recommended by the American Association of Physicists in 
Medicine (AAPM) Task Group 101 protocol [14], were used to assess the dose gradient 
around the tumour and dose inhomogeneity inside the tumour volume. 
 
 
The dose fall-off index was defined as follows [14]: 
 
Dose fall-off =  𝐓𝐡𝐞 𝐕𝐨𝐥𝐮𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝟓𝟎% 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐢𝐬𝐨𝐝𝐨𝐬𝐞 
𝐏𝐓𝐕 𝐕𝐨𝐥𝐮𝐦𝐞         ( 8-2) 
        
The HI was defined as follows [28]: 
      
HI =     𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝐝𝐨𝐬𝐞 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐛𝐲  𝟓% 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐓𝐕 ( 𝐃𝟓)   
𝐋𝐨𝐰𝐞𝐬𝐭 𝐝𝐨𝐬𝐞 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐛𝐲 𝟗𝟓% 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐓𝐕 (𝐃𝟗𝟓)        ( 8-3) 
 
The dose fall-off index explains the dose spillage around the PTV, and therefore a lower dose 
fall-off index indicates less dose spillage outside the PTV [214]. When the HI is close to 1, there 
is better dose homogeneity inside the PTV, and hence a high index represents higher dose 
heterogeneity of the PTV [28]. The maximum dose (Dmax) and the dose received by 2 cm3 of 
OAR were recorded for the heart, oesophagus and spinal cord. In addition, the percentage 
volume of the right, left and whole lung that received 5 Gy (V5) and 20 Gy (V20) were recorded 
for all studied cases. Right lung V5 and V20 were calculated for right lung tumours and Left 
lung V5 and V20 were calculated for left lung tumours. 
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The statistical analyses were performed by Graph Pad PRISM 6 software, v. 6.03. A one-way 
ANOVA, with repeated measures utilising multiple comparison was used to investigate the 
statistical significances (p <0.05) and mean differences between the three treatment techniques 
(C-VMAT, NC-IMRT and NC-3D CRT). 
 
8.4 Results  
The dose distribution of the three treatment systems (C-VMAT, NC-IMRT and NC-3D CRT) for 
a typical case is illustrated in (Figure 8-1). The two upper rows demonstrate the beam 
orientations of each technique, calculated by the Acuros XB algorithm and AAA, and the 
lower two rows illustrate the isodose lines for the PTV of the three systems obtained using the 
AAA and Acuros XB. Figures 8-2 and 8-3 depict the dose volume histograms of the right and 
left lungs, heart, oesophagus, spinal canal and PTV obtained using the three different treatment 
methods (NC-3D CRT, NC-IMRT and C-VMAT) and the AAA and Acuros XB algorithm, 
respectively. 
 
The CIs for C-VMAT, NC-IMRT and NC-3D CRT were 1.21, 1.28 and 1.38 for the AAA, 
respectively and 1.17, 1.26 and 1.36 for the Acuros XB algorithm, respectively (Table 8-2). An 
optimum treatment plan should have a low index, ideally close to one. The one-way ANOVA 
revealed a significant difference in the CI between C-VMAT and NC-3D CRT plans using the 
AAA, whereas the Acuros XB algorithm showed statistically significant differences between all 
the three plans. There were also statistically significant differences in all three plans 
235 
 
according to the HI, using both the AAA and Acuros XB algorithm. The dose spillage outside 
the target volume was determined by the calculation of the dose fall-off index (Equation 8-2). 
The mean dose fall-off index for C-VMAT, NC-IMRT, NC-3D CRT using the AAA was 
5.25±0.4, 5.36±0.51, and 6.06±0.44 respectively, and the Acuros XB was 5.15±0.39, 5.18±0.34 
and 5.66±0.63 respectively. Table 8-2 illustrates the dose received by 2% of the target volume 
(D2), 5% of the target volume (D5), 95% of the target volume (D95), 98% of the target volume 
(D98) and the target mean dose for all three plans planned with the AAA and Acuros XB 
algorithm. For the AAA, the statistical analysis using Graph Pad PRISM 6 software showed 
no significant differences in D95 and D98 among the three treatment techniques. The CI for C-
VMAT was significantly lower than the CI for the NC-3D CRT.  The Acuros XB algorithm 
revealed significant variation between treatment techniques for a majority of the above 
parameters, except for D95 and D98 PTV. These findings showed that C-VMAT resulted in a 
better CI and lower dose spillage, with more homogeneity inside the PTV as compared to the 
NC-IMRT and NC-3D CRT systems using both the AAA and Acuros XB algorithm. On the 
other hand, the NC-3D CRT treatment technique resulted in a higher CI, HI and dose fall-off, 
representative of poor dosimetry as compared to the other two treatment plans using both the 
AAA and Acuros XB algorithm.  
 
Table 8-3 shows the V5 and V20 for the right, left and normal lungs calculated by the AAA and 
Acuros XB algorithm for the C-VMAT, NC-IMRT and NC-3D CRT plans. It clearly shows 
that statistically significant (p<0.05) amount of right lung volume receives the 5 Gy (V5) and 20 
Gy (V20) doses with C-VMAT compared to the NC-IMRT and NC-3D CRT methods, using 
both the AAA and Acuros XB algorithm. The V5 and V20 for the left and normal lungs with C-
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VMAT plan are relatively higher than the NC-IMRT and NC-3D CRT. The liver, ribs and chest 
wall volumes that received the 20 Gy and 30 Gy doses were almost zero in all cases. Table 8-4 
shows the maximum dose delivered  to  the  heart,  oesophagus  and  spinal  cord  with  the  C-
VMAT,  NC-IMRT, NC-3D CRT  methods  using  both  the  AAA  and  Acuros  XB  algorithm. 
These results clearly indicated that the C-VMAT treatment method planned using both the 
AAA and Acuros XB algorithm delivered a statistically significant dose to the oesophagus 
and spinal canal as compared to the NC-IMRT and NC-3D CRT treatment plans. Table 8 -5  
illustrates the mean dose delivered to internal skin via the C-VMAT, NC-IMRT and NC-3D 
CRT systems. The mean dose delivered to the internal skin was relatively lower using the NC-
IMRT and NC-3D CRT  methods  as  compared  to  the  C-VMAT  technique  by  (52.83%)  and  
(39.65%)  for  AAA algorithm, and by 49% and 41.37% for the Acuros XB algorithm 
respectively. 
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Figure  8-1: The dose distribution for the three treatment techniques C-VMAT, NC-IMRT and 
NC- 3D CRT on the transversal plane. The isodose distributions indicate better dose conformity 
to the PTV (zoom in of white coloured contour) for the C-VMAT and NC-IMRT compared with 
the NC-3D CRT; the prescription dose of 26 Gy (zoom in of yellow coloured isodose line) is 
more conformal around the PTV with the C-VMAT technique for both algorithms. 
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Figure  8-2: OARs curves of NC-3D CRT and PTV curves of the three different techniques 
calculated by AAA algorithms. 
 
 
Figure  8-3: OARs curves of NC-3D CRT and PTV curves of the three different techniques 
calculated by Acuros XB algorithms.  
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Table  8-2: Dmean, D2, D5, D95, D98 and plan evaluation parameters for the three different 
techniques C-VMAT, NC-IMRT and NC-3D CRT calculated by AAA and Acuros XB 
algorithms. The data presented in this table was the result of three independent measurements 
(n=3). * and + indicates statistical significance of C-VMAT based on one-way ANOVA multiple 
comparison with repeated measures (p-value < 0.05) compared to the corresponding NC-IMRT 
and NC-3D CRT plans respectively. 
AAA algorithms calculation 
 
C-VMAT 
Mean±Stdev 
 
NC-IMRT 
Mean±Stdev 
 
NC-3D CRT 
Mean±Stdev 
 
     Conforming Index 1.21±0.08+ 1.28±0.12 1.38±0.22 
 Homogeneity Index 
 
1.07±0.05*+ 1.15±0.05 1.17±0.04 
 
Dose fall-off 5.25±0.4*+ 5.36±0.51 6.06±0.44 
 
D2 PTV (Gy) 28.99±2.07*+ 32.43±1.43 32.09±1.26 
 
D5 PTV (Gy) 28.6±1.97*+ 32.26±1.39 31.93±1.26 
 
D95 PTV (Gy) 27.06±0.88 27.23±0.28 27.31±0.57 
 
D98 PTV (Gy) 26.48±0.15 26.56±0.18 26.68±0.21 
 
D mean (Gy) 27.91±1.16* 29.88±1.27   27.18±8.32 
Acuros XB algorithms calculation 
     Conforming Index 1.17±0.07*+ 1.26±0.13 1.36±0.15  
Homogeneity Index 1.05±0.04*+ 1.09±0.03 1.1±0.04  
Dose fall-off 5.15±0.39*+ 5.18±0.34 5.66±0.63 
 
D2 PTV (Gy) 30.01±1.84*+ 33.49±1.85 32.36±1.37 
 
D5 PTV (Gy) 29.82±1.75*+ 33.29±1.81 32.12±1.34 
 
D95 PTV (Gy) 27.06±0.64 27.64±0.42 27.39±0.29 
 
D98 PTV (Gy) 26.56±0.6 26.81±0.27 26.85±0.21 
 
Dmean (Gy) 28.65±1.13*+ 30.98±1.18 29.9±0.77 
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Table  8-3: The mean volumes percentage of the right, left and whole lungs that received 5 and 
20 Gy for the three techniques computed by the AAA and Acuros XB algorithms. The data 
presented in this table was the result of three independent measurements (n=3). * and + indicates 
statistical significance of C-VMAT based on one-way ANOVA multiple comparison with 
repeated measures (p-value < 0.05) compared to the corresponding NC-IMRT and NC-3D CRT 
plans respectively.  
 
AAA algorithms calculation 
 C-VMAT 
Mean±Stdev 
 
NC-IMRT 
Mean±Stdev 
NC-3D CRT 
Mean±Stdev 
 Right Lung V5 (%) 13.44±1.06+ 12.3±1.04 11.87±1.52 
 
Right Lung V20 (%) 5.17±0.61*+ 3.11±1.68 3.06±1.44 
 Left Lung V5 (%) 11.48±1.17 11.4±1.79 11.14±1.22 
 
Left Lung V20 (%) 2.68±1.47* 2.52±1.41 2.44±1.11 
 
Normal lung V5 (%) 5.95±1.68 5.69±1.33 5.55±1.87 
 
Normal lung V20 (%) 1.86±0.99 1.48±0.74         1.44±0.86 
Acuros XB algorithms calculation 
Right Lung V5 (%) 13.41±1.11+ 12.2±1.04 11.78±1.49 
 Right Lung V20 (%) 5.04±0.61*+ 3.06±1.66 3.01±1.43 
 
Left Lung V5 (%) 11.36±1.16 11.23±1.8 11.06±1.21 
 
Left Lung V20 (%) 2.58±1.47 2.49±1.42 2.44±0.99 
 Normal lung V5 (%) 5.91±1.69 5.61±1.36 5.48±1.9 
 
Normal lung V20 (%) 1.78±0.97 1.44±0.74        1.4±0.86 
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Table  8-4: Mean doses to Heart, Oesophagus and Spinal Canal with C-VMAT, NC-IMRT and 
NC-3D CRT. The data presented in this table was the result of three independent measurements 
(n=3). * and + indicates statistical significance of C-VMAT based on one-way ANOVA multiple 
comparison with repeated measures (p-value < 0.05) compared to the corresponding NC-IMRT 
and NC-3D CRT plans respectively.  
AAA algorithms calculation 
 C-VMAT 
  Mean±Stdev 
NC-IMRT 
  Mean±Stdev 
NC-3D CRT 
      Mean±Stdev 
     Heart (max dose) (Gy)   6.71±5.46        5.94±4.5 5.67±4.37 
     Heart (cm3) (Gy)   6.79±6.45 5.75±4.93 5.18±4.17 
     Oesophagus (max dose) 
 
5.08±5.63*+ 4.23±5.92 3.44±4.63 
     Oesophagus (2 cm3) (Gy) 3.85±4.52*+ 2.63±3.68 2.49±3.02 
     Spinal canal (max dose) 
 
7.02±3.02*+ 4.33±2.57 4.31±2.53 
 Spinal canal (2 cm3) (Gy)   5.48±2.52*+           3±1.9        2.99±1.92 
Acuros XB algorithms calculation 
      Heart (max dose) (Gy)  6.69±5.39        5.78±4.47 5.37±4.26 
       Heart (2 cm3) (Gy)  5.83±5.31        5.68±4.91 5.07±4.12 
 Oesophagus (max dose) 
 
4.84±5.18*+        3.7±4.45 3.41±4.6 
       Oesophagus (2 cm3) (Gy) 3.56±3.88*+        2.61±3.66 2.45±3.01 
 Spinal canal (max dose) 
 
6.96±3.03*+        4.3±2.58 4.22±2.48 
       Spinal canal (2 cm3) (Gy)  5.34±2.46*+         3±1.93          2.9±1.86 
Table  8-5: Mean doses to internal skin for three different techniques: C-VMAT, NC-IMRT 
and NC-3D CRT. The data presented in this table was the result of three independent 
measurements (n=3). * and + indicates statistical significance of C-VMAT based on one-way 
ANOVA multiple comparison with repeated measures (p-value < 0.05) compared to the 
corresponding NC-IMRT and NC-3D CRT plans respectively.   
AAA algorithms calculation 
 C-VMAT 
   Mean±Stdev 
NC-IMRT 
   Mean±Stdev 
NC-3D CRT 
     Mean±Stdev 
Internal skin (Gy) 0.81±0.49* 0.53±0.17 0.58±0.21 
Acuros XB algorithms calculation 
Internal skin (Gy) 0.82±0.5* 0.55±0.19 0.58±0.21 
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8.5 Discussion 
This study compared three different SABR treatment techniques for lung cancer: C-VMAT, NC-
IMRT and NC-3D CRT, utilising two algorithms, AAA and Acuros XB, integrated into the 
Eclipse treatment planning system. Figure 8-1 shows the comparison of the isodose lines for the 
three SABR treatment techniques. It indicates, relatively better dose conformity to the PTV 
using the C-VMAT and NC-IMRT plans compared with the NC-3D CRT plan. The 
prescription dose of 26 Gy (yellow coloured contour) was more conformal around the PTV in 
the C-VMAT technique using both algorithms. The one-way ANOVA revealed statistically 
significant differences between the AAA and Acuros XB algorithm for the HI, dose fall-off 
index, D2 and D5. Better homogeneity, lower D2 and D5 and less dose fall-off were observed 
using the C-VMAT method. The results also revealed that the CI obtained using the Acuros 
XB algorithm was better than that achieved using the AAA with all three SABR techniques. This 
finding may be explained by Acuros XB being a better dose calculation model for very low-
density models the dose at the lung-tissue interface [42]. Our planning study results also 
indicated that C-VMAT resulted in the best dose conformity around the PTV and tightest dose 
distribution, with low spillage, followed by NC-IMRT. The highest D2 PTV (near maximum 
dose)   value recorded  for  NC-IMRT  (AAA)  and  NC-IMRT  (Acuros  XB)  was  32  Gy  and  
33Gy, respectively. The D98 value (near minimum dose) was almost the same for all the 
treatment techniques (~26 Gy). With all three treatment methods, the dose received by 95% of 
the PTV was almost similar (27 Gy), and the dose received by 5% of the PTV was between 28 
Gy and 33 Gy. 
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With C-VMAT, the percentage volume that received 5 Gy (V5) and 20 Gy (V20) doses to the 
right, left and whole lungs was high as compared to the other treatment techniques using both 
dose calculation algorithms. The aforementioned is a drawback of C-VMAT, but this is offset by 
a reduced treatment time, better dose conformity and reduced intra-fraction motion. The 
dosimetric values V20 and V30 for liver, ribs and chest wall were close to zero in all cases. 
Hence, these parameters were not considered in the data analysis in this study. There was no 
significant difference in the max dose or dose delivered to the heart (2 cm3) with the three 
SABR techniques and two algorithms. With respect to the dose received by the OAR, the C-
VMAT and NC-IMRT delivered the maximum dose to the surrounding healthy tissues.   Holt et 
al., 2011 [227] compared coplanar VMAT and NC-IMRT and reported a small increase in the 
mean dose (V20) delivered to a healthy lung using C-VMAT [227]. Moreover, they 
demonstrated that the maximal dose was delivered to the spinal cord using C-VMAT rather 
than NC-IMRT in all cases, although the dose was below the acceptable limit of 18 Gy of 
physical dose [227]. The results from the present study are in agreement with those of Holt et al., 
2011 [227] for healthy lung tissue (V20). The results of the current study also revealed an 
increase in the dose delivered to the spinal cord (within tolerance limits) using the C-VMAT 
technique as compared to the NC-IMRT and NC-3D CRT methods. 
 
Table 8-5 illustrates the dosimetric impact of the C-VMAT technique on the internal body. As 
shown in the table, the mean doses received by the internal volume of the body minus 5 mm 
were  low  using  the  non-coplanar  techniques  compared  to  the  coplanar  VMAT method. 
However, in all cases, it was well below the clinically acceptable limit of 24 Gy of physical 
dose. The maximal dose to the oesophagus was also tolerable, with a clinically acceptable 
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limit of 18 Gy of physical dose [227]. As evidenced by the tumour dosimetry; the C-
VMAT technique resulted in better CIs, HIs and dose fall-off indices. However, this technique 
was also associated with relatively high doses to the surrounding normal tissues. According to 
Cai et al., 2014 [74] if the delivery of a low dose to a large amount of healthy tissue is not 
of clinical concern, C-VMAT can aid short-term delivery, making this technique more 
convenient and having less of a biological effect in the presence of decreased intra-fraction 
motion due to prolonged fraction delivery [74]. 
 
Both the treatment planning system and algorithms used in dose calculations can influence 
dosimetric results. In the present study, the Acuros XB algorithm was better than the AAA as 
regards the investigation of the three treatment techniques. As shown by the results of the 
indices used to compare the treatment plans (CI, HI and dose fall-off), the Acuros XB 
demonstrated lower values for all these three parameters. Liu et al., 2014 [228] investigated 
dosimetric parameters  using  the  AAA  and  Acuros  XB  algorithm  in  77  treatment  plans  of   
SABR patients [228]. They  used  two prescription  doses:  48  Gy  in  four  fractions  and  60  
Gy  in 10 fractions. They reported lower CIs using the Acuros XB algorithm than using the 
AAA. A study by Rana et al., 2013 [123] recorded similar results when using the Acuros XB 
algorithm in lung cancer cases treated with SABR [123]. The results of the present study are 
in agreement with those of both previous studies in terms of the CI and the performance of 
the Acuros XB algorithm. 
 
The Acuros XB algorithm provides comparable accuracy to Monte Carlo simulation, as it 
attempts  to  simulate  all  the  physical  processes  affected  by  beam  particles.  The dose 
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calculation  process  of  the  Acuros  XB  is  faster  than  that  of  Monte  Carlo    simulations. 
Therefore,   it   is   less   time   consuming,   although   the   two   methods   have comparable 
accuracy [118, 123, 124]. 
 
8.6 Conclusion  
The C-VMAT technique provided better CIs and HIs as compared to the NC-IMRT and NC-3D 
CRT treatment techniques. In the present study, both the integral dose and dose delivered to the 
normal lung were high using the C-VMAT method as compared to the NC-IMRT and NC-3D 
CRT techniques. This study proves that the results obtained for the three treatment techniques 
using the Acuros XB algorithm are superior to those obtained using the AAA, especially 
when treating a heterogeneous medium, such as lung. 
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This Chapter formatted for publication as: Tajaldeen A, Ramachandran P, and Geso M. 
“Feasibility of using ArcCheck as a tool for Patient Specific QA in Stereotactic Ablative 
Radiotherapy”. Journal of Medical Physics, 2017 (under review).  
 
Chapter 9 Feasibility of Using ArcCheck as a Tool 
for Patient Specific QA in Stereotactic Ablative 
Radiotherapy 
 
9.1 Summary  
The aim of this study is to assess the feasibility of using ArcCheck as an alternative method 
to replace film dosimetry for patient-specific QA. Twenty-five patients with a varied 
diagnosis of lung, spine, sacrum, sternum, ribs, scapula and femur undergoing SABR were 
selected for this study. Pre-treatment quality assurance QA was performed for all the patients 
using ionisation chamber and film dosimetry. Measurements were also carried out on an 
ArcCheck phantom. The planned and measured doses from the ArcCheck device and EBT3 
films were compared using four different gamma criteria: 2% / 2 mm, 3% / 2 mm, 3% / 1 mm 
and 3% / 3 mm. In case of spine, the gamma criteria were tightened due to the closeness of 
spinal cord to the planning target volume. Our results show that ArcCheck provides good 
results for all VMAT SABR plans. The ArcCheck results at 3% / 3 mm were in good 
agreement with film dosimetry for most cases. A significant reduction in QA time was 
observed on using ArcCheck for SABR QA. This study showed that ArcCheck could replace 
film dosimetry for all studied sites except for spine IMRT SABR. 
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9.2 Introduction  
Stereotactic Ablative Radiotherapy (SABR) also known as Stereotactic Body Radiation 
Therapy (SBRT) is one of the most preferred treatment techniques for early stage lung cancer 
[12]. SABR delivers a very high dose of radiation in a short period, and it is usually delivered 
either as a single fraction or as fractionated high dose radiotherapy in less than five fractions  
[123]. SABR is exclusively used for well-defined small tumours with clear margins. Delivery 
of high dose of radiotherapy in a short period requires rigorous quality assurance to ensure 
the target receives the prescription dose with a rapid dose fall-off outside the target volume 
[14]. AAPM TG 101 protocol [14] recommends a high level of confidence in the entire chain 
of the treatment process that includes immobilization, imaging/simulation, treatment 
planning, transfer of treatment parameters to the delivery system, treatment delivery, 
verification of target position before treatment delivery and continual monitoring during 
treatment. Quality assurance in radiotherapy can be grouped into two broad categories: 
machine related and patient specific. AAPM TG-142 [229] recommends daily, monthly and 
annual QA for radiotherapy imaging and treatment delivery systems. It imposes tighter 
tolerances for SRS/SBRT/SABR treatment techniques compared to IMRT and 3D CRT 
treatments [229]. Patient-specific quality assurance, also known as an end to end test is an 
important component of the treatment process which aids the physicist to identify any issues 
associated with the treatment plan or the delivery system.  
 
With the success of SABR in lung cancers, the technique has been extended to other 
treatment sites like spine, liver, scapula, sternum, kidney, hip, adrenal glands and prostate. 
This has resulted in an increased physics QA time on treatment machine. In SABR, pre-
treatment quality assurance / patient-specific QA includes both absolute and relative 
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dosimetry. Absolute dosimetry is usually performed in a water equivalent phantom, and the 
dose is measured using an ionisation chamber at a predefined depth. Relative dosimetry 
employs the use of film at a predefined plane inside the phantom. Both these process are 
time-consuming and may involve a significant amount of physics time outside normal clinical 
hours.  
Recently, the use of 2D or 3D detectors arrays such as MapCheck [230], 2D ion chamber 
array and the Octavius phantom [154, 231],  ArcCheck phantom [232], ScandiDos Delta4 
detectors [233] etc., for intensity modulated radiation therapy and volumetric modulated 
radiation therapy has become more common in radiotherapy and saves a significant amount 
of physics time by mininmising the use of ionisation chamber and film based patient-specific 
QA. However, point dose measurement would be required in situations where gamma 
analysis or second MU fails. The use of small fields in SABR techniques require high spatial 
resolution device to mimic the film dosimetry. In addition to this, the detector capability to 
record the dose for targets positioned away from the isocentre needs to be assessed. Hence, 
this study has been designed to investigate the feasibility of using ArcCheck as a tool for 
conducting pre-treatment quality assurance for SABR treatment plans of different sites with 
setup time. 
9.3 Material and Methods 
Twenty five patients with different diagnosis of lung, spine, sacrum, sternum, rib, scapula and 
head of the femur (Acetabulum) undergoing SABR were selected for this study. The ethics 
approval for this study was approved by Peter MacCullum Cancer Centre and the registration 
certificate was issued from college human ethics by RMIT university (See appendices I, II, 
III and IV). In case of lung, the maximum intensity projection (MIP) images were used to 
define the target volume to account for tumour motion during treatment. The MIP and 
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average intensity projection (AIP) images used for dose calculation were reconstructed on a 
Philips BrillianceTM CT scanner (Koninklijke Philips Electronics, Amsterdam, The 
Netherlands) utilising the Philips Bellows system to acquire a breathing trace during the scan 
acquisition. Figure 9-1 illustrates the beam arrangements and PTV coverage for six different 
sites used in this study.  Prior to treating the patients, pre-treatment QA was performed on all 
approved treatment plans including ion chamber measurements and film dosimetry. A grid 
size of 2.5 mm was used for dose calculation in all cases. A CC13 ionisation chamber (IC) 
was placed inside an in-house designed solid Perspex phantom known as Rod phantom 
[Figure 9-2 (A)] (The Rod phantom is described in Chapter 3, Section 3.8). The IC converts 
the ions into doses by using equation 3-1 (the IC is described in Chapter 3, Section 3.11). 
Before performing patient specific QA in rod phantom, a known dose for the 10 x 10 cm2 
field at the patient specific beam energy was delivered to measure a known dose 
simultaneously by using the ion chamber (CC13).  
 
 
  
Figure  9-1: Treatment plans of six different SABR cases. A) Lumber spine/IMRT/20Gy. B) 
Ribs /VMAT/20Gy. C) Head of femur/3D CRT/20Gy. D) Left lung/3D CRT/26Gy. E) Right 
lung/3D CRT/28Gy. F) Sternum/3D CRT/20Gy. 
 
A B C
D E F
251 
 
The radiochromic films used in this study was manufactured by the International Specialty 
Products (ISP) and supplied by CMS Alphatech as Gafchromic EBT3 films [234]. To 
generate calibration curves, EBT3 films were cut into 2 x 2 cm2 sizes and irradiated to 
different doses (0 to prescription dose (PD) in steps of 3 Gy, PD + 3 Gy, PD + 5 Gy) scaled 
according to the prescription dose [(Figure 9-3 (A)]. Prior to QA, the EBT3 films were 
resized to 12.5 x 20.5 cm2 [(Figure 9-3 (B)] to fit into the film slot designed inside the Rod 
phantom. The calibrated and the irradiated films were marked at three corners with unique 
marks: ∆, X, O [(Figure 9-3 (B)]. Also, these marks were aligned to sharp pins on the corners 
of the Perspex slabs to identify the placement of films after exposure. These marks aid in 
scanning the films at the same orientation utilised to scan the calibration films. The handling 
and the calibration of radiochromic films follow the recommendations of AAPM TG 55  
[152].  
 
The films were scanned by Epson Perfection V700 photo scanner in transmission mode and 
saved in RGB uncompressed image file format (TIFF). The scan settings used a colour depth 
of 48-bit colour and 72 dpi resolution without colour or sharpness correction. The 
commercial filmQA proTM software (Ashland, USA) was used to assess different gamma 
criteria. The multichannel dosimetry method was adopted to eliminate any uncertainty with 
film response at high doses.  The minimum required gamma passing rate for each SABR plan 
to pass QA and proceed to treatment with film is 95% for gamma criterion of 3% and 3 mm.  
 
The ArcCheck is a cylindrically shaped phantom with dimensions of 21 cm array length and 
21 cm array diameter [Figure 9-2 (B)]. The ArcCheck phantom is described in Chapter 3, 
Section 3.9 [40, 154]. The SNC Patient™ software (Ver. 6.6) enables the user to compare the 
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measured the calculated dose imported from the treatment planning system. The ArcCheck 
phantom was scanned in a Philips BrillianceTM CT scanner, and a Hounsfield value of 165 
(1.15 g/cm3) was assigned to the entire phantom in Eclipse treatment planning system (V 
13.6, Varian Medical Systems, , Palo Alto,CA). The verification plans were created by 
importing the ArcCheck phantom and overlaying the SABR treatment plans on to the 
imported ArcCheck phantom. Figure 9-3 (C) illustrates the comparison between ArcCheck 
measured fluence and extracted fluence at measurement points from DICOM RT dose and 
DICOM RT plan.  The planned and measured doses from the ArcCheck device were 
compared using four different gamma criteria: 2%, 2 mm, 3%, 2 mm, 3%, 1 mm and 3%, 3 
mm.  The gamma evaluation was done in absolute mode with 10% threshold and global 
normalization was adopted for the analysis. Also, the relationship between field size and 
passing rate was investigated by calculating the equivalent square field size (ESF) of the 
complicated treatment plans as suggested by ICRU [235]. The ESF was calculated using the 
standard 4*Area/ Perimeter relation expressed by the following relation: [(2 ab)/ (a+b)]. The 
minimum field size was restricted to 3 x 3 cm2.  
 
The statistical analyses were performed by Graph Pad PRISM 6 software, v. 6.03. A paired t-
test was used to investigate the statistical significances (p <0.05) and mean differences 
between the two methods (ArcCheck and EBT3 films). 
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Figure  9-2: A) In-house designed Rod phantom with a CC13 ion chamber inserted to 
measure absolute dose at reference point. B) ArcCheck phantom aligned to the isocentre 
for measurement. 
 
A B 
254 
 
 
Figure  9-3: A) The calibrated films were cut in (2 x 2 cm2) and irradiated to different doses 
from 0 – 30 Gy. The unique marks: ∆, X, O are pointed with blue arrows in 0 Gy EBT3 film.  
B) EBT3 films in (12.5 x 20.5 cm2) represent individual case (lung SABR case). C) 
Measurement vs TPS plan comparison using ArcCheck of Lung SABR (3 %, 3 mm Gamma 
agreement of 99.3%).  
A B 
C 
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9.4 Results 
The evaluations of gamma criteria for all twenty five clinical cases were divided into three 
groups: 1) Lung (A), 2) Spine (B) and 3) Others (C) that includes sternum, ribs, sacrum, 
scapula and femur. The differences in gamma passing rates between the ArcCheck and the 
EBT3 films utilising four different gamma criteria for 3D CRT, IMRT and VMAT treatment 
techniques are shown in Table 9-1.  
 
For a gamma criterion of 3% / 3 mm, group A and group C passed at higher passing rates for 
both ArcCheck and EBT3 measurements (>95%). The mean passing percentage for lung 
cases (A) were 98.48 ± 0.76 and 98.91 ± 1.19 for ArcCheck and EBT3 films respectively. 
Similarly, the mean passing rates for group C were 99.1 ± 0.83 and 99.71 ± 0.48 for 
ArcCheck and EBT3 films respectively. Group C patients had better passing rates 
(97.18±1.23) with ArcCheck even at 3% / 2 mm gamma criteria. The distribution of the 
gamma criteria 3% / 1 mm, 2% / 2 mm, 3% / 2 mm and 3% / 3 mm are demonstrated in 
Figures 9-4, 9-5 and 9-6 for groups A, B and C. 
 
Figure 9-4 illustrates that the distribution of gamma criterion 3% / 3 mm for ArcCheck (AC) 
is close to EBT3 films with a passing rate of above 95% for all lung patients. Similarly, the 
performance of the ArcCheck measurements was in good agreement with EBT3 films 
measurements for group C. Both techniques have very similar distribution for 3% / 3 mm 
measurements (Figure 9-6). The statistical analysis showed no significant differences 
between EBT3 films and the ArcCheck technique for the clinical cases of groups (A & C) for 
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3% / 3 mm criterion. The distributions of gamma criterion at 3% / 2 mm for the groups A and 
C were close to each other (Figures 9-4 and 9-6).  
 
The differences between the ArcCheck and the EBT3 films for group A and C patients 
ranged from 0.3% to 14.59% and 0.59% to 5.2% respectively at a gamma criterion of 3% / 2 
mm. In case of spine SABR, the gamma criteria was tightened from 3% / 3 mm to 3% / 2mm 
to account for the tight CTV to PTV margin and the closeness of PTV to spinal cord. The 
mean passing rates at 3% / 2 mm for ArcCheck and films for spine VMAT SABR were 
98.76±0.42 and 99.43±0.27 respectively. With spine SABR planned by IMRT, the mean 
passing rates with ArcCheck and films were 87.15±2.45 and 99.79±0.14 respectively.  
 
All patients planned by VMAT including spine and sacrum showed more than 95% passing 
rates at  3% / 2 mm and 3% / 3 mm with ArcCheck device and also correlates well with film 
measurements. However, for all IMRT spine SABR patients, the ArcCheck results were poor 
at 3% / 2mm gamma criteria.  
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 Table  9-1: Comparison of ArcCheck and EBT3 results. The data presented in this table was the result of three independent measurements (n=3). 
  Gamma Passing rates (%) Treatment planning 
technique/prescription 
dose (one fraction) Group Case No. Treatment site 
ArcCheck EBT3 ArcCheck EBT3 ArcCheck EBT3 ArcCheck EBT3 
3% 1mm 2% 2mm 3% 2mm 3% 3mm 
A 
1 Left Lung 79.0 96.1 89.1 95.9 92.8 98.6 97.1 99.5 3D CRT/26Gy 
2 Right Lung 80.6 91.4 90.7 94.5 92.7 95.7 98.4 97.1 3D CRT/28Gy 
3 Right lung 80.3 92.0 96.1 97.1 98.28 98.3 99.4 99.9 3D CRT/18Gy 
4 Right Lung 80.4 92.3 87.8 93.0 94.0 96.1 98.3 97.4 3D CRT/28Gy 
5 Left lung 82.9 96.0 92.1 98.7 92.8 99.4 99.3 100.0 3D CRT/26Gy 
6 Right Lung 74.5 96.1 85.4 98.2 90.7 99.4 98.4 99.6 3D CRT/26Gy 
1-6 Mean±Stdev 79.62±2.56 93.99±2.1 90.2±3.38 96.23±2.01 93.55±2.34 97.92±1.49 98.48±0.76 98.91±1.19  
B 
7 Thoracic Spine 61.3 97.1 79.9 99.22 85.3 99.6 92.2 99.9 IMRT/20Gy 
8 Thoracic Spine 66.7 95.9 83.8 99.68 85.4 100.0 93.9 100.0 IMRT/20Gy 
9 Lumbar Spine 69.4 92.4 89.2 98.94 91.3 99.7 99.0 100.0 IMRT/20Gy 
10 Lumbar Spine 56.2 91.6 85.6 99.01 86.6 99.8 94.2 100.0 IMRT/10Gy 
7-10 Mean± Stdev 63.4±5.08 94.24±2.29 84.63±3.35 99.21±0.29 87.15±2.45 99.79±0.14 94.83±2.53 99.98±0.04  
11 Cervical Spine 95.3 98.1 97.5 98.21 98.0 99.5 98.8 99.9 VMAT/20Gy 
12 Thoracic Spine 96.4 96.9 97.5 98.79 98.4 99.0 99.1 99.4 VMAT/10Gy 
13 Thoracic Spine 97.5 98.1 98.3 99.2 99.1 99.8 99.8 100.0 VMAT/20Gy 
14 Thoracic Spine 95.1 97.4 97.7 99.3 99.2 99.6 99.5 100.0 VMAT/20Gy 
15 Thoracic Spine 96.3 97.7 96.5 98.43 99.0 99.6 99.7 100.0 VMAT/20Gy 
16 Lumbar Spine 94.4 97.1 96.5 98.5 98.5 99.1 99.3 99.9 VMAT/20Gy 
17 Thoracic Spine 96.9 97.9 98.6 98.1 99.1 99.4 99.6 99.9 VMAT/20Gy 
11-17 Mean± Stdev 95.99±1.01 97.6±0.43 97.51±0.75 98.65±0.43 98.76±0.42 99.43±0.27 99.4±0.33 99.88±0.2 
 
7-17 Mean± Stdev 84.14±15.99 96.38±2.16 92.83±6.55 98.85±0.47 94.54±5.79 99.56±0.29 97.74±2.69 99.91±0.17 
C 
18 Sacrum 96.1 98.8 97.2 99.0 98.6 99.2 99.1 99.9 VMAT/10Gy 
19 Sacrum 82.8 99.9 93.1 100.0 94.8 100.0 97.4 100.0 3D CRT/20Gy 
20 Sternum 82.8 98.9 91.0 98.8 97.5 99.9 100.0 100.0 3D CRT/20Gy 
21 Sternum 89.9 97.2 95.3 97.5 97.4 98.3 99.2 98.7 3D CRT/20Gy 
22 Ribs 85.5 97.1 92.7 97.4 96.6 98.7 99.1 100.0 VMAT/10Gy 
23 Ribs 81.3 96.0 95.4 96.2 97.1 98.3 98.3 99.1 VMAT/20Gy 
24 Scapula 85.0 98.2 98.0 99.7 99.0 100.0 100.0 100.0 3D CRT/20Gy 
25 Acetabulum (Head of Femur) 86.1 96.62 93.9 98.9 96.4 99.8 99.7 99.9 3D CRT/20Gy 
 18-25 Mean± Stdev 86.19±4.48 97.84±1.24 94.58±2.2 98.45±1.2 97.18±1.23 99.28±0.71 99.1±0.83 99.71±0.48  
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Figure  9-4:  Comparison of passing rates of lung cases for different gamma criteria. 
 
Figure  9-5:  Comparison of passing rates of spine cases for different gamma criteria. 
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Figure  9-6: Comparison of passing rates of Sacrum, Sternum, Ribs, Scapula, Humerus and 
Femur Cases for different gamma criteria.  
 
Figure 9-7 shows the relation between gamma passing rates and field size. It clearly shows 
that passing rate is dependent on the field size. Of all the studied IMRT spine SABR patients, 
a lumbar spine (patient no. 9) passed at 99.0% and 100% at 3% / 3 mm for ArcCheck and 
EBT3 films respectively. The higher passing rate at 3% / 3 mm gamma criterion is mainly 
because of a larger field size (5.8 cm) compared to other IMRT spine SABR cases. There is a 
good correlation between the equivalent field sizes of four identical plans of 
IMRT/20Gy/10Gy and gamma passing rate of 3% / 3 mm with r2 =0.94 (Figure 9-7). The 
gamma passing rates at 3% / 3 mm for all spine cases with ArcCheck measurements ranged 
between 92.20% and 99.8%, and the mean percentage of all spine cases was 97.74±2.69 
(Table 9-1). Applying a strict gamma-index criterion of 2% / 2 mm at 90% passing rate for all 
cases resulted in none of the IMRT spine cases in group B passing the gamma criteria 
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whereas in group A, three out of six lung cases passed the strict gamma criterion for 
ArcCheck measurements. The gamma passing rates with group B (cervical, thoracic and 
lumbar) ranged between 79.90% and 98.6% for the same gamma criterion (Table 9-1). In 
group (C), all studied cases passed the 2% / 2 mm gamma criterion at 90%. 
 
 
Figure  9-7: The relationship between equivalent square field size and passing rates of 
IMRT plans for 3%, 3 mm gamma criterion. The correlation coefficient parameters of 
fitted line are shown in the inset of the graph. 
9.5 Discussion 
This work investigated the feasibility of using the ArcCheck as a replacement to film 
dosimetry. The comparisons between these two techniques were achieved by using the 
established gamma index method based on the concept of distance to agreement (DTA) and 
dose differences within predefined dose limits. The DTA is the distance between a measured 
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data point and the closest point in the calculated dose distribution that displays the same dose 
[236]. The comparison between the ArcCheck and the EBT3 films in this study is mainly 
focused on the results of the two gamma index criteria as these gamma criteria are widely 
accepted elsewhere [161, 162]: 3% dose difference and 3 mm distance to agreement with 
95% pass rate, 2% dose difference and 2 mm distance to agreement with 90% pass rate [161, 
162].  
 
The gamma passing rate of 3%, 3 mm for the first and the third clinical groups (A & C) 
showed excellent agreement between the two techniques. Similarly, the mean doses for the 
ArcCheck and EBT3 films for both groups were almost the same (at the 98% and 99% 
respectively) with a small standard deviation (1.19%). Three out of 6 cases in group A and all 
cases in group C passed at 2% and 2 mm gamma criterion. Similarly, group A and C passed 
at 3% and 2 mm gamma criterion. The group (B) (IMRT spine cases) recorded lower gamma 
passing rates for the ArcCheck technique compared with the EBT3 results for all gamma 
criteria. This is because the spine tumours tend to be small and located close to critical 
structures like spinal cord resulting in reduced planned doses on the ArcCheck diodes [237]. 
This leads to smaller maximum planned doses, which suggest that low gamma passing rates 
of the spine cases can be correlated to the slim margin of error presented by these reduced 
doses [237]. The spine cases that passed the 3%, 3 mm gamma criterion were closely 
evaluated. Four IMRT spine cases out of eleven in this study were selected which have 
identical IMRT plans (all plans have the same beam configurations, gantry angles and 
collimator rotation). The gamma passing rates of all these cases were found to have a positive 
correlation with the increased field size (Figure 9-7).  
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The statistical analysis showed no significant differences between EBT3 films and the 
ArcCheck technique for the clinical cases of groups (A & C) for 3% / 3 mm criterion, 
suggesting that the latter technique can be utilised instead of the former for these cases. 
However, for spine cases our study indicates that the routine film measurements are required 
in most cases. Moreover, in case of spine SABR treatments, the spinal cord is so close to the 
target volume and a slight setup error would compromise the dose delivered to the target 
volume and it requires a high spatial resolution device to detect the sharp diode or ionisation 
chamber base array device uses an interpolation algorithm which may not predict the dose 
fall-off precisely and could lead to erroneous results. Hence, it is highly recommended to use 
EBT3 films for all SABR spine cases.  
 
A study by Hussein et al., 2013 [40] using five commercial QA systems (PTW 2D-Array, 
Scandidos Delta4, SunNuclear ArcCheck, Varian EPID, and Gafchromic EBT2 film) showed 
lower concordance of the correlation coefficient for the EBT2 films with the predicted 
gamma index. This is due to noise artefacts caused by the intrinsic film heterogeneity. 
Moreover, the gamma index analyses in EBT2 films are disrupted with the variability of the 
scanning procedures. The only difference between the EBT2 and EBT3 used in this study is 
that the Polyester layers of the EBT3 are symmetrical resulting in reduced artefacts [151, 
238]. In contrast, the ArcCheck technique results for the same study demonstrated closest 
statistical agreement with the predicted gamma value for the gamma passing criteria of 3%, 3 
mm and 3%, 2 mm respectively [40]. The results of the ArcCheck for the first, third group 
and spine VMAT SABR of the second group emphasize the use of ArcCheck as replacement 
to film dosimetry.  ArcCheck was specifically designed for VMAT QA and our results have 
demonstrated beyond doubt that ArcCheck could replace film dosimetry for spine VMAT 
SABR QA. ArcCheck uses diodes with excellent reproducibility and acceptable angular 
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response. It provides good sensitivity for the detection of small gantry rotation offset and 
scaling errors as well as phantom setup error [232]. The introduction of SABR technique in 
radiotherapy has prolonged the working hours of clinical physicists. This increased workload 
necessitates an alternate QA method to manage the Physics workload. The standard 
ionisation chamber and film dosimetry involve a series of procedures that includes output 
measurement, film calibration, film scanning, pre and post film processing, a specialised 
software to verify measured film and calculated dose. The EBT3 films usually consume 
significant time before and after the radiation exposure. Proper handling and preparing 
process include cutting to specific size (to create the curve calibration and patient QA), and 
labelling the films must be considered before the radiation exposure. The use of ArcCheck 
would decrease physics QA time significantly. Also, it enhances the physics throughput and 
minimizes human errors in busy radiotherapy centres. 
 
In this study, despite the low passing rates of the spine cases for ArcCheck measurements at 
the standard gamma criterion (3% / 3 mm) and (2% / 2 mm), the ArcCheck provided a good 
agreement with the EBT3 films for the first and third clinical groups. For spine cases, the size 
of the treatment field should be considered when using the ArcCheck for QA as it could 
affect the gamma passing rates. 
9.6 Conclusion 
The ArcCheck results at 3% / 3 mm were in good agreement with the EBT3 films dosimetry 
for lung, sacrum, sternum, ribs, scapula and femur. A significant reduction in QA time was 
observed on using ArcCheck for SABR QA. This study showed that ArcCheck could replace 
film dosimetry for all sites except spine SABR planned by IMRT. 
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Chapter 10 Conclusions, Limitations and Future 
Directions 
 
10.1  Conclusions 
The focus of this thesis research was to assess the efficiency of delivering an accurate dose to 
the tumour volume in SABR of lung cases. As SABR delivers high radiation doses in a small 
fraction number, special attention needs to be paid to all aspects of the treatment for each 
patient, including simulation/imaging, treatment, and delivery planning. The SABR of lung 
poses several challenges such as tumour motion during patient respiration, an increase of the 
CPD effect due to the low density of the lung tissue, which affects the dose calculation, and 
the relatively long time period for patient-specific quality assurance (QA) using traditional 
EBT films. Due to the respiratory motion, the use of SABR to treat lung cancer requires good 
delineation of the tumour target, including gross tumour volume (GTV) and planning target 
volume (PTV), accurate dose calculation algorithms that can reflect the actual dose 
distribution, and pre-treatment QA techniques to validate the treatment delivery doses to the 
patients before the treatment.  
 
The main findings of this thesis are demonstrated as follows: 
 The MIP based planning method (conventional method) that has been used in most radiation 
therapy centres may increase the PTV volume, and hence, increase the radiation doses to the 
surrounding normal tissues. The phase specific planning method provides a significant 
reduction to the PTV by tracking the tumour volume in each respiratory phase. Also, this 
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method recorded lower radiation doses to the PTV compared to the conventional method. 
This conclusion is related to (Aim 1, Hypothesis 1). 
 
 The results of PRESAGE 3D dosimeters showed excellent dose distribution in both static and 
dynamic conditions in the three axes, X, Y and Z, using an in-house custom-designed thorax 
dynamic phantom. This thesis establishes a method to quantify the dosimetric differences 
results from the tumour motion. By using PRESAGE 3D dosimeters, a dynamic phantom, 
and advanced software, the variations between the static and dynamic plans of SABR 
techniques were measured in millimetres. This could be helpful in clinical cases when the 
oncologist needs to check the coverage of the prescription dose (e.g., 28 Gy) during the 
tumour motion and display the data in three dimensions. This conclusion is related to (Aim 1, 
Hypothesis 1).  
 
  The comprehensive investigation of the commercially available algorithms implemented in 
TPS showed a significant variation among the algorithms’ performances for in-field and out-
of-field measurements using the IPSM phantom. This thesis highlights the preferable dose 
calculation algorithms for different densities, such as water, lung, rib, and dense bone. For in-
field measurements, the Acuros XB algorithms were close to the actual measurements by IC. 
In the out-of-field measurements, the CCC exhibited better performance compared to the 
other algorithms. This conclusion is related to (Aim 2, Hypothesis 2).  
 
 The investigation of dose calculation algorithms for AAA, PBC, Acuros XB, and 
Superposition using the CIRS thorax phantom and two retrospective clinical cases showed 
that the calculation of the latter two algorithms were close to the IC measurements. 
Moreover, the 21 clinical studies using 3D CRT of lung SABR showed better conformity, 
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homogeneity, and dose fall-off for the Acuros XB and Superposition algorithms compared to 
the other algorithms. This conclusion is related to (Aim 2, Hypothesis 2). 
 
 
 The findings of this thesis from the IPSM phantom, CIRS thorax phantom, and 21 SABR 
lung cases suggested that the Acuros XB and Superposition algorithms are the most accurate 
algorithms to calculate and predict the actual dose in low densities, such as lung. This 
conclusion is related to (Aim 2, Hypothesis 2).  
 
 For treating the lung tumours with SABR techniques, the C-VMAT provides better dose 
conformity, reduced treatment time, and hence, decreased intra-fraction motion compared to 
the NC-3D CRT and NC-IMRT techniques. The same experiment emphasised the importance 
of selecting the appropriate dose calculation algorithms when treating lung cancer. The 
Acuros XB algorithms with the C-VMAT plans showed the best conformity, homogeneity 
inside the PTV, and dose fall-off compared to the other two plans (NC-3D CRT and NC-
IMRT). This conclusion is related to (Aim 3, Hypothesis 3). 
 
 In SABR cases, the ArcCheck phantom results exhibited a significant reduction in patient-
specific QA time compared to the traditional EBT films. The post-irradiation time that is 
required for EBT films darkening to saturate (approximately eight hours) is replaced with 
near real-time results obtained by the ArcCheck phantom. This would enhance the efficiency 
of the patient-specific QA time in radiation therapy centres for SABR cases, including lung 
cancer. This conclusion is related to (Aim 4, Hypothesis 4).  
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10.2   Limitations  
 
This thesis represents the results of ongoing improvement of an in-house custom-designed 
thorax dynamic phantom using PRESAGE 3D dosimeters. However, the designed phantom 
lacked the tumour motion simulation in the right/left direction (X-axis). Also, the study of the 
tumour motion in this thesis was limited to a retrospective clinical case of lung SABR with a 
relatively small tumour movement distance and regular breathing. 
  
10.3   Future Direction  
The in-house custom-designed thorax dynamic phantom could be improved by adding a 
motion in the right/left direction (X-axis). This modification would include developing codes 
for the current software design (appendix X) to simulate the tumour motion accordingly. 
Further study is needed to include irregular tumour motion or irregular breathing cases and to 
investigate the dosimetric effect of these motions in three SABR techniques. Moreover, the 
interplay effect [239] that occurs in IMRT and VMAT can be investigated using the dynamic 
phantom and PRESAGE 3D dosimeters.  
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